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Abstract
Skeletal muscle atrophy is a devastating condition, contributing to increased 
morbidity and mortality during many chronic disease states. Skeletal muscle atrophy 
is a result of decreased rates of protein synthesis and/or increased rates of protein
degradation. Understanding the molecular mechanisms that regulate these processes 
is therefore a prerequisite to develop therapeutic strategies to target muscle atrophy 
and improve clinical outcomes. The transcriptional coactivators peroxisome 
proliferator-activated receptor-gamma coactivator-1alpha (PGC-ĮDQG3*&-ȕ are 
both positive regulators of many functions important for maintaining skeletal muscle 
health. Notably, many of their actions in skeletal muscle depend on the 
transcriptional coactivator, estrogen-related receptor alpha ((55Į). Recent evidence 
suggests that PGC-Į DQG 3*&-ȕ PD\ EH DWWUDFWLYH WDUJHWV WR DWWHQXDWH PXVFOH
wasting, as their overexpression attenuates muscle atrophy via decreased activity of 
signalling pathways involved in protein degradation. As protein synthesis rates are 
also significantly reduced during many catabolic states, identifying ways to increase 
protein synthesis is also vital. The role of PGC-ĮDQG3*&-ȕ LQ VNHOHWDOPXVFOH
protein synthesis has not been thoroughly investigated, and therefore further research 
is required. If PGC-ĮDQGRU3*&-ȕFDQ LQFUHDVHSURWHLQV\QWKHVLV LQDGGLWLRQ WR
attenuating protein degradation, this may provide a basis for the development of 
treatment strategies to alleviate the debilitating effects of muscle atrophy. 
The aims of the first study were to determine if PGC-ĮDQGRU3*&-ȕFDQLQFUHDVH
protein synthesis under basal or catabolic conditions, and if this was dependent on 
Akt/mTOR signalling or the transcription factor, (55Į This study showed that 
overexpression of PGC-Į RU 3*&-ȕ LQFUHDVHG SURWHLQ V\QWKHVLV DQG P\RWXEH
diameter in C2C12 myotubes. Secondly, the increase in protein synthesis was 
independent of Akt and mTOR, members of a signalling pathway known to stimulate 
protein synthesis in skeletal muscle. Lastly, knockdown of the transcription factor 
(55ĮXVLQJVL51$SUHYHQWHGWKH3*&-Į- and PGC-ȕ-induced increase in protein 
V\QWKHVLVDQGP\RWXEHGLDPHWHUZKLOHFRQVWLWXWLYHO\DFWLYH(55Įincreased protein 
synthesis and myotube diameter. Like many other important PGC-Į- or PGC-ȕ-
xiv 
 
PHGLDWHGSURFHVVHVLQVNHOHWDOPXVFOH(55Įactivity is therefore essential for PGC-
ĮDQG3*&-ȕWRLQFUHDVHSURWHLQV\QWKHVLVLQ&&P\RWXEHV
The downstream targets that PGC-Į(55ĮDQG PGC-ȕ(55ĮUHJXODWHWRLQFUHDVH
protein synthesis are unknown. The primary aims of the second study were to
identify global gene and protein expression changes that occur in response PGC-Į
and PGC-ȕ RYHUH[SUHVVLRQ LQ &&P\RWXEHV, and to create an unbiased gene 
expression signature (GES) characterising the PGC-Į- and PGC-ȕ- driven protein 
synthesis. Gene set enrichment analysis (GSEA) identified several Gene Ontology 
(GO) terms and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways 
differentially regulated in response to PGC-ĮRU3*&-ȕRYHUH[SUHVVLRQLQ&&
myotubes, including mitochondrial biology, energy metabolism, nucleotide binding, 
and the ribosome and ribonucleoprotein complex; the latter supporting the roles of 
PGC-Į DQG 3*&-ȕ LQ protein synthesis. Genes and proteins differentially 
expressed, specifically by PGC-ȕ DOVR FOXVWHUHG VLJQLILFDQWO\ ZLWK PXVFOH
contractile and cytoskeletal related GO terms. 
The unbiased GES led to the identification of 7 novel genes regulated by PGC-Į
and PGC-ȕZKLOHRWKHUhighly regulated genes, which may potentially be involved 
in muscle growth, were biasedly selected and also explored. Similar to PGC-Į
expression, many of the up-regulated genes were increase in human skeletal muscle 
following resistance exercise, a model of stimulated muscle protein synthesis,
suggesting that they may be involved in the positive regulation of protein synthesis. 
In contrast, many of these genes were decreased in skeletal muscle of amyotrophic 
lateral sclerosis (ALS) patients, a clinical model of skeletal muscle atrophy,
paralleled with reduced PGC-ĮDQG3*&-ȕP51$. Furthermore, genes that were 
down-regulated by PGC-Į DQG 3*&-ȕ displayed inverse expression in these 
models, suggesting that their decreased expression by PGC-Į DQG 3*&-ȕ PD\
contribute to the attenuation of muscle atrophy. Together these observations provide 
novel avenues to investigate the effects of PGC-ĮDQG3*&-ȕRQ skeletal muscle 
protein turnover.
Another mechanism by which PGC-Į DQG 3*&-ȕPD\ UHJXODWH skeletal muscle 
mass is via creatine transport into muscle cells. Creatine supplementation increases 
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strength, fat-free mass, and muscle fibre size when used in combination with 
resistance training or for the treatment of myopathies presenting with muscle 
atrophy. However, Creatine transporter (CrT) levels are decreased in many 
myopathies associated with muscle wasting, suggesting that increasing CrT levels 
may be an effective strategy to maximise the potential benefits of creatine 
supplementation. However the molecular mechanisms regulating CrT expression are 
unknown. As PGC-Į DQG 3*&-ȕ UHJXODWH RWKHU LPSRUWDQW DVSHFWV RI HQHUJ\
metabolism, it is plausible that they may also regulate creatine uptake via increasing 
the expression of the CrT. This may also partially explain how PGC-ĮDQG3*&-ȕ
positively influence skeletal muscle mass. The aims of the third study were to 
determine if PGC-Į DQG 3*&-1ȕ LQFUHDVH CrT mRNA and creatine uptake in L6 
P\RWXEHV DQG ZKHWKHU WKLV LV YLD (55Į, and to determine whether PGC-Į DQG
PGC-ȕ LQFUHDVH SURWHLQ V\QWKesis via up-regulating CrT expression and creatine 
uptake. PGC-Į DQG 3*&-ȕ overexpression increased CrT mRNA and creatine 
uptake in L6 myotubes. This effect was GHSHQGHQWRQ(55ĮDQG3*&-ĮDQG(55Į
directly bind to the CrT promoter to induce its expression. Lastly, the PGC-Į- and 
PGC-ȕ-induced increase in protein synthesis and myotube diameter was not 
dependent on the CrT, and therefore other mechanisms may be responsible for the 
increase in muscle mass seen in response to increasing intracellular creatine. These 
observations increase the understanding of the molecular mechanisms regulating
creatine transport in skeletal muscle, and may provide a basis for a treatment strategy 
aimed at improving various skeletal muscle diseases characterised by reduced 
intracellular creatine levels. 
The findings of this thesis expand the current knowledge of the PGC-Į- and PGC-
ȕ-regulated functions in skeletal muscle. In addition to their already known 
attenuation of protein degradation, these observations show that PGC-ĮDQG3*&-
ȕ FDQ also increase protein synthesis and creatine uptake in myotubes. The 
downstream molecular pathways regulated by PGC-Į DQG 3*&-ȕ present as 
attractive targets for the development of treatment strategies to alleviate the 
debilitating effects of muscle atrophy.
1 
Chapter 1
Literature Review
1.1 Skeletal muscle
Skeletal muscle is the most abundant tissue in the human body, representing about 
40% of total body mass and 50-75% of total body protein [1]. It is an essential tissue 
in the body which controls movement, the maintenance of posture, and occupies a 
fundamental role in whole body metabolism [2]. Skeletal muscle is a highly 
adaptable tissue, and can alter its size, structure and function in response to many 
different stimuli [3, 4]. The most powerful stimulus for skeletal muscle adaptation is 
physical activity. Endurance exercise increases the oxidative capacity and improves 
the metabolic profile of skeletal muscle [5-7], while resistance exercise increases the 
size, strength and function of skeletal muscle [8-10]. In contrast, inactivity, aging, 
malnutrition, and many chronic diseases result in impairments in skeletal muscle 
function, metabolism and growth [11-14].
Skeletal muscle atrophy is a devastating condition characterised by a decrease in the 
size of the muscle fibres and overall muscle mass, resulting in a loss of strength and 
mobility. Muscle atrophy is a hallmark of many conditions including neuromuscular 
disorders such as Duchenne muscular dystrophy (DMD) and amyotrophic lateral 
sclerosis (ALS) [15, 16], as well as sepsis, critical illness myopathy, sarcopenia and 
immobilisation following acute injuries [17-21]. Muscle atrophy is also common 
during chronic diseases such as cancer, heart disease, diabetes, chronic obstructive 
pulmonary disease (COPD), and acquired immuno deficiency syndrome (AIDS), and 
is a major limiting factor to successful treatment, contributing to increased rates of
morbidity and mortality [11, 13, 18, 22-26]. While exercise training can attenuate 
muscle atrophy and increase strength and functional capacity in conditions such as 
sarcopenia [27], exercise is often not possible in many of these disease states. 
Furthermore, the intracellular signalling responses to exercise are often blunted in 
diseased skeletal muscle [11, 28-30]. Understanding the molecular and physiological 
mechanisms involved in the regulation of muscle mass is therefore a prerequisite for 
2 
 
developing therapeutic interventions to improve clinical outcomes and reduce the 
burden on health care systems.
1.1.1 Regulation of skeletal muscle mass
Skeletal muscle mass is regulated by a fine balance between protein synthesis and 
protein degradation [31]. When the rate of protein synthesis exceeds that of protein 
degradation, there is a resultant increase in muscle growth, or hypertrophy, which is 
characterised by an increase in the size of pre-existing muscle fibres. In contrast,
decreased rates of protein synthesis compared to protein degradation, results in 
muscle atrophy, which causes a decrease in muscle fibre size and muscle mass, 
resulting in a loss of strength and mobility [31]. Skeletal muscle mass can be affected
by a variety of factors that result in alterations to the balance between protein 
synthesis and protein degradation. Stimuli such as resistance exercise [32-35], amino 
acids [36, 37], and some hormones (insulin, insulin-like growth factor-1 and 
testosterone) [38-42] are known to increase net skeletal muscle protein content and 
stimulate hypertrophy, while inactivity, malnutrition, disease and trauma result in 
decreased skeletal muscle protein and muscle atrophy.
1.1.2 Molecular regulation of protein synthesis and protein degradation
Several signalling pathways involved in skeletal muscle protein synthesis and 
degradation have been identified. Some of those involved in muscle growth include 
the calcineurin/nuclear factor of activated T-cells (NFAT) pathway [43, 44], the 
mitogen-activated protein kinase (MAPK) pathway [45, 46], and the 
phosphatidylinositol 3-kinase (PI3K)/Acute transforming retrovirus thymoma (Akt)/ 
mammalian target of rapamycin (mTOR) pathway [31, 47]. Although the role of the 
calcineurin/NFAT and MAPK pathways in protein synthesis are debateable [47-49],
several studies have clearly shown the role of the PI3K/Akt/mTOR in skeletal 
muscle protein synthesis [39, 47]. Furthermore, this signalling pathway is also linked 
with protein degradation, as activation of Akt inhibits the forkhead box O (FOXO) 
transcription factors that are known to increase protein degradation [50, 51].
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1.1.3 Protein synthesis
Akt is phosphorylated and activated via upstream signalling involving IGF-1 and 
PI3K. When active, Akt increases protein synthesis via mTOR and glycogen 
synthase kinase- ȕ *6.-ȕ (Figure 1.01) [47]. Firstly, Akt activates mTOR by 
direct phosphorylation on its ser2448 site [52], and by removing the inhibitory effect 
of the tuberous sclerosis complex 1 and 2 proteins (TSC1/2) on mTOR [53, 54].
mTOR phosphorylates p70 ribosomal S6 protein kinase (p70S6k), which increases 
the activity of ribosomal protein S6, a positive regulator of protein synthesis [55].
mTOR also phosphorylates and inactivates the translation repressor, 4E-BP1, a 
negative regulator of the eukaryotic initiation factor 4E (eIF-4E) [56]. Secondly, Akt 
phosphorylates and inactivates GSK-ȕ UHPRYLQJ LWV LQKLELWLRQ RI WUDQVODWLRQ
initiation factor eIF2B, leading to an increase in translation initiation and therefore 
protein synthesis [57-59].
Compensatory hypertrophy of the plantaris muscle in rats is associated with 
increased phosphorylation of Akt, GSK-ȕDQGS6k, and decreased inhibition of 
eIF-4E by 4E-BP1 [47]. In contrast, the opposite effects are seen during muscle 
atrophy induced via hindlimb suspension in rats. Likewise, 8 weeks of resistance 
training in humans results in muscle hypertrophy and is associated with increases in 
phosphorylated Akt, GSK-ȕ DQG P725 ZKLOH  ZHHNV RI GHWUDLQLQJ UHVXOWV LQ
muscle atrophy and decreased phosphorylation of these proteins [60]. Constitutive 
activation of Akt in skeletal muscle of mice leads to dramatic hypertrophy, 
confirming a role for Akt in the positive regulation of muscle mass [47]. This is 
dependent on mTOR activity, as rapamycin, an mTOR inhibitor, completely blocks 
this effect. The Akt/mTOR pathway is therefore seen as a major positive regulator of 
protein synthesis in skeletal muscle.
1.1.4 Protein Degradation
During skeletal muscle atrophy, the majority of protein degradation occurs via two 
mechanisms, the ubiquitin proteasome pathway (UPP) and the autophagic-lysosomal 
pathway [61, 62]. In the UPP, proteins targeted for degradation are first tagged with 
chains of ubiquitin via the activities of three enzymatic components, E1 (ubiquitin 
activating enzyme), E2 (ubiquitin carrier protein) and E3 (ubiquitin protein ligase) 
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[63]. This process leads to their recognition by the proteasome, degrading these
proteins into small peptides. In skeletal muscle, two muscle-specific E3 ubiquitin 
ligases, Atrogin-1 and Muscle Ring Finger-1 (MuRF1), have been identified, and 
their expression is highly induced during skeletal muscle atrophy [64, 65]. Mice 
deficient in either Atrogin-1 or MuRF1 are resistant to atrophy [66]. The UPP is 
thought to be responsible for the degradation of most cytosolic and myofibrillar 
proteins in skeletal muscle [63].
The autophagic-lysosomal pathway also plays a role in the degradative processes 
during skeletal muscle atrophy [61, 62, 67, 68]. Autophagy involves portions of the 
cytoplasm and cell organelles being sequestered into autophagosomes, which then 
fuse with lysosomes and are digested by lysosomal hydrolases [67, 68]. Expression 
of genes involved in autophagy including microtubule-associated protein 1 light 
chain 3 (LC3), BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 (Bnip3),
GABA receptor-associated protein like-1 (Gabarapl1), and the lysosomal hydrolase 
cathepsin-L, are also induced during skeletal muscle atrophy, suggesting that a
combination of both proteasomal and lysosomal proteolysis contribute to the 
increased rate of protein degradation.
A characteristic of both of these proteolytic mechanisms is their regulation by the 
FOXO family of transcription factors (FOXO1 and FOXO3a) (Figure 1.01). When 
dephosphorylated and active, FOXO transcription factors are located in the nucleus 
where they regulate the expression of genes involved in the UPP (Atrogin-1 and 
MuRF1) and autophagy (LC3, Bnip3, Gabarapl1, and cathepsin-L) [61]. These genes 
have been termed ‘atrogenes’ due to their involvement in skeletal muscle atrophy 
[64, 65]. Expression of a constitutively active FOXO3a induces both lysosomal and 
proteasomal proteolysis in muscle cells and in skeletal muscle in vivo [61, 62]. In 
contrast, phosphorylation of FOXOs by Akt reduces FOXO activity, and therefore 
attenuates protein degradation [51, 69, 70]. Treatment with IGF-1, or activation of 
Akt, inactivates FOXO transcription factors and consequently antagonises the up-
regulation of ubiquitin ligases, Atrogin-1 and MuRF1 [40, 50, 51, 69]. Similarly, Akt 
may regulate autophagy via FOXOs, as inhibition of Akt results in increased 
FOXO3a activity and is associated with an increase in lysosomal proteolysis [62].
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These findings show that in addition to being a major stimulator of protein synthesis, 
Akt also regulates muscle mass via the inhibition of protein degradation pathways.
Figure 1.01 Schematic of Akt signalling pathways involved in protein synthesis and degradation.
When activated by PI3K, Akt increases protein synthesis by increasing mTOR activity and inhibiting 
GSK-ȕ$NWDOVRSKRVSKRU\ODWHVDQGLQKLELWV)2;2DQGDUHGXFLQJWKHOHYHOVRI$WURJLQ-1 and 
MuRF1, members of the ubiquitin proteasome pathway. FOXO3a increases lysosomal proteolysis,
and inhibition of Akt also causes an increase in FOXO3a phosphorylation and increased expression of 
lysosomal genes.  
 
1.1.5 Fibre-type specific muscle atrophy
It is worth noting that the atrophy that occurs during many catabolic conditions does 
not always affect muscle fibres equally. Skeletal muscle is composed of several 
different fibre types which each have specific metabolic and contractile properties. 
The three main fibre types in human skeletal muscle are type I (slow-oxidative), type 
IIa (oxidative-glycolytic) and type IIx (fast glycolytic), while rodents also express 
another fast-glycolytic fibre, type IIb [71, 72]. The atrophy observed during 
inactivity and denervation is more profound in type I oxidative muscle fibres [73-76],
and causes a shift from oxidative to a higher proportion of glycolytic muscle fibres 
[73, 74]. In contrast, muscle atrophy seen during ageing [77, 78], COPD [25], heart 
failure [79, 80], and sepsis [81, 82], is generally more specific to fast-twitch 
glycolytic muscle fibre types. These findings suggest that intracellular signalling 
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pathways involved in protein synthesis and protein degradation may be regulated 
differently among fibre types. However, others have shown that the transcriptional 
changes induced during muscle atrophy appear to be similar in response to many 
different stimuli, including denervation/disuse and systemic wasting diseases [64,
65].
1.1.6 Muscle atrophy and mitochondrial dysfunction
Recent evidence suggests that the regulation of skeletal muscle mass may be 
associated with mitochondrial health. Mitochondrial dysfunction is thought to be 
involved in the pathogenesis of sarcopenia [83-85], and is observed in most 
conditions associated with muscle atrophy including chronic disuse [86], diabetes 
[26], ALS [87], and DMD [88, 89]. The greater sensitivity of type II muscle fibres to 
systemic muscle wasting may therefore be due to their lower mitochondrial content. 
However, this does not explain the rapid atrophy seen in type I fibres during disuse
and denervation. In fact, disuse atrophy is associated with a decrease in 
mitochondrial content, alterations in morphology, increased mitochondrial reactive 
oxygen species (ROS) and mitochondrial dysfunction (reviewed in [90]). Therefore it 
appears that alterations to the overall mitochondrial network may contribute to 
muscle atrophy, and mitochondrial impairments have been shown to contribute to 
both denervation- and fasting-induced atrophy in vivo [91]. Key proteins linking 
mitochondrial function to skeletal muscle mass are the transcriptional coactivators, 
peroxisome proliferator-activated receptor-gamma coactivator-1alpha (PGC-Į) and 
PGC-ȕ 3*&-Į DQG 3*&-ȕ DUH ZHOO-known regulators of mitochondrial 
biogenesis and function, and more recently their regulation of skeletal muscle mass
has become of interest. 
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1.2 PGC-1ĮDQG3*&-ȕ transcriptional coactivators
PGC-Į DQG 3GC-ȕ DUH SDUW RI WKH 3*&-1 family of transcriptional coactivators,
which also includes the PGC-1 related coactivator (PRC) [92-94]. Transcriptional 
coactivators promote gene transcription via their interaction with transcription 
factors. PGC-Į was first identified in brown adipose tissue as a regulator of 
adaptive thermogenesis during cold exposure through its interaction with the 
transcription factor, peroxisome proliferator–DFWLYDWHG UHFHSWRU JDPPD 33$5Ȗ
[94]. PGC-ȕ was then identified on the basis of its similarity to PGC-Į [93, 95],
although unlike PGC-Į, its expression was not dramatically induced during cold 
exposure. PGC-Į and PGC-ȕ are highly expressed in oxidative tissues including 
skeletal muscle, heart, brown adipose tissue, kidneys and brain [93-99]. Structurally, 
PGC-ȕ contains similar domains to PGC-Į along the protein, but with an extended 
middle region [93, 95, 100]. Both PGC-Į and PGC-ȕ coactivate a diverse set of 
transcription factors to coordinate the expression of genes that regulate mitochondrial 
biogenesis, respiration, oxidative metabolism, and energy homeostasis in many 
tissues [98, 101]. In addition, they each coactivate their own distinct set of 
transcription factors in certain tissues, leading to different functional outcomes. For 
example, in liver, PGC-Į coactivates hepatocyte nuclear factor-Į +1)-ĮDQG
FOXO1 to induce gluconeogenesis [102-105], while PGC-ȕ coactivates the sterol 
regulatory element-binding protein-1 (SREBP-1) and liver X receptor-Į (LXRĮ to 
stimulate hepatic lipogenesis [106, 107]. Moreover, PGC-1Į DQG PGC-1ȕ can 
modulate different biological programs in a tissue specific manner. For example, in 
skeletal muscle, both PGC-Į and PGC-ȕ can improve insulin resistance [100, 108],
whereas in liver, they contribute to the induction of insulin resistance [107, 108].
This section will focus only on PGC-1ĮDQG PGC-1ȕ in relation to their function and 
transcriptional activity in skeletal muscle.
1.2.1 Regulation of PGC-ĮDQG3*&-ȕLQVNHOHWDOPXVFOH
In skeletal muscle, PGC-Į DQG 3*&-ȕ SOD\ VLPLODU UROHV LQ UHJXODWLQJ PDQ\
processes associated with oxidative energy metabolism; however their regulation 
differs quite significantly. The expression and/or activity of PGC-Į LV LQGXFHG LQ
response to situations of metabolic stress such as adrenergic stimulation [109, 110],
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cold exposure [94, 111], fasting [112], and exercise [113-115]. In fact, the effects of 
overexpressing PGC-Į LQ VNHOHWDO PXVFOH SDUDOOHO PDQ\ RI WKH EHQHILFLDO
adaptations to endurance exercise (reviewed in [7, 116-118]). PGC-ĮP51$DQGRU
protein levels are significantly increased after endurance exercise [113-115, 119] and 
training [120-122], and high intensity interval exercise [123, 124]. Therefore it is 
generally viewed that PGC-Įmediates many of the physiological adaptations seen 
with endurance exercise and training [110, 125, 126]. Furthermore, many of the 
intracellular signalling pathways activated during exercise regulate PGC-ĮDFWLYLW\
and expression. Calcineurin and the calmodulin-dependent protein kinase IV 
(CaMKIV) are activated in response to increased intracellular calcium during 
exercise [127, 128], and both increase PGC-Į H[SUHVVLRQ in vivo [129-132]. The 
AMP-activated protein kinase (AMPK) is an energy sensor in the cell, and is 
activated by changes in energy status such as during exercise [115, 123, 133].
Pharmacological activation of AMPK increases PGC-1Į H[SUHVVLRQ in vivo and in 
vitro [134, 135]. Furthermore, AMPK can directly phosphorylate PGC-Į RQ LWV
threonine-177 and serine-538 sites, increasing its activity [136]. The p38 mitogen-
activated protein kinase (MAPK) is also activated in response to exercise [45, 122,
137], and activation of p38 MAPK increases PGC-Į H[SUHVVLRQ in vivo [122].
Finally, PGC-Į LV DOVR DFWLYDWHG E\ VLUWXLQ-1 (SIRT1), which acts as a metabolic 
sensor in the cell [138, 139]. SIRT1 is increased after endurance exercise and fasting 
in skeletal muscle [112, 140], whereby it deacetylates PGC-ĮUHVXOWLQJLQLQFUHDVHG
PGC-Į activity [112]. SIRT1 can also bind to the PGC-ĮSURPRWHU DQGHQKDQFH
the recruitment of PGC-Į WR LWV RZQ SURPRWHU UHJLRQ to increase its expression 
[138].
In contrast to PGC-Į, PGC-ȕH[SUHVVLRQGRHVQRWincrease in response to fasting, 
cold exposure or adrenergic stimulation [93, 99, 100]. Furthermore, PGC-ȕ LVQRW
elevated following acute endurance exercise [99, 119, 141], and in fact decreases 
over time post endurance exercise [119], and with endurance exercise training [141].
However, PGC-ȕDFWLYLW\ FDQEH LQGXFHGE\6,573*&-ȕ LV DFHW\ODWHGE\ WKH
acetyl transferase, general control of amino-acid synthesis (GCN5), which inhibits 
PGC-ȕ-regulated transcriptional activity [142]. The expression of SIRT1 reverses 
this acetylation by GCN5, thereby promoting PGC-ȕ DFWLYLW\ $OWKRXJK 3*&-ȕ
expression is not increased in response to the same physical stimuli as SIRT1, 
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perhaps its deacetylation by SIRT1 may increase its transcriptional activity under 
such conditions. However, further investigation into this mechanism is required. 
Due to differences in their regulation, it has been suggested that PGC-ĮDQG3*&-
ȕPD\SOD\FRPSOHPHQWDU\UROHV in regulating energy homeostasis [99, 143]. PGC-
ȕPD\SOD\more of a general role, such as maintaining oxidative metabolism for 
basal energy requirements, while PGC-Į PD\ FRordinate the response to acute 
metabolic stressors such as exercise, cold and fasting. Supporting this, whole body 
PGC-ȕ NQRFNRXW PLFH VKRZ LQFUHDVHG H[SUHVVLRQ RI 3*&-Į LQ VNHOHtal muscle 
[144], while muscle specific PGC-ĮNQRFNRXWKDVQRHIIHFWRQ3*&-ȕH[SUHVVLRQ
[145, 146].
On the other hand, PGC-ȕ LV GRZQ-regulated in a similar manner to PGC-Į
Interestingly, skeletal muscle PGC-ĮDQG3*&-ȕP51$DQGRUSURWHLQLVUHGXFHG
in conditions associated with perturbed metabolic function and muscle atrophy, 
including ageing [147, 148], denervation [65], heart failure [80, 149], sepsis [150],
obesity [151], Huntington’s disease [152], cancer cachexia, uraemia and diabetes 
[153] in rodents; and COPD [154], ALS [155], ageing [156], and insulin-resistance 
and diabetes [156-158] in humans. These observations further link mitochondrial 
function to the pathogenesis of skeletal muscle atrophy.
1.2.2 Role of PGC-Į and PGC-ȕ in skeletal muscle
In skeletal muscle, PGC-Į DQG 3*&-ȕ play similar, but not identical, roles in 
coactivating a diverse set of transcription factors to coordinate the expression of 
genes that regulate many functions involved in skeletal muscle health. These
functions include, but are not limited to, mitochondrial biogenesis and fusion [159-
162], skeletal muscle fibre type [145, 163-165], glucose transport [142, 166], fatty 
acid oxidation [167, 168], and angiogenesis [110, 169, 170].
Mitochondrial biogenesis and oxidative phosphorylation
PGC-ĮDQG3*&-ȕDUHPDVWHUUHJXODWRUVRIPLWRFKondrial biogenesis and oxidative 
phosphorylation (OXPHOS) in skeletal muscle. Overexpression of PGC-ĮRU3*&-
ȕ LQ URGHQWP\RWXEHV in vitro, or skeletal muscle in vivo, increases mitochondrial 
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biogenesis and expression of genes involved in OXPHOS, including several 
FRPSRQHQWV RI WKH UHVSLUDWRU\ FKDLQ VXFK DV WKH ȕ VXEXQLW RI $73 V\QWKDVH ȕ-
ATPase), cytochrome c oxidase subunit II (COX II), IV (COX IV) and V (COX V), 
cytochrome c (CytC), uncoupling protein 2 (UCP2), and mitochondrial transcription 
factor A (mtTFA, also known as TFAM), an inducer of mitochondrial DNA 
replication [162, 171, 172]. PGC-Į DQG 3*&-ȕ DOVR LQFUHDVH WKH H[SUHVVLRQ RI
mitofusin 1 (MFN1) and MFN2 and hence, mitochondrial fusion [155, 159, 161,
173], a critical process required for maintaining mitochondrial function and 
mitochondrial DNA integrity [174]. In contrast, PGC-Į RU 3*&-ȕ NQRFNRXW RU
mutant mice show a decrease in mitochondrial OXPHOS gene expression and 
impaired mitochondrial function, resulting in an impaired exercise performance [144,
145, 175, 176].
Muscle fibre type
PGC-Į is preferentially expressed in type I and type IIa oxidative muscle fibres in 
mice and humans [120, 126, 163]. Overexpression of PGC-Į LQ W\SH ,,JO\FRO\WLF
muscles of transgenic mice causes a fibre-type conversion to types I and IIa oxidative 
fibres [163]. These fibres are redder due to increased myoglobin, show increased 
expression of OXPHOS genes, and have greater resistance to fatigue. In contrast, 
PGC-ĮPXVFOH-specific knock-out mice show a decrease in type I and IIa oxidative 
fibres, and an increase in type IIx and IIb glycolytic fibres [145]. They also show 
greater susceptibility to fatigue and a reduction in mitochondrial gene expression.
Similar to PGC-Į3*&-ȕH[SUHVVLRQ is also positively correlated with mRNA for 
type I and IIa oxidative fibres in humans [177]. However, PGC-ȕ H[SUHVVLRQ LV
highest in type IIx muscle fibres in rodents, which are prevalent in muscles such as 
the extensor digitorum longus (EDL) [126, 164]. In rodents, type IIx fibres are 
glycolytic and have faster twitch properties than the oxidative types I and IIa fibres, 
although they have more mitochondria and oxidative properties than the glycolytic 
type IIb fibres [178, 179]. Transgenic expression of PGC-ȕLQJO\FRO\WLFPXVFOHVRI
mice results in a large increase of these type IIx muscle fibres, and a decrease in 
types I, IIa and IIb [164]. Interestingly, these mice also have redder muscles, and 
show an increase in mitochondrial biogenesis and enhanced oxidative capacity 
during treadmill running; adaptations that would not normally be seen in the 
presence of decreased type I and IIa fibres. It is therefore unlikely that the increase in 
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oxidative capacity would be a result of these fibre-type changes. In addition, the full 
role of PGC-ȕRQVNHOHWDOPXVFOHILEUHW\SHUHPDLQVXQNQRZQVLQFHLWLVVWLOl highly 
expressed in the oxidative soleus muscle despite its low proportion of type IIx fibres 
[164], and infection of PGC-ȕ LQ SULPDU\ UDW P\RWXEHV UHVXOWV LQ D FRQWUDVWLQJ
decrease in MHC IIx mRNA expression [180].
Substrate metabolism- Fatty acid and glucose uptake and oxidation
PGC-ĮDQG3*&-ȕSOD\DIXQGDPHQWDOUROHLQWKHUHJXODWLRQRIJOXFRVHDQGIDWW\
acid uptake and metabolism. Overexpression of PGC-Į RU 3*&-ȕ LQ URGHQW
skeletal muscle in vivo, or myotubes in vitro, results in increased expression of the 
glucose transporter type 4 (GLUT4), with parallel increases in insulin-stimulated 
glucose transport [142, 166, 167]. PGC-Į DOVR LQFUHDVHV EDVDO JOXFRVH WUDQVSRUW
[167], although PGC-ȕGRHVQRWKDYHWKLVVDPHHIIHFW[142]. Interestingly though, 
PGC-Į DFWXDOO\ GHFUHDVHV JOXFRVH R[LGDWLRQ DQG LQFUHDVHV WKH H[SUHVVLRQ RI
pyruvate dehydrogenase kinase 4 (PDK4) in C2C12 mouse myotubes [181]. PGC-Į
is therefore thought to increase muscle glycogen stores via increased glucose 
transport and PDK4 activity, while increasing fatty acid oxidation [181]. Evidently,
PGC-ĮDQG3*&-ȕLQFUHDVHWKHH[SUHVVLRQRIWKHIDWW\DFLGWUDQVSRUWHU&'DV
well as many genes associated with fat oxidation in skeletal muscle including 
medium-chain acylcoenzyme A dehydrogenase (MCAD), and carnitine 
palmitoyltranferase 1 (CPT1) [100, 126, 164, 167, 172, 182]. PGC-ĮDQG3*&-ȕ
also increase fat oxidation in skeletal muscle [167, 182, 183].
Because of their effect on energy metabolism, PGC-ĮDQG3*&-ȕDUHWKRXJKWWREH
important targets for opposing insulin resistance and type II diabetes [118, 182, 184],
which are characterised by decreased glucose and fatty acid oxidation, as well as 
impaired mitochondrial function. Indeed, transgenic expression of PGC-ȕ
antagonises insulin resistance caused by a high-fat diet in mice [100]. PGC-ĮDQG
PGC-ȕDUHGRZQ-regulated in skeletal muscle of type II diabetic patients [156, 158].
Moreover, single nucleotide polymorphisms (SNPs), defective activation, and/or 
decreased levels of PGC-Į DUH DSSDUHQW LQ LQVXOLQ UHVLVWDQW DQG GLDEHWLF VNHOHWDO
muscle, and this has been proposed to contribute to the pathogenesis of these 
conditions [156-158, 185-188]. Interestingly, insulin stimulation also increases PGC-
ĮDQG3*&-ȕP51$H[SUHVVLRQLQKXPDQVNHOHWDOPXVFOH[156], suggesting that 
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reduced PGC-ĮRU3*&-ȕOHYHOVPD\FRQWULEXWHWRRUEHDFRQVHTXHQFHRILQVXOLQ
resistance; however this has not been confirmed. 
Angiogenesis
An important requirement of increased oxidative metabolism is sufficient blood 
vessel density within the muscle to match metabolic needs. This is achieved via 
angiogenesis, or the formation of new blood vessels, which occurs in response to 
increased metabolic stress such as endurance exercise or ischemia. Transgenic 
expression of PGC-ĮRU3*&-ȕ LQ URGHQW VNHOHWDOPXVFOH VWLPXODWHV DQJLRJHQHVLV
via increased expression of the vascular endothelial growth factor (VEGF) [110, 169,
170]. In contrast, exercise or exposure to hypoxic conditions fail to stimulate 
angiogenesis in PGC-Į NQRFNRXW PXVFOH [110, 170], showing that PGC-Į LV
required for this adaptation in response to metabolic stress. 
1.2.3 Transcriptional activity by PGC-Į and PGC-ȕ in skeletal muscle
PGC-Į and PGC-ȕmediate their effects in skeletal muscle via coactivation of 
several transcription factors. This process consists of docking on transcription factors 
when bound to their respective response elements on the promoter of target genes, 
resulting in enhanced gene transcription initiation and/or elongation [101]. Some of 
the well-known transcription factors regulated by PGC-ĮDQGRU3*&-ȕLQVNHOHWDO
muscle include the nuclear respiratory factors (NRFs), peroxisome proliferator-
activated receptors (PPARs), myocyte enhancer factor 2s (MEF2s), Ying-Yang 1 
(YY1; PGC-ĮRQO\DQGWKHHVWURJHQ-related receptors (ERRs) [101, 189].
Nuclear Respiratory Factors (NRFs)
Nuclear respiratory factor-1 (NRF-1) and NRF-2 (also known as GA binding protein; 
GABP) are transcription factors which regulate the expression of genes involved in 
mitochondrial biogenesis and OXPHOS [101]. In C2C12 myotubes, expression of 
PGC-Įincreases the expression of and coactivates NRF-1 and NRF-2, leading to an 
increase in mitochondrial biogenesis, oxygen consumption and expression of 
OXPHOS genes [171, 190]. In particular, PGC-Į FRDFWLYDWHV 15)-1 on the 
promoter for mtTFA, an inducer of mitochondrial DNA replication [171]. PGC-ȕ
also interacts with NRF-1, and NRF-1 is required for the PGC-ȕ-induced increase 
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in mitochondrial biogenesis in C2C12 myotubes [172]. More recently, PGC-ĮKDV
been shown to stimulate the transcription of genes involved in the neuromuscular 
junction via coactivation of NRF-2 (GABP), showing that the role of this 
transcription factor extends beyond the mitochondria [191]. This has implications for 
neuromuscular diseases such as DMD, which is characterised by skeletal muscle 
atrophy. In fact, overexpression of PGC-ĮDPHOLRUDWes muscular dystrophy in mdx 
mice [191], a rodent model for DMD.
Peroxisome Proliferator Activated-Receptors (PPARs)
PGC-ĮDOVRFRDFWLYDWHVPHPEHUVRI WKHperoxisome proliferator activated-receptor 
(PPAR) family, a group of nuclear receptors that are known to regulate many genes 
involved in energy metabolism, and in particular, lipid transport and oxidation [192-
196]. 0HPEHUVRIWKH33$5IDPLO\LQFOXGH33$5Į33$5įDQG33$5ȖAlthough 
PGC-ĮZDVILUVWLGHQWLILHGDVDFRDFWLYDWRURI33$5ȖLQEURZQDGLSRVHWLVVXH[94],
and H[SUHVVLRQRI33$5ȖLQVNHOHWDOPXVFOHSURWHFWV IURPLQVXOLQ UHVLVWDQFH [197],
its basal expression is relatively low in skeletal muscle [198, 199]. In contrast,
33$5įLVKLJKO\H[SUHVVHGLQVNHOHWDOPXVFOHwhile 33$5Įis moderately expressed
[194]. Overexpression of PGC-Į LQ&&P\RWXEHVFDXVHVDPDUNHG LQFUHDVH LQ
33$5Į[183] DQG33$5į[200], with an associated increase in fatty acid oxidation, 
and expression of fatty acid transporter CPT1 and MCAD [183, 200]33$5įDOVR
coactivates and increases the expression of PGC-Į VKRZLQJ D IHHG-forward loop 
regulating PGC-Į expression [200, 201]. Furthermore, transgenic expression of 
33$5įLQVNHOHWDOPXVFOHLQFUHDVHVR[LGDWLYHPHWDEROLVPDQGcauses a shift towards 
more oxidative muscle fibres [202, 203]VXJJHVWLQJWKDW33$5įPD\EHLQYROYHGLQ
these processes regulated by PGC-Į However, the direct interaction of PGC-ĮRU
PGC-ȕZLWK33$5VLQVNHOHWDOPXVFOHKDVQRWEHHQVKRZQIn fact, as PP$5įFDQ
increase PGC-Į H[SUHVVLRQ LW LV SRVVLEOH LWV HIIHFW RQ ILEUH W\SH VZLWFKLQJ PD\
actually be via induction of PGC-Į[101].
Myocyte Enhancer Factors-2s (MEF2s)
In skeletal muscle, myocyte enhancer factor-2 (MEF2) transcription factors mediate 
the expression of genes involved in the determination of slow-twitch fibre types 
[204, 205], mitochondrial oxidative metabolism [98, 206], glucose transport [207,
208], and muscle differentiation and regeneration [2]. Both PGC-Į DQG 3*&-ȕ
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interact with MEF2 transcription factors in skeletal muscle [163, 164, 166]. In 
C2C12 myotubes, PGC-ĮFRDFWLYDWHVMEF2C and MEF2D on type I troponin and 
myoglobin promoters, which is thought to be responsible for the PGC-Į-induced 
switch towards slow twitch muscle fibres in vivo [163]. The binding and coactivation 
of MEF2C by PGC-Į DOVR UHVXOWV LQ LQFUHDVHd GLUT4 expression and glucose 
transport in rodent myotubes [166]. PGC-Į also induces its own expression via 
MEF2, as the coactivation of MEF2s in C2C12 myotubes results in MEF2 binding 
and activating the PGC-ĮSURPRWHU [209]. Lastly, PGC-ȕalso coactivates MEF2D,
which is thought to be responsible for the increase in myosin heavy chain (MHC) IIx 
in PGC-ȕ WUDQVJHQLFPLFH [164]. Supporting this, the activation of the MHC IIx 
promoter by PGC-ȕ LQ 7 FHOOV LV GHSHQGHQW RQ WKH FRDFWLYDWLRQ RI0()'
[164].
Ying Yang-1 (YY1)
PGC-Į also coactivates Ying Yang-1 (YY1) to increase the expression of 
mitochondrial genes in C2C12 myotubes [210]. YY1 also increases the activity of 
the PGC-ĮSURPRWHUVKRZLQJDQRWKHUPHFKDQLVPZKHUHE\3*&-ĮFDQLQGXFHLWV
own expression. Interestingly, the interaction between PGC-Į DQG << LV
dependent on the activity of mTOR, a potent regulator of protein synthesis. In 
addition, treatment with rapamycin, an mTOR inhibitor, decreases the expression of 
PGC-Į[210].
Estrogen-Related Receptors (ERRs)
Estrogen-related receptor-Į (55Į(55ȕDQG(55ȖDUHorphan nuclear receptors 
that play a major role in skeletal muscle energy metabolism, but only when partnered 
by coactivators such as PGC-Į DQG 3*&-ȕ [211]. ERRs are known to regulate 
almost all aspects of energy metabolism including substrate uptake and oxidation, 
mitochondrial biogenesis and function, and oxidative capacity (reviewed in [101,
211] 7KH EHVW FKDUDFWHULVHG RI WKH WKUHH (55ĮPHGLDWHVPDQ\ RI WKH HIIHFWV RI
PGC-ĮDQG3*&-ȕLQVNHOHWDOPXVFOH (Figure 1.02).
(55ĮLVKLJKO\H[SUHVVHGLQWLVVXHVZLWKKLJKHQHUJ\GHPDQGDQGLWVH[SUHVVLRQLQ
skeletal muscle is induced by physiological stimuli in a similar manner to PGC-Į
such as exposure to cold temperatures [212] and endurance exercise [173]. In fact, 
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PGC-Į KDV EHHQ VKRZQ WR UHJXODWH (55Į DFWLYLW\ YLD WZR PHFKDQLVPV E\
LQFUHDVLQJ (55Į JHQH H[SUHVVLRQ DQG E\ SK\VLFDOO\ LQWHUDFWLQJ ZLWK (55Į WR
regulate its transcriptional activity [190, 212]. It is thought that initially, PGC-Į
LQFUHDVHV (55Į JHQH H[SUHVVLRQ YLD DPHFKDQLVP LQYROYLQJ*$%3 (NRF-2), and 
WKHUHDIWHU WKH LQFUHDVHG OHYHOV RI (55Į SHUPLW LQFUHDVHG FRDFWLYDWLRQ E\ 3*&-Į
[190]. ,QWHUHVWLQJO\ RYHUH[SUHVVLRQ RI (55Į LQFUHDVHV 3*&-Į SURmoter activity, 
resulting in a feed-forward loop to further increase PGC-ĮDQG(55ĮDFWLYLW\[213].
Likewise, PGC-ȕ increases (55Į JHQH H[SUHVVLRQ [214], and also coactivates 
(55Į WR LQFUHDVH JHQH WUDQVFULSWLRQ [164]. Furthermore, PGC-ȕ DQG (55Į DFW
synergistically to activate the PGC-ȕ SURPRWHU VKRZLQJ WKDW 3*&-ȕ LV DOVR
involved in a positive feedback loop to regulate its own activity [164]. Interestingly, 
PGC-1ȕLQFRPELQDWLRQZLWK(55ĮFDQDOVRELQGWRWKH3*&-ĮSURPRWHUVKRZLQJ
that PGC-ȕPD\EHDEOHWRUHJXODWH3*&-ĮDFWLYLW\[164]. Whether this results in 
increased PGC-1ĮDFWLYLW\KRZHYHULVXQNQRZQ When co-activated by PGC-ĮRU
PGC-ȕ (55Į LQGXFHV JHQH H[SUHVVLRQ E\ ELQGLQJ WR (55 UHVSRQVH HOHPHQWV
(ERREs) on the promoter region of target genes [212]. ERREs are highly enriched in 
several OXPHOS related genes, and in particular, those known to be regulated by 
PGC-ĮRU3*&-ȕ[190].
2QH RI WKH HDUOLHVW VWXGLHV VKRZLQJ WKH LQYROYHPHQW RI (55Į LQ 3*&-1-mediated 
mitochondrial biogenesis investigated mitochondrial gene expression in response to 
PGC-Į RYHUH[SUHVVLRQ LQ sarcoma osteogenic (SAOS2) cells [160]. Inhibition of 
(55Į XVLQJ VL51$ LQ WKHVH FHOOV SUHYHQWHG WKH 3*&-Į-induced increase in the 
expression of genes involved in mitochondrial DNA replication, mitochondrial 
transport, fatty acid oxidation and oxidative phosphorylation. Interestingly, inhibition 
RI(55ĮKDGQRHIIHFWRQPLWRFKRQGULDOJHQHH[SUHVVLRQLQWKHDEVHQFHRI3*&-Į
RYHUH[SUHVVLRQVKRZLQJ WKDW(55ĮLV UHTXLUHG IRU3*&-Į-induced, but not basal, 
mitochondrial gene expression. Since then, many experiments using siRNA or 
SKDUPDFRORJLFDOLQKLELWRUVIRU(55ĮKDYHOHGWRWKHGLVFRvery of several genes and 
functions that UHTXLUH(55ĮDFWLYLW\WREHLQGXFHGE\3*&-ĮRU3*&-ȕ
(55ĮLVUHTXLUHGIRUWKH3*&-Į- and PGC-ȕ-induced regulation of mitochondrial 
biogenesis, cellular respiration and induction of several OXPHOS genes in C2C12 
myotubes [172, 190]. The PGC-Į(55Į and PGC-ȕ(55Į WUDQVFULSWLRQDO
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pathways also regulate the expression of MFN1 and MFN2 [155, 159, 161, 173], and 
PGC-ĮDQG3*&-ȕLQFRPELQDWLRQZLWK(55ĮGLUHFWO\ELQGWRWKH(55(RQWKH
MFN1 and MFN2 promoters in C2C12 myotubes [155]. PGC-ĮDQG3*&-ȕPD\
also UHJXODWHIDWW\DFLGR[LGDWLRQLQVNHOHWDOPXVFOHYLD(55ĮDV0&$'DSLYRWDO
enzyme LQYROYHG LQ IDWW\DFLGR[LGDWLRQ LVDNQRZQWDUJHWRI(55Į[215]. Indeed, 
the increase in MCAD by PGC-ĮLQ6$26FHOOVLVGHSHQGHQWRQ(55Į[212], and 
PGC-1ȕdirectly coactivates (55ĮRQ WKH0&$'SURPRWHU LQ7-L1 cells [100].
PGC-Į DOVR LQFUHDVHV 3'. H[SUHVVLRQ YLD (55Į LQ P\RWXEHV resulting in 
decreased glucose and increased fatty acid oxidation [181]. In addition, PGC-ȕ
cRDFWLYDWHV(55Į WR LQFUHDVH FDUQLWLQHDF\OFDUQLWLQH WUDQVORFDVH &$&7 LQ&&
myotubes [214], a protein essential in the oxidation of long-chain fatty acids. The 
PGC-Į(55Į WUDQVFULSWLRQDO SDWKZD\ DOVR LQFUHDVHV K\SR[LD-LQGXFLEOH IDFWRU Į
+,)ĮLQSULPDU\P\RWXEHVUHVXOWLQJLQDFWLYDWLRQRIDVORZ-twitch gene program 
[165]. This pathway is therefore thought to be involved in the PGC-Į-induced 
switch to slow-oxidative muscle fibres in vivo. Lastly, PGC-Į DQG 3*&-ȕ DOVR
LQFUHDVH9(*)H[SUHVVLRQLQVNHOHWDOPXVFOHYLDFRDFWLYDWLRQRI(55ĮOHDGLQJWRDQ
increase in angiogenesis [169, 170]. The effects of PGC-Į DQG 3*&-ȕ DUH
therefore dependent on the coactivation of (55Į for the majority of their roles in 
skeletal muscle including mitochondrial biogenesis and fusion, substrate oxidation, 
fibre-type determination and angiogenesis. Further studies will likely identify 
additional gene targets that are regulated by this transcriptional axis.  
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Figure 1.02 Regulation and transcriptional activity of PGC-Į(55Į DQG 3*&-ȕ(55Į 3*&-Į
and PGC-ȕLQFUHDVHWKHH[SUHVVLRQRI(55ĮDQGFRDFWLYDWH(55ĮRQWKHSURPRWHURIVHYHUDOJHQHV
to control many functions in skeletal muscOH:KHQSDUWQHUHGZLWK(55Į3*&-ĮDQG3*&-ȕDOVR
increase their own expression in a feed-forward manner, resulting in overall increased PGC-Į(55Į
and PGC-ȕ(55ĮWUDQVFULSWLRQDODFWLYLW\3*&-ȕDOVRFRDFWLYDWHV(55ĮRQWKH3*&-ĮSURPRWHU
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1.3 PGC-ĮDQGPGC-1ȕ in the regulation of skeletal muscle mass
Many conditions characterised by skeletal muscle atrophy are associated with 
impaired mitochondrial function [84, 86, 91], suggesting that the molecular 
mechanisms regulating both of these processes may be linked. As mentioned 
previously, skeletal muscle PGC-1ĮDQG3*&-ȕP51$DQGRUSURWHLQLVUHGXFHGLQ
conditions associated with perturbed metabolic function and muscle atrophy, such as 
ageing [147, 156], denervation [65, 216], heart failure [80, 149], sepsis [150], COPD 
[154], ALS [155], ageing [156], cancer cachexia [153], uraemia [153], glucocorticoid 
treatment [150, 217], Huntington’s disease [152], and insulin-resistance and diabetes 
[26, 157, 158]. Two weeks of hindlimb unloading in rats results in marked atrophy of 
the soleus with a simultaneous decrease in PGC-ĮSURWHLQ OHYHOV [218]. This also 
coincides with decreased percentage of slow twitch muscle fibres. During reloading 
and subsequent hypertrophy of the soleus muscle, PGC-ĮOHYHOVUHWXUQDQGIXUWKHU
increase above control, suggesting that PGC-Į PD\ EH LQYROYHG LQ SURFHVVHV
regulating both skeletal muscle atrophy and hypertrophy. These observations have 
led to the investigation of the potential role of PGC-ĮDQG PGC-ȕ in the regulation 
of muscle mass. Indeed, many recent studies are starting to reveal a major role for 
PGC-Į DQG SRWHQWLDOO\ 3*&-ȕ LQ WKH SURWHFWLRQ IURP PXVFOH DWURSK\ GXULQJ
many catabolic states [150, 153, 191, 219, 220].
Transgenic overexpression of PGC-ĮRU3*&-ȕLQPLFHKDVEHHQVKRZQWRSUHYHQW
the loss of muscle mass that occurs during catabolic conditions such as denervation
and fasting [153, 219]. Using this model, PGC-ĮRU3*&-ȕis overexpressed under 
the control of a muscle creatine kinase (MCK) promoter which is predominantly 
active in type IIb glycolytic muscles, and therefore results in greater overexpression 
in these fibres. Since glycolytic muscle fibres are preferentially targeted for 
degradation in several systemic catabolic states [81, 82, 221], the PGC-Į-induced 
increase in oxidative fibres may therefore protect from atrophy by reducing the 
content of glycolytic fibres. However, this does not explain the protective effect of 
PGC-Į or PGC-ȕ during denervation, as the atrophy associated with disuse is 
predominantly seen in oxidative muscle fibres [73, 222]. Further in vitro studies 
revealed that PGC-ĮDQG3GC-ȕSURWHFWIURPDWURSK\in C2C12 myotubes via the 
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attenuation of both proteasomal and lysosomal protein degradation [219]; processes 
known to be regulated by FOXO3a [62]. Furthermore, overexpression of PGC-ĮRU
PGC-ȕ SUHYHQWV WKH )2;23a-dependent increase in Atrogin-1, MuRF1, and 
lysosomal hydrolase cathepsin-L expression, and inhibits a constitutively active form 
of FOXO3a from binding to the Atrogin-1 promoter and causing muscle fibre 
atrophy in vivo [153, 219] (Figure 1.03). Rather than coactivating FOXO3a, PGC-1Į
and PGC-ȕDSSHDU WRDFWDV WUDQVFULSWLRQDOUHSUHVVRUV LQWKLVFDVH Using the same
PGC-Į transgenic mouse line, PGC-1Į also protects from sarcopenia and prevents a
gain in adipose tissue mass in aged mice (22 months) [148]. The reduction in age-
related muscle wasting in these mice is also thought to be due to a decrease in
proteasomal and lysosomal degradation, as well as apoptosis, as markers of these 
processes are suppressed in the muscle. More recently, transgenic expression of 
PGC-Į KDV EHHQ VKRZQ WR SURWHFW Irom muscle atrophy and improve muscle 
function in superoxide dismutase 1 (SOD1) mutant mice, a rodent model for ALS 
[223]. Furthermore, transgenic expression of PGC-Į SUHYHQWV PXVFOH GDPDJH LQ
mdx mice by increasing the expression of several neuromuscular junction genes 
[191]. These mice show a reduced number of centrally located nuclei, a characteristic 
of regenerating muscle and a marker for muscle damage. PGC-ĮPD\WKHUHIRUHEH
an attractive therapeutic target to improve muscle regeneration, reduce muscle 
atrophy and enhance muscle growth.
The above studies suggest that PGC-ĮDQG3*&-ȕFDQSUHYHQWPXVFOHDWURSK\in 
vivo by attenuating the rate of protein degradation in skeletal muscle. However a 
decline in protein synthesis is also a major contributor to muscle atrophy during 
many disease states [224-227], while the stimulation of protein synthesis may even
be more important in some cases [12, 227, 228]. In fact, elderly sarcopenic subjects
show similar rates of protein degradation compared to younger subjects, and 
therefore the decline in protein synthesis with age may be a more significant 
contributor to the cause of muscle loss during aging [228]. An ideal therapeutic 
strategy to combat muscle wasting would be to target both protein degradation and 
protein synthesis in skeletal muscle. Although it is thought that PGC-ĮDQG3*&-ȕ
do not regulate protein synthesis [219], their principal role as transcriptional 
coactivators which results in increased gene and protein expression would suggest
otherwise. In fact, aged PGC-Į WUDQVJHQLF PLFH DOVR H[KLELW LQFUHDVHG
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phosphorylation levels of Akt and mTOR in skeletal muscle when compared to age-
matched control mice [148], suggesting that PGC-1ĮPD\ increase protein synthesis
via increased Akt/mTOR activity (Figure 1.03). Whether PGC-Į DQGRU 3*&-ȕ
can regulate protein synthesis in healthy or atrophying skeletal muscle has not been 
thoroughly examined and therefore warrants further investigation.
Figure 1.03 The Akt signalling pathway and its potential interaction with PGC-ĮDQG3*&-ȕ PGC-
Įand PGC-ȕinhibit the expression of FOXO3a-dependent genes involved in both proteasomal and 
lysosomal degradation. Whether PGC-Į DQG 3*&-ȕ Fan increase protein synthesis is unknown, 
however it is hypothesis that they may do so via Akt and mTOR signalling. 
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1.4 PGC-ĮDQGCreatine in skeletal muscle
In addition to decreased PGC-Į DQG 3*&-ȕ OHYHOV PDQ\ FRQGLWLRQV DVVRFLDWHG
with skeletal muscle atrophy also display decreased intracellular creatine levels 
[229]. Creatine is found at high concentrations in highly metabolically active tissues 
such as skeletal muscle, heart and brain [230]. In addition to glucose and fatty acids, 
creatine is also an essential fuel source within skeletal muscle, where it plays an 
important role in maintaining cellular energy homeostasis by resynthesising ATP 
when in its phosphorylated form, phosphocreatine. Traditionally, creatine 
supplementation, in combination with resistance training, has been used to assist with 
skeletal muscle growth [231-233]. More recently, its use in the clinical setting has 
become of interest. Skeletal muscle creatine levels are reduced in many conditions 
associated with skeletal muscle atrophy, such as in patients with muscular dystrophy, 
and inflammatory, congenital and mitochondrial myopathies [229]. Supplementation 
with creatine monohydrate in these patients leads to gains in muscular strength and 
total body weight [234]. Creatine supplementation also stimulates muscle 
hypertrophy during rehabilitative strength training following limb immobilisation 
[235],  attenuates corticosteroid-induced muscle wasting in rats [236], and reduces 
muscular degeneration in mdx mice [237]. Interestingly, these effects are comparable 
to when PGC-Į RU 3*&-ȕ DUH RYHUH[SUHVVHG LQ VNHOHWDO PXVFOH XQGHU VLPLODU
conditions [150, 153, 191, 219]. However, creatine supplementation does not always 
increase intracellular creatine content, which is controlled via the Na+/Cl- dependent 
Creatine transporter (CrT) [238]. Long-term creatine supplementation decreases CrT 
expression in rat skeletal muscle [238], and may therefore not be effective for longer 
term use. Furthermore, CrT mRNA is significantly reduced in skeletal muscle of 
patients with various myopathies, suggesting that CrT levels may be the limiting 
factor to increase intracellular creatine content in response to creatine 
supplementation [239, 240]. Understanding the molecular mechanisms regulating the 
expression and/or activity of the CrT is therefore important to maximise the 
efficiency and benefits of creatine supplementation in skeletal muscle.
Currently, little is known about how the CrT is regulated. In healthy rodent skeletal 
muscle, high-dose creatine supplementation (initially increasing intracellular 
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creatine) decreases CrT expression [238], while depletion of intracellular creatine by 
ȕ-*XDQLGLQRSURSULRQLF DFLG ȕ-GPA), a competitive inhibitor of the CrT, increases 
sarcolemmal CrT expression [241, 242]. Similar to PGC-ĮDQG3*&-ȕthe CrT is 
more abundant in slow-oxidative muscle fibres, resulting in increased rates of 
creatine uptake when compared to fast-glycolytic fibres [243, 244]. However the 
molecular mechanisms regulating these changes in CrT and therefore creatine uptake 
in skeletal muscle are unknown. It is noteworthy that many conditions associated 
with decreased CrT levels and reduced muscle mass [234, 239], also show reduced 
levels of PGC-ĮRU3*&-ȕ[65, 245]. As PGC-ĮDQG3*&-ȕSOD\a major role in 
energy metabolism and regulate the expression of glucose and fatty acid transporters 
in skeletal muscle [142, 164, 167], it would be interesting to determine if they also 
regulate expression of the CrT, and therefore creatine uptake, in skeletal muscle. 
Furthermore, as many of the metabolic effects that PGC-ĮDQGRU3*&-ȕKDYHRQ
VNHOHWDOPXVFOHKHDOWKLQYROYHWKHFRDFWLYDWLRQDQGUHJXODWLRQRI(55ĮLWLVSRVVLEOH
that PGC-Į DQG 3*&-ȕPD\ UHJXODWH WKH&U7 DQG FUHDWLQH XSWDNH LQ DQ (55Į-
dependent manner.
Lastly, while creatine supplementation in vivo increases muscle growth, the 
molecular mechanisms regulating this occurrence remain elusive. Studies that have 
investigated the effect of creatine supplementation on protein synthesis have shown 
varying results [246, 247], although creatine has been shown to increase the 
synthesis of contractile proteins in differentiating myotubes in vitro [248, 249].
Therefore it is possible that PGC-ĮDQG3*&-ȕPD\LQFUHDVHSURWHLQV\QWKHVLVE\
regulating CrT levels and increasing intracellular creatine content, however further 
investigation is required to test this hypothesis. 
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1.5 Summary and significance of research
Skeletal muscle atrophy is a devastating condition, contributing to increased 
morbidity and mortality during many chronic disease states. Skeletal muscle atrophy 
is a result of decreased rates of protein synthesis in combination with increased rates
of protein degradation. Understanding the molecular mechanisms that regulate these 
processes is therefore a prerequisite to developing therapeutic strategies to target 
muscle atrophy and improve clinical outcomes. The transcriptional coactivators 
PGC-Į DQG3*&-ȕ DUH ERWK SRVLWLYH UHJXODWRUV RIPDQ\ functions important for 
maintaining skeletal muscle health. Notably, many of their actions in skeletal muscle 
GHSHQG RQ WKH WUDQVFULSWLRQDO FRDFWLYDWRU (55Į Recent evidence suggests that
PGC-ĮDQG3*&-ȕmay be attractive targets to attenuate muscle wasting, and they 
have been shown to reduce protein degradation via decreased activity of signalling 
pathways involved in muscle atrophy. As protein synthesis rates are also 
significantly reduced during many catabolic states, identifying ways to increase 
protein synthesis is equally as important. The role of PGC-ĮDQG3*&-ȕLQVNHOHWDO
muscle protein synthesis has not been thoroughly investigated, and therefore further 
research is required. If PGC-Į DQGRU 3*&-ȕ FDQ LQFUHDVH SURWHLQ V\QWKHVLV LQ
addition to attenuating protein degradation, this may provide a basis for the 
development of treatment strategies to alleviate the debilitating effects of muscle 
atrophy.
Another mechanism by which PGC-Į DQG 3*&-ȕPD\ UHJXODWH VNHOHWDOPXVFOH
mass is via the CrT. Creatine supplementation is known for its ability to stimulate 
muscle growth in vivo. However, CrT levels are significantly decreased in many 
myopathies associated with muscle wasting, suggesting that increasing CrT levels 
may be an effective strategy to maximise the potential benefits of creatine 
supplementation. However the molecular mechanisms regulating CrT expression are 
unknown. As PGC-Į DQG 3*&-ȕ UHJXODWH RWKHU LPSRUWDQW DVSHFWV RI HQHUJ\
metabolism, it is plausible that they may also regulate creatine uptake via increasing 
the expression of the CrT. This may partially explain how PGC-Į DQG 3*&-ȕ
positively influence skeletal muscle mass. Furthermore, as the role of creatine on 
protein synthesis is ambiguous, it would be interesting to determine if increased CrT 
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expression, potentially via PGC-Į DQG 3*&-ȕ FDQ affect protein synthesis in 
skeletal muscle. Understanding the regulation of the CrT, and how CrT levels affect 
muscle growth, may provide a basis to improve the efficiency of creatine 
supplementation in the clinical setting.
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1.6 Aims and Hypothesis
This PhD thesis will investigate the roles of both PGC-Į and PGC-1ȕ in the 
regulation of C2C12 myotube protein synthesis. The general working hypothesis is 
that PGC-Į and PGC-ȕ can positively regulate skeletal muscle protein turnover by 
increasing the rates of protein synthesis, and therefore maintaining or increasing their 
levels will protect against skeletal muscle atrophy. 
 
1.6.1 Specific Aims:
1. To determine if overexpressing PGC-ĮDQGRU3*&-ȕin C2C12 myotubes can 
increase myotube diameter and protein synthesis under basal and catabolic 
conditions, and to determine if this is dependent on Akt/mTOR signalling or 
(55Į
2. a. To identify global gene and protein expression changes that occur in response 
PGC-ĮDQG3*&-ȕRYHUH[SUHVVLRQLQ&&P\RWXEHs and create an unbiased
gene expression signature (GES) characterising PGC-Į- and PGC-ȕ- driven 
protein synthesis.
b. To measure the expression of the unbiased GES selected genes in human 
models of increased and decreased muscle protein synthesis.
3. a. To determine if PGC-ĮDQG3*&-ȕLQFUHDVHWKHH[SUHVVLRQ of the CrT and 
creatine uptake in L6 myotubes and ZKHWKHUWKLVLVYLD(55Į.
b. To determine whether PGC-Į DQG 3*&-ȕ LQFUHDVH SURWHLQ V\QWKHVLV E\
increasing CrT expression and creatine uptake. 
1.6.2 Specific Hypotheses:
1. Overexpression of PGC-Į DQG/or PGC-ȕ ZLOO LQFUHDVH SURWHLQ V\QWKHVLV LQ
C2C12 myotubes under basal and catabolic conditions, and this will be via 
increased Akt/mTOR signalling, and dependent on the transcription factor, 
(55Į
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2. Global gene and protein expression changes that occur in response PGC-ĮDQG
PGC-ȕRYHUH[SUHVVLRQ LQ&&P\RWXEHV will represent signalling pathways 
involved in protein synthesis and growth, and lead to the identification of new 
PGC-Į3*&-ȕJHQH WDUJHWV WKDWPD\EH LQYROYHG LQ SURWHLQ V\QWKHVLV7KHVH
targets will be up- and down-regulated in models of increased and decreased
protein synthesis, respectively. 
3. Overexpression of PGC-ĮDQG3*&-ȕwill increase CrT mRNA and creatine 
uptake in L6 myotubes, and WKLV ZLOO EH YLD WKH FRDFWLYDWLRQ RI (55Į
Furthermore, PGC-Į DQG 3*&-ȕ will increase protein synthesis via their 
increased expression of CrT mRNA and creatine uptake.
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Chapter 2
The Role of PGC-ĮDQG3*&-ȕLQ&&
Myotube Protein Synthesis
2.1 Introduction
Skeletal muscle mass is regulated by a fine balance between protein synthesis and 
protein degradation [31]. Decreased rates of protein synthesis and increased rates of 
protein degradation result in skeletal muscle atrophy, a devastating condition and a 
hallmark of neuromuscular disorders such as Duchenne muscular dystrophy (DMD) 
and amyotrophic lateral sclerosis (ALS) [15, 16]. Muscle atrophy is also a 
consequence of many chronic diseases including cancer, heart disease, chronic 
obstructive pulmonary disease (COPD), and AIDS, as well as sepsis, critical illness 
myopathy, sarcopenia and immobilisation following acute injuries [13, 17-20, 22].
Muscle atrophy secondary to these conditions is a major limiting factor to successful 
treatment and recovery, and contributes to an increase in morbidity and mortality 
[11, 23, 24]. Understanding the molecular and physiological mechanisms involved in 
the regulation of muscle mass is essential for developing therapeutic interventions to 
improve clinical outcomes and reduce the burden on health care systems.
The transcriptional coactivators, peroxisome proliferator-activated receptor-J
coactivator-1D (PGC-1D) and its much less studied homologue, PGC-ȕ, have been 
identified as potential molecular targets that contribute to the positive regulation of 
skeletal muscle mass. In skeletal muscle, PGC-ĮDQG3*&-ȕFRDFWLYDWHDGLYHUVH
set of transcription factors to coordinate the expression of genes that regulate 
mitochondrial biogenesis and fusion [159-162], skeletal muscle fibre type [145, 163,
164], glucose transport [142, 166], lipid oxidation [167, 168], and angiogenesis [110,
169]. These transcription factors include, but are not limited to, peroxisome 
proliferator-activated receptors (PPARs), nuclear respiratory factors (NRFs),
myocyte enhancer factor 2 (MEF2), and the estrogen-related receptors (ERRs) [101,
189].
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The expression of PGC-ĮDQGRU3*&-ȕLVUHGXFHGLQFRQGLWLRQVDVVRFLDWHGZLWK
muscle atrophy and perturbed metabolic function, such as ageing [147], denervation 
[65], heart failure [80, 149], sepsis [150], Huntington’s disease [152], cancer 
cachexia, uraemia and diabetes [153] in rodents, and chronic obstructive pulmonary 
disease (COPD) [154], ALS [155], ageing [156], insulin-resistance and diabetes 
[157, 158] in humans. Recently, transgenic overexpression of PGC-Į or PGC-ȕ in 
mice has been shown to prevent the loss of muscle mass that occurs during catabolic
conditions such as denervation, fasting or sarcopenia [148, 153, 219]. This is thought 
to be via a decrease in protein degradation, as overexpression of PGC-ĮRU3*&-ȕ
in C2C12 myotubes inhibits both proteasomal and lysosomal protein degradation;
processes known to be regulated by the transcriptional activity of forkhead box O 
protein 3a (FOXO3a) [62, 219]. However, a decline in protein synthesis is also a 
major contributor to muscle atrophy during many disease states [224-227], and 
therefore an effective therapeutic strategy would target both protein degradation and 
protein synthesis. While it is thought that PGC-1Į DQG 3*&-ȕ GR QRW regulate 
protein synthesis [219], their principal role as transcriptional coactivators which 
results in increased gene and protein expression would suggest otherwise. Whether 
PGC-ĮDQGRU3*&-ȕUHJXODWHSURWHLQV\QWKHVLV LQhealthy or atrophying skeletal 
muscle has not been thoroughly examined and therefore warrants further 
investigation.
The Akt/mTOR signalling pathway is a major intracellular signalling pathway 
known to regulate protein synthesis in skeletal muscle [39, 47]. The activation of Akt
by PI3K leads to the phosphorylation of mTOR and its downstream substrates 
p70S6k and 4E-BP1, resulting in translation initiation and elongation [39]. The 
activation of mTOR/p70S6k and protein synthesis can also be induced by mechanical 
stimulation independently of Akt [250]. PGC-Į WUDQVJHQLFPLFH WKDWDUHSURWected 
from sarcopenia show increased phosphorylation of Akt and mTOR compared to 
their control littermates [148], suggesting that PGC-Į PD\ LQ IDFW UHJXODWH this 
signalling pathway and consequently protein synthesis. Supporting this, PGC-ĮKDV
been shown to activate the Akt pathway in non-small cell lung carcinoma (NSCLC)
cells [251]. Furthermore, mTOR is required for PGC-Į WR FRDFWLYDWH << DQG
induce the expression of many mitochondrial genes in C2C12 myotubes [210]. Akt 
also inhibits protein degradation by decreasing FOXO activity and the expression of 
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genes involved in the ubiquitin proteasome pathway [50, 51]; a role similar to that of 
PGC-Į DQG 3*&-ȕ [153, 219]. Whether PGC-Į RU 3*&-ȕ can regulate the 
activity of the Akt/mTOR signalling pathway to regulate protein synthesis is 
unknown.
Lastly, many of the effects that PGC-Į DQGRU 3*&-ȕ KDYH RQ VNHOHWDl muscle 
health involve the coactivation of the orphan nuclear receptor, (55Į When 
activated by PGC-ĮRU PGC-ȕ(55ĮLQFUHDVHVWKHWUDQVFULSWLRQRILWVWDUJHWJHQHV
by binding to the ERR response element (ERRE) in their promoter regions [101].
(55ĮLVUHTXLUHGIRUWKH3*&-Į- and PGC-ȕ-induced regulation of mitochondrial 
biogenesis and induction of several OXPHOS genes [172, 190], mitochondrial fusion 
[155], angiogenesis [169, 170] and substrate oxidation [181, 214] in skeletal muscle.
It may therefore be possible that any effect PGC-ĮRU3*&-ȕPD\KDYHRQSURWHLQ
V\QWKHVLVPD\LQYROYH(55Į
The primary aim of this study was to determine if PGC-Į DQGRU PGC-ȕ FDQ
regulate protein synthesis in mouse C2C12 myotubes under basal or catabolic 
conditions. A secondary aim was to determine if PGC-Į RU 3*&-ȕ DFW YLD WKH
Akt/mTOR signalling pathway to regulate protein synthesis. Finally, it was of
interest to determine whether PGC-ĮRU3*&-ȕFDQUHJXODWH protein synthesis via 
their coDFWLYDWLRQRI(55Į
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2.2 Methods
2.2.1 Cell culture
C2C12
Mouse C2C12 myoblasts (American type culture collection; ATCC, Manassas, VA)
were incubated at 37°C with 5% CO2, in high-glucose Dulbecco’s Modified Eagle 
Medium (DMEM) supplemented with 10% foetal bovine serum (FBS), 100 U/ml
penicillin and 100 μg/ml streptomycin (Invitrogen, Carlsbad, CA). Myoblasts were
plated at a density of 1.5 x 104/cm2 in 6 and 12-well plates. Upon confluence (~48 
hrs), medium was changed to high-glucose DMEM supplemented with 2% horse 
serum (HS; Invitrogen), 100 U/ml penicillin and 100 μg/ml streptomycin for 4-5
days until multinucleated myotubes had formed. Medium was changed every 48 
hours.
CRE8- used for adenovirus amplification
Human embryonic kidney cells (HEK293) expressing CRE recombinase (CRE8) 
were a donation from Natasha Kralli (Scripps Research Institute, La Jolla, CA). 
CRE8s were incubated at 37°C and 5% CO2, in high-glucose DMEM supplemented 
with 10% FBS, and 200μg/mL of geneticin (G418; Sigma-Aldrich, St Louis, MO),
an antibiotic used for selection.
2.2.2 Adenovirus amplification, purification and titration
Amplification
Adenoviruses expressing human PGC-Į (hPGC-Į KXPDQ 3*&-ȕ (hPGC-ȕ), 
VL(55Į VL683(593-(55ĮDQG93-control were a gift from Natasha Kralli 
(Scripps Research Institute, La Jolla, CA). Green fluorescent protein (GFP) 
adenovirus was a donation from the metabolic research unit (Deakin University, 
Geelong, Vic). All adenoviruses were under the control of the cytomegalovirus 
promoter as described previously [212, 252]. To amplify each adenovirus, 3 μL of 
adenovirus stock was added to 7.32 x 107 CRE8 cells in suspension. After mixing, 
cells were split and plated into 5 x 150 mm dishes and the adenovirus was taken up 
and amplified in these cells. Cells were incubated for 3-5 days, until 50% of the 
cytopathic effect (CPE) was complete. The CPE refers to the morphological changes 
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that the cells undergo after infection. Cells typically round up and detach, and 50% 
CPE represents 50% of these cells being detached. Cells were then harvested and 
centrifuged for 10 min at 1,500 rpm, and the pellet was resuspended in 5 mL fresh
DMEM.
Purification
Cells were lysed by 3 consecutive freeze/thaw cycles in a dry ice/ethanol bath and 
37°C water bath respectively. Each adenovirus was then purified using the Adeno-X
Maxi Purification Kit (Clontech, Mountain View, CA), according to manufacturer’s 
protocol.
Titration
Adenoviruses were titrated using the Adeno-X qPCR Titration Kit (Clontech). 
Briefly, the viral genomic DNA was purified using NucleoSpin Virus spin columns. 
Viral DNA was then amplified using real-time quantitative PCR (qPCR), and the 
DNA copy number was determined from a standard curve generated by serial 
dilutions of the Adeno-X DNA control template. The amount of virus to use for 
experiments was calculated using the multiplicity of infection (MOI), which is the 
desired amount of viral copies per cell:
Amount of virus per well = (no. of cells to infect) x (desired MOI) / (copy 
number/mL).
Adenovirus optimisation
To determine the optimal MOI to use for each adenovirus, C2C12 myotubes were 
infected using an MOI of 50, 100 and 200. To infect cells, the required amount of 
adenovirus was added to fresh cell culture medium and then added to each well. 
Cells were harvested after 48 hours of infection and mRNA expression was 
determined via real-time qPCR.
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Adenoviral Infections
GFP, PGC-ĮDQG3*&-ȕH[SHULPHQWV
Myotubes were infected with adenoviruses expressing GFP, hPGC-ĮRUK3*&-ȕ
using an MOI 100. Cells were harvested after 72 hours for RNA, protein and protein
synthesis assays. 
siERRa combined with PGC-1 experiments
Myotubes were infected with an adenovirus expressing short interfering RNA 
VL51$ IRU (55Į VL(55Į RU LWV FRQWURO VL6UPER, using an MOI 200, as 
described previously [155, 172, 253]. After 24 hours, myotubes were infected with 
DQ DGGLWLRQDO GRVH RI VL(55Į RU LWV FRQWURO YHFWRU DVZHOO DV*)3 K3*&-ĮRU
hPGC-ȕ at an MOI of 100. Cells were harvested after 96 hours for RNA, protein
and protein synthesis assays. 
VP16-(55ĮH[SHULPHQWV
MyotubHVZHUHLQIHFWHGZLWKDQDGHQRYLUXVH[SUHVVLQJ(55ĮZLWKDKHWHURJHQHRXV
strong transcriptional activation domain, VP16-(55Į RU LWV FRQWURO93-control, 
using an MOI of 100. Cells were harvested after 72 hours for RNA, protein and
protein synthesis assays.
2.2.3 Cell culture treatments 
Following 48 hours infection with PGC-1ĮRU3*&-ȕ adenoviruses, myotubes were 
treated with or without 10 μM LY-294002 (Sigma-Aldrich, St Louis, MO) or 20 
ng/mL rapamycin (Sigma-Aldrich), for 24 hours to inhibit PI3K and mTOR 
respectively [39, 50].
2.2.4 Messenger RNA (mRNA) expression
RNA extraction
RNA was extracted using Tri-Reagent solution (Ambion Inc., Austin, TX) according 
to manufacturer’s protocol. RNA concentrations were determined using the 
NanoDrop 2000 (NanoDrop products, Wilmington, DE). RNA (1 μg) was reverse 
transcribed to complementary DNA (cDNA) using a High Capacity cDNA reverse 
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transcription kit (Applied Biosystems, Forster City, CA) according to manufacturer’s 
protocol.
Real-time polymerase chain reaction
Real-time qPCR was performed using a Stratagene Mx3000P QPCR System and the 
MxPro qPCR software (Stratagene, La Jolla, CA). Cycling conditions for the qPCR 
consisted of one denaturing cycle at 95°C for 2 minutes, followed by 40 cycles of 
denaturing at 95°C for 5 seconds and annealing at 60°C for 20 seconds, and 
elongation at 72°C for 60 seconds. A dissociation curve was generated to show that 
only one product had been amplified during the PCR. Each 20 μL reaction contained
0.5 x Power SYBR Green PCR Master Mix (Applied Biosystems), 25 ng of cDNA, 
and the forward and reverse primers for the gene of interest. Primers were designed
across exons using Primer 3 (www.primer3.sourceforge.net) and the sequences cross 
checked for gene specificity using a BLAST search (www.ncbi.nlm.gov/BLAST). 
Primers were synthesised by Gene Works (Adelaide, SA). Genes amplified in the 
qPCR are shown in Table 2.1. To compensate for variations in input RNA amounts 
and efficiency of the reverse transcription, data was normalised to ribosomal protein, 
36B4 (also known as RPLPO) mRNA. 
 
Table 2.01 Primers used in the real-time qPCR.
Primer GenBank accession no. Forward Primer (5’-3’) Reverse Primer (5’-3’)
Human-PGC-Į NM_013261.3 TCAGTCCTCACTGGTGGACA  TGCTTCGTCGTCAAAAACAG 
Human-PGC-ȕ NM_133263.3 CTGCTGGCCCAGATACACTGA  ATCCATGGCTTCATACTTGCT 
Mouse COX IV NM_009941.2 ACTACCCCTTGCCTGATGTG GCCCACAACGTCTTCCATT 
0RXVH(55Į NM_007953.2 TTGAAGATGCTGAGGCTGTG CCAGCTTCACCCCATAGAAA 
Mouse 36B4 NM_007475.5 TTGTGGGAGCAGACAATGTG AGTCCTCCTTGGTGAACACG 
2.2.5 Protein expression
Protein extraction
Myotubes were lysed in RIPA buffer (Merck-Millipore, Kilsyth, VIC) with 1 μL/mL 
protease inhibitor cocktail (Sigma-Aldrich) and 10 μL/mL Halt Phosphatase 
Inhibitor Single-Use Cocktail (Thermo Scientific, Rockford, IL). Protein 
concentrations were determined using the bicinchoninic acid (BCA) Protein Assay 
Kit (Thermo Scientific) according to the manufacturer’s protocol, and absorbance 
36 
 
was measured at 562 nm on a Synergy 2 Microplate Reader (BioTek, Winooski, 
VT).
Western Blotting
Electrophoresis was performed using a 4-12% NuPAGE® Novex Bis-Tris Gel 
(Invitrogen) in NuPAGE® SDS MOPS Running Buffer (Invitrogen). Twenty 
micrograms of protein was loaded into each well of a 10-well gel. Protein transfer 
was performed in a Bjerrum buffer containing 50 mM Tris, 17 mM glycine and 10 % 
methanol using polyvinylidene difluoride (PVDF) membranes (Merck-Millipore).
The membranes were blocked with 5 % bovine serum albumin (BSA; Sigma-
Aldrich) in PBS for one hour, and incubated overnight at 4ºC with the following 
primary antibodies diluted in 5% BSA in PBS: PGC-Į0HUFN-Millipore); PGC-ȕ
(Novus Biologicals, Littleton, CO); (55Į (SLWRPLFV %XUOingame, CA);
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH; Sigma-Aldrich); Phospho-
Akt (ser473), Akt, Phospho-p70S6k (thr389), and p70S6k (Cell Signalling 
Technology, Danvers, MA). All primary antibodies were diluted 1:1,000, except for 
GAPDH which was diluted 1:10,000. Antibodies for PGC-Į DQG 3*&-ȕ ZHUH
sensitive to both human and mouse, and therefore showed endogenous as well as 
overexpressed levels of these proteins. Following washing, the membranes were 
incubated for 1 hour with either IRDye® 800CW Goat Anti-Rabbit IgG (H+L) (LI-
COR Biosciences, Lincoln NE), or Alexa Fluor® 680 Rabbit Anti-Mouse IgG (H+L)
(Invitrogen), diluted 1:5,000 in PBS containing 50% Odyssey Blocking Buffer (LI-
COR Biosciences). Proteins were visualised on an Odyssey Infrared Imaging System 
(LI-COR Biosciences) and densitometry was achieved using Odyssey Application 
Software 3.0 (LI-COR Biosciences). All blots were normalised to GAPDH protein.
2.2.6 Protein synthesis
Protein synthesis was determined by measuring the incorporation of radio-labelled 
[3H]-tyrosine (Perkin Elmer, Boston, MA) into the myotubes (modified from [254]). 
After adenoviral infections, myotubes were treated for 24 hours with or without 10 
μM dexamethasone (DEX; Sigma-Aldrich) to induce catabolic stress [224]. During 
this time, myotubes were incubated in 1 μCi/ml of radio-labelled [3H]-tyrosine and 2 
mM L-tyrosine (Sigma-Aldrich). The use of excess non-radioactive tyrosine in the 
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medium gives an accurate indication of protein synthesis rates without alterations in 
the free intracellular tyrosine pool [255]. The reaction was stopped by washing the 
cells with cold phosphate buffered saline (PBS), and then 0.5 ml of cold 10% 
trichloroacetic acid (TCA; Sigma-Aldrich) was added to each well. After scraping, 
myotubes sat on ice for 1 hour to precipitate the protein, followed by centrifugation 
at 20,000 x g for 10 minutes. The supernatant was removed, and the precipitates were 
dissolved in 0.1 M NaOH/1% Triton X-100 (Sigma-Aldrich) overnight at room 
temperature. The samples were mixed with Ultima Gold scintillation liquid (Perkin 
Elmer) and myotube protein radioactivity was measured using a Wallac 1409 DSA 
liquid scintillation counter (Perkin Elmer) and expressed as counts per minute 
(CPM). Counts were normalised to total genomic DNA which was extracted using 
the Allprep DNA/RNA mini kit (Qiagen, Clifton Hill, VIC) as per the 
manufacturer’s protocol. DNA was quantified using the NanoDrop 2000.
2.2.7 Myotube Diameter
Myotubes were visualised using an Olympus IX70 microscope (Olympus, Mt 
Waverly, VIC), and digital images were obtained using a DS-U3 microscope camera 
and NIS-Elements imaging software (Nikon Instruments Inc., Melville, NY). 
Approximately 10 myotubes from 10 different fields of view were analysed for 
myotube diameter from each of the different adenoviral infections. Three 
measurements along each myotube were made to allow for differences in diameter 
across the length of the myotube. 
2.2.8 Statistics
Statistical analyses were performed using either a t-test or a two-way analysis of 
variance (ANOVA) (Prism, GraphPad Software, La Jolla, CA). Multiple t-tests were 
used for post-hoc analysis to determine differences between groups if significant 
interactions were found. The level of significance was set at P < 0.05 for paired t-test 
analysis, while a Bonferroni adjustment was used for the two-way ANOVA reducing 
the level of significance to P < 0.0125. All data is presented as mean ± standard error 
of the mean (SEM) and as fold-change relative to GFP control, unless otherwise 
stated.
38 
 
2.3 Results
2.3.1 PGC-ĮDQGPGC-ȕ adenovirus optimisation
To overexpress PGC-ĮDQG3*&-ȕLQ&&P\RWXEHVDGHQRYLUXVHVH[SUHVVLQJ
the human PGC-Į K3*&-Į DQG 3*&-ȕ K3*&-ȕ ZHUH XVHG $ *)3
adenovirus was used as the infection control. To determine the efficiency of the 
hPGC-Į DQG K3*&-ȕ DGHQRYLUXVHV && P\RWXEHV ZHUH LQIHFWHG XVLQJ D
multiplicity of infection (MOI) of 50, 100 and 200. PGC-Į DQG 3*&-ȕP51$
levels increased as the MOI was increased from between MOI 50 to MOI 100; no 
further increase in mRNA levels was observed when increasing the MOI from 100 to 
200 (Figure 2.01A&B). PGC-ĮDQG3*&-ȕP51$H[SUHVVLRQOHYHOVFRXOGQRWEH
compared to the GFP infected group as the adenovirus encoded the human PGC-Į
and PGC-ȕ, which is not endogenously expressed in mouse cell lines. Therefore, 
the expression of COX IV mRNA was measured as it is known to be induced by both 
PGC-ĮDQG3*&-ȕ [159, 171]. Figure 2.01C shows that hPGC-ĮDQGK3*&-ȕ
infection led to increases in COX IV mRNA expression, with no differences between 
MOIs for each virus. An MOI of 100 was therefore chosen to be used for all 
remaining experiments. Using an MOI of 100, PGC-ĮDQG3*&-ȕRYHUH[SUHVVLRQ
lead to a 2.2-fold and 2.6-fold increase in PGC-Į )LJXUH 01D) and PGC-ȕ
(Figure 2.01E) protein levels, respectively.
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Figure 2.01 PGC-ĮDQG3*&-ȕRYHUH[SUHVVLRQLQ&&P\RWXEHV$+XPDQ3*&-ĮDQG%
human PGC-ȕH[SUHVVLRQZKHQPHDVXUHGKRXUVDIWHULQIHFWLRQXVLQJDPXOWLSOLFLW\RILQIHFWLRQ
(MOI) of 50, 100 and 200. Values were normalised to 36B4 mRNA expression. n = 3 per group. *P <
0.01 compared to MOI 50. (C) COX IV mRNA expression in GFP, PGC-ĮDQGPGC-ȕ LQIHFWHG
C2C12 myotubes using an MOI of 50, 100 and 200 for 48 hours. Values were normalised to 36B4 
mRNA expression. n = 4 per group. *P < 0.0125 compared to GFP for each MOI. (D) PGC-ĮDQG
(E) PGC-ȕSURWHLQOHYHOVZKHQPHDVXUHG48 hours after infection, using an MOI of 100. Bands were 
normalised to GAPDH protein. n = 4 per group. *P < 0.01, compared to GFP.
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2.3.2 PGC-ĮDQG3*&-ȕincrease protein synthesis and myotube 
diameter in C2C12 myotubes.
To investigate the effect of PGC-Į DQG 3*&-ȕ RYHUexpression on protein 
synthesis, the incorporation of [3H]-tyrosine was measured over 24 hours following 
adenovirus infections. Protein synthesis was measured under basal conditions, or 
with dexamethasone (DEX) to induce catabolic stress [224]. Overexpression of PGC-
Į DQG 3*&-ȕ LQFUHDVHG WKH EDVDO UDWH RI SURWHLQ V\QWKHVLV E\  DQG 
respectively when compared to GFP (Figure 2.02). DEX treatment decreased basal 
protein synthesis by 14% (Figure 2.02). DEX decreased protein synthesis in the 
myotubes overexpressed with PGC-Į and PGC-ȕ+RZHYHUPGC-ĮRU3*&-ȕ
still increased protein synthesis when compared to GFP-DEX, and therefore PGC-Į
and PGC-ȕFDQLQFUHDVHSURWHLQV\QWKHVLVXQGHUFDWDEROLFFRQGLWLRQV
Figure 2.02 Protein synthesis in GFP, PGC-Į DQG 3*&-ȕ LQIHFWHG myotubes. Shows protein 
synthesis rates under basal and DEX-treated conditions, when measured for 24 hours following 48
hours of infection with GFP, hPGC-ĮDQGK3*&-ȕ adenoviruses. n = 5-10 per group, repeated in 3 
experiments. *P < 0.0125, compared to GFP-Basal; #P < 0.0125, compared to GFP-DEX.
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Overexpression of PGC-Į DQG 3*&-ȕ LQFUHDVHGP\RWXEH GLDPHWHU E\ 38% and
52% respectively (Figure 2.03A).  
Figure 2.03 Myotube diameter in GFP, PGC-Į DQG 3*&-ȕ LQIHFted myotubes. (A) Average 
myotube diameter from 10 myotubes per visual field (10 visual fields for each group). (B) 
Representative images of myotubes infected with GFP, hPGC-ĮDQGhPGC-ȕDGHQRYLUXVHVIRU
hours. *P < 0.0125, compared to GFP. 
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2.3.3 PGC-ĮDQG3*&-ȕUHJXODWHSURWHLQV\QWKHVLVLQGHSHQGHQWO\RI
Akt/mTOR signalling.
To investigate whether the Akt/mTOR pathway is regulated by PGC-ĮRU3*&-ȕ
the expression of key proteins in this pathway were measured via Western blot 
analysis. Figure 2.04 shows the protein expression of phosphorylated-Akt (ser473), 
total Akt protein, phosphorylated-p70S6k (thr389), and total p70S6k protein. 
Overexpression of PGC-ĮDQG3*&-ȕOHGWRDGHFUHDVHLQWKHSKRVSKRU\ODWLRQRI
Akt (Figure 2.04A) and p70S6k (Figure 2.04C). There was also a small decrease in 
total Akt protein with PGC-ĮRYHUH[SUHVVLRQ )LJXUH4B), and p70S6k protein 
with PGC-ȕRYHUH[SUHVVLRQ)LJXUH4D). 
 
Figure 2.04 Western blot analysis of Akt/mTOR pathway proteins in GFP, PGC-Į DQG PGC-ȕ
infected C2C12 myotubes. (A) phospho-Akt (ser473), (B) total Akt protein, (C) phospho-p70S6k 
(thr389), and (D) total p70S6k protein expression. Samples were harvested after 72 hours of infection.
Bands were normalised to GAPDH protein. n = 5 per group. *P < 0.01, #P < 0.05, compared to GFP.
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To further investigate whether Akt/mTOR signalling is involved in the PGC-Į- and 
PGC-ȕ-induced stimulation of protein synthesis, myotubes were treated with a 
PI3K inhibitor, LY294002, or an mTOR inhibitor, rapamycin. Figure 2.05 shows that 
when compared to the basal group, treatment with LY294002 and rapamycin 
decreased protein synthesis by 18-20 % and 35-43 % respectively, in the GFP, PGC-
Į- and PGC-ȕ-infected myotubes. The per cent increase due to PGC-ĮDQd PGC-
ȕ ZDV QRW FKDQJHG These results show that both PGC-Į DQG 3*&-ȕ LQFUHDVH
protein synthesis independently of Akt/mTOR signalling.
Figure 2.05. Protein synthesis in GFP, PGC-Į DQG3*&-ȕ LQIHFWHG&&P\RWXEHVMyotubes 
were treated with LY294002 (LY294) or Rapamycin and compared to basal conditions. n = 10, 
repeated in 3 experiments. #P < 0.0125 when compared to LY294 or Rapamycin treatment for the 
same infection group. *P < 0.0125 when compared to GFP within each treatment group.  
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2.3.4 E55ĮLVLQYROYHGLQWKH3*&-Į- and PGC-ȕ-induced increase in 
protein synthesis.
7RGHWHUPLQHLI(55ĮLVLQYROYHGLQWKH3*&-Į- and PGC-ȕ-induced increase in
protein synthesis, C2C12 myotubes were infected with an adenovirus expressing 
VL51$IRU(55ĮVL(55ĮRUDFRQWUROVL51$YHFWRUVL683(5To determine the 
HIILFLHQF\ RI VL(55Į infection, myotubes were infected using a multiplicity of 
infection (MOI) of 50, 100 and 200. Figure 2.06 VKRZVWKDW LQIHFWLRQZLWKVL(55Į
lead to a 51%, 62%, and 72% decreasHLQ(55ĮP51$H[SUHVVLRQIRU02,VRI
100 and 200 respectively, when compared to siSUPER. An MOI of 200 was used for 
all remaining experiments as described previously [155, 172, 253].
Figure 2.06 (55ĮP51$LQ&&P\RWXEHVLQIHFWHGZLWKVL(55ĮP51$ZDVPHDVXUHGKRXUV
after infection, using a multiplicity of infection (MOI) of 50, 100 and 200. siSUPER was used as a 
control. Values were normalised to 36B4 mRNA expression. n = 3 per group. *P < 0.01 compared to 
siSUPER for each MOI.
Next, myotuEHVZHUHLQIHFWHGZLWKHLWKHUVL(55ĮRUsiSUPER, followed by infection 
with GFP, PGC-ĮRU3*&-ȕDGHQRYLUXVHV$VH[SHFWHG [100, 190], PGC-ĮDQG
PGC-ȕ RYHUH[SUHVVLRQ OHDG WR D VLJQLILFDQW LQFUHDVH LQ (55Į P51$ )LJXUH
2.07A) and protein expression (Figure 2.07B). Infection with siERRĮ decreased 
(55Į P51$ DQG SURWHLQ E\  DQG 87% respectively, when compared to 
siSUPER. Furthermore, knockdown of (55Į SUHYHQWHG WKH LQFUHDVH LQ (55Į
mRNA expression that was seen with PGC-ĮDQG3*&-ȕRYHUH[SUHVVLRQ Figures
2.08A and B show protein expression for PGC-Į DQG 3*&-ȕ UHVSHFWLYHO\, to 
confirm their overexpression in these samples. PGC-ĮH[SUHVVLRQZDVLQFUHDVHd in 
45 
 
ERWKWKHVL683(5DQGVL(55ĮJURXSVZKHQFRPSDUHGWR*)3)LJXUH8A). PGC-
ȕH[SUHVVLRQZDVDOVRLQFUHDVHGLQERWKJURXSVKRZHYHULWZDVORZHULQWKH3*&-
ȕ-VL(55ĮJURXSZKHQFRPSDUHGWRWKH3*&-ȕ-siSUPER group (Figure 2.08B). 
Figure 2.07 (55Į H[SUHVVLRQ LQ&&P\RWXEHV LQIHFWHGZLWK VL(55ĮDQG3*&-1 adenoviruses. 
0\RWXEHVZHUHLQIHFWHGZLWKHLWKHUVL683(5RUVL(55ĮDWDQ02,RIIROORZHGE\LQIHFWLRQZLWK
GFP, hPGC-ĮRUK3*&-ȕ6DPSOHVZHUHKDUYHVWHGDIWHUKRXUV $(55ĮP51$H[SUHssion, 
QRUPDOLVHGWR%%(55ĮSURWHLQexpression, normalised to GAPDH. n = 4 per group. 
 
Figure 2.08 PGC-ĮDQG3*&-ȕSURWHLQH[SUHVVLRQLQ&&P\RWXEHVLQIHFWHGZLWKVL(55ĮDQG
PGC-1 adenoviruses. Myotubes were infected with either siSUPER or VL(55ĮIROORZHGE\LQIHFWLRQ
with GFP, hPGC-ĮRUK3*&-ȕ Samples were harvested after 72 hours. (A) PGC-ĮSURWHLQDQG
(B) PGC-ȕ SURWHLQ %DQGV ZHUH QRUPDOLVHG WR *$3'+ SURWHLQ n = 4 per group. *P < 0.0125 
compared to GFP-siSUPER; #P < 0.0125 compared to PGC-ȕ-siSUPER.
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Overexpression of PGC-Į DQG 3*&-ȕ LQFUHDVHG SURWHLQ Vynthesis under basal 
conditions (Figure 2.09A.QRFNGRZQRI(55ĮKDGQRHIIHFWRn protein synthesis 
in the GFP-infected group. However, when overexpressed with PGC-ĮRU3*&-ȕ,
NQRFNGRZQ RI (55Į DWWHQXDWHG WKH 3*&-Į- and PGC-ȕ-induced increase in
protein synthesis. 6LPLODUO\NQRFNGRZQRI(55Į did not affect myotube diameter in 
the GFP-infected myotubes but reduced the PGC-Į- and PGC-1ȕ-induced increase 
in myotube diameter (Figure 2.09B & C).
Figure 2.09 Protein synthesis and myotube diameter LQ&&P\RWXEHVLQIHFWHGZLWKVL(55ĮDQG
PGC-1 adenoviruses. 0\RWXEHVZHUHLQIHFWHGZLWKHLWKHUVL683(5RUVL(55ĮIROORZHGE\LQIHFWLRQ
with GFP, hPGC-Į RU K3*&-ȕ. (A) Protein synthesis, measured via [3H]-tyrosine incorporation 
during the 24 hours after infections. n = 6 per group, repeated in 3 experiments. (B) Average myotube 
diameter from 10 myotubes per visual field (10 visual fields for each group). (C) Representative 
images of GFP-, PGC-Į- and PGC-ȕ-infected myotubesZLWK VL683(5RU VL(55Į *P < 0.0125
compared to GFP-siSUPER. #P < 0.0125 compared to siSUPER for each group.
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As it was shown that PGC-Į and PGC-ȕ UHGXFH WKH DFWLYLW\ RI WKH $NWP725
signalling pathway, Akt and p70S6k were also measured in these samples to see if 
NQRFNGRZQRI(55ĮDIIHFWHGWKHVHUHVXOWV)LJXUH2.10A shows that knockdown of 
(55Į LQFUHDVHG WKH SKRVSKRU\ODWLRQ RI $NW LQ WKH *)3 DQG 3*&-Į, but not the 
PGC-ȕ-infected myotubes when compared to the siSUPER control. There were no 
significant changes in the total Akt protein (Figure 2.10B), phosphorylated p70S6k 
(Figure 2.10C), or total p70S6k protein (Figure 2.10D). 
 
Figure 2.10 Western blot analysis of Akt/mTOR pathway proteins in C2C12 myotubes infected with 
VL(55ĮDQG3*&-1 adenoviruses. Myotubes were infected with either siSUPER or VL(55ĮDQGDIWHU
24 hours infected with GFP, hPGC-ĮRUK3*&-ȕ$SKRVSKR-Akt (ser473), (B) total Akt protein, 
(C) phospho-p70S6k (thr389), and (D) total p70S6k protein expression. Bands were normalised to 
GAPDH protein. n = 6 per group. *P < 0.0125 compared to siSUPER for each group; #P < 0.0125
compared to GFP-VL(55Į; † P < 0.05 when compared to GFP-siSUPER.
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2.3.5 CRQVWLWXWLYHO\DFWLYH(55ĮLQFUHDVHVSURWHLQV\QWKesis and myotube 
diameter.
7KHSUHYLRXVUHVXOWVVKRZWKDW(55ĮPD\UHJXODWHSURWHLQV\QWKHVLVZKHQDFWLYDWHG
by PGC-ĮRU3*&-ȕEXW had no effect under basal conditions. To further support 
the role (55Įin increasing protein synthesis, C2C12 myotubes were expressed with 
D FRQVWLWXWLYHO\ DFWLYH IRUP RI (55Į 93-(55Į RU LWV FRQWURO 93-control) 
[160]. Figure 2.11$ VKRZV (55Į P51$ OHYHOV DIWHU LQIHFWLRQ ZLWK 93-(55Į
using an MOI of 50, 100 and 200. (55ĮP51$ZDVLQFUHDVHGE\DSSUR[LPDWHO\-
, 91- and 103- fold respectively. An MOI of 100 was chosen for remaining 
experiments. Figure 2.11B shows that infection with VP16-(55ĮDWDQ0OI of 100 
LQFUHDVHG(55ĮSURWHLQOHYHOVE\DSSUR[LPDWHO\-fold.
Figure 2.11 (55ĮP51$ DQG SURWHLQ LQ &&P\RWXEHV LQIHFWHG ZLWK 93-(55Į and VP16-
control DGHQRYLUXVHV $ (55Į P51$ OHYHOV DIWHU LQIHFWLRQ ZLWK 93-(55Į DGHQRYLUus using 
MOIs of 50, 100 and 200. VP16-control was used as the control adenovirus. Samples were harvested 
after 48 hours. Values were normalised to 36B4 expression. n = 3 per group.*P < 0.0125 compared to 
VP16-control. % (55Į SURWHLQ H[SUHVVLRQ XVLQJ DQ MOI of 100 for 48 hours. Bands were 
normalised to GAPDH protein. n = 3 per group. *P < 0.01 compared to VP16-control. 
49 
 
VP16-(55ĮLQIHFWLRQLQFUHDVHG the rate of protein synthesis by 52% compared to the 
VP16-control (Figure 2.12A), which also resulted in an increase in myotube diameter 
(Figure 2.12B & C).
Figure 2.12 Protein synthesis and myotube diameter in C2C12 myotubes infected with VP16-(55Į
and VP16-control adenovirus. (A) Protein synthesis, measured by [3H]-tyrosine incorporation for 24 
hours following adenovirus infection. n = 6 per group, repeated in 3 experiments. (B) Average 
myotube diameter from 10 myotubes per visual field (10 visual fields for each group). (C)
Representative images of myotubes infected with VP16-control or VP16-(55Į for 72 hours. *P <
0.01 compared to VP16-control.
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Lastly, as it was shown that PGC-ĮDQG3*&-ȕRYHUH[SUHVVLRQUHGXFHVWKHDFWLYLW\
of the Akt/mTOR signalling pathway, these proteins were also measured in samples 
infected with VP16-(55Į )LJXUH 2.13 shows that expression of a constitutively 
DFWLYH (55Į GHFUHDVHG SKRVSKRU\ODWHG $NW )LJXUH 2.13A) and p70S6k (Figure 
2.13C) in C2C12 myotubes by 78% and 82% respectively. Furthermore, total Akt 
(Figure 2.13B) and p70S6k (Figure 2.13D) protein levels were reduced by 42% and 
47% respectively.
 
Figure 2.13 Western blot analysis of Akt/mTOR pathway proteins in C2C12 myotubes infected with 
VP16-(55Į$SKRVSKR-Akt (ser473), (B) total Akt protein, (C) phospho-p70S6k (thr389), and (D) 
total p70S6k protein expression. Bands were normalised to GAPDH protein. n = 6 per group. *P < 
0.01, #P < 0.05, compared to VP16-control. 
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2.4 Discussion
Understanding the molecular mechanisms that regulate protein synthesis in skeletal 
muscle is essential for developing therapeutic interventions to combat muscle 
atrophy during diseases characterised by perturbed skeletal muscle growth. The 
transcriptional coactivators, PGC-ĮDQG3GC-ȕregulate the expression of a wide 
range of genes in skeletal muscle including those involved in oxidative metabolism 
and protein degradation [96, 219]. This study aimed to determine whether PGC-Į
and PGC-ȕcan regulate protein synthesis in mouse C2C12 myotubes. Several novel 
observations were made. Firstly, it was shown that overexpression of PGC-Į RU
PGC-ȕOHd to an increase in the rate of protein synthesis and myotube hypertrophy.
Secondly, this increase in protein synthesis was independent of Akt and mTOR 
signalling. And lastly, the PGC-Į- and PGC-ȕ-induced increase in protein 
synthesis and myotube hypertrophy ZDVGHSHQGHQWRQ(55Į
PGC-Į DQG 3*&-ȕ are down-regulated in many models of muscle atrophy; a 
process characterised by increased protein degradation and decreased protein 
synthesis. Several studies have shown that overexpression of PGC-ĮDQGRU3*&-1ȕ
in rodents can protect from muscle atrophy in many catabolic states including 
sarcopenia [148], DMD [191, 256], denervation and fasting-induced atrophy [153,
219]. Using a similar cell culture model to the current study, Brault et al. observed
that this protective effect of PGC-Į DQG 3*&-ȕ LV YLD D GHFUHDVH LQ SURWHLQ
degradation, with no effect on protein synthesis [219]. However the results from the 
present study show that overexpression of PGC-ĮDQG3*&-ȕcan increase the rate 
of protein synthesis under basal and catabolic conditions induced by dexamethasone 
treatment; the latter suggesting that PGC-ĮDQG3*&-ȕPD\EHDWWUDFWLYHWDUJHWVWR
increase protein synthesis during systemic wasting diseases. Several methodological 
differences may have contributed to these different observations between studies.
Firstly, Brault et al. measured protein synthesis after 24 and 48 hours infection with 
PGC-Į- and PGC-ȕ- overexpressing adenoviruses for two hours only, while the 
present study measured protein synthesis over a 24 hour period from 48-72 hours 
after infection. The effect of PGC-Į DQG 3*&-ȕ RYHUH[SUHVVLRQ RQ SURWHLQ
synthesis may therefore be time-dependent. Furthermore, Brault et al. measured 
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citrate synthase activity, a marker of mitochondrial content, as a measure of PGC-Į
and PGC-ȕactivity. The greatest increase in citrate synthase activity occurred from 
48-62 hours post-infection and it is therefore likely that a PGC-ĮDQG3*&-ȕeffect 
on protein synthesis would have also occurred during this time. Another difference 
between the studies was the methodology used to measure protein synthesis. Brault 
et al. normalised [3H]-tyrosine incorporation to protein content in the myotubes. As 
an increase in protein synthesis would be expected to increase total protein content, 
normalising to protein content would potentially negate the increase in protein 
synthesis. The present study normalised protein synthesis levels to DNA content
which was unchanged in mature myotubes, a method previously used by Quinn et al.
[257]. Therefore using the current methodology, this study has clearly shown that 
overexpression of PGC-Įor PGC-ȕ leads to an increase in protein synthesis and 
myotube diameter in C2C12 myotubes, when measured 48-72 hours post adenoviral 
infection. 
The Akt and mTOR signalling pathways are well known regulators of protein 
synthesis in skeletal muscle [31]. It was therefore of interest to determine if the effect 
of PGC-Į DQG 3*&-ȕ RQ SURWHLQ V\QWKHVLV ZDV YLD WKH $NW DQG/or mTOR 
signalling pathways. After 72 hours, overexpression of PGC-Į DQG 3*&-ȕ
decreased the phosphorylation of Akt and p70S6k, the latter phosphorylated and 
activated by mTOR. This is in contrast to findings by Wende et al., whereby the 
transgenic expression of PGC-Į LQFUHDVHG the phosphorylation of Akt and mTOR
and protected from skeletal muscle atrophy of aged mice [148]. Whether this was 
associated with an increase in protein synthesis however, was not determined. As 
Akt and p70S6k phosphorylation was only measured after 72 hours, it may be 
possible that their phosphorylation was increased at an earlier time point following
PGC-ĮRU PGC-ȕRYHUH[SUHVVLRQIn fact, the phosphorylation of Akt and p70S6k
are increased acutely following resistance exercise in trained subjects, but return to 
baseline within 4 hours although protein synthesis rates remain elevated [258]. The 
effect of PGC-Į DQG 3*&-ȕ RQ SURWHLQ V\QWKHVLV LQ WKH SUHVHQW VWXG\ PD\
therefore be due to the long-lasting effects of the acute activation of these signalling 
pathways. To test this hypothesis, myotubes were treated with LY294002 and 
rapamycin to inhibit PI3K (Akt) and mTOR respectively. Although these inhibitors 
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decreased the overall rate of protein synthesis in all adenovirus treatment groups
(GFP, PGC-ĮDQG3*&-ȕ, overexpression of PGC-ĮRU3*&-ȕVWLOO LQFUHDVHG
protein synthesis rates above the GFP-infected myotubes. These findings show that 
PGC-ĮDQG3*&-ȕ UHJXODWHSURWHLQ V\QWKHVLV LQ&&P\RWXEHV LQGHSHQGHQWO\
of Akt and mTOR signalling pathways.
As many of the effects of PGC-Į DQG 3*&-ȕ LQ VNHOHWDO PXVFOH LQYROYHG WKH
orphan nucleDUUHFHSWRU(55ĮLWZDVRILQWHUHVWWRGHWHUPLQHif PGC-ĮDQG3*C-
ȕUHJXODWHSURWHLQV\QWKHVLVYLD(55Į7KLVVWXG\VKRZVWKDWNQRFNGRZQRI(55Į
using siRNA prevents the PGC-Į- and PGC-ȕ-induced increase in protein 
synthesis and myotube hypertrophy. However, there was no effect on the basal rate 
RISURWHLQV\QWKHVLVDQGWKHUHIRUH(55ĮPD\only be involved in the regulation of 
protein synthesis when stimulated by PGC-Į RU 3*&-ȕWhile (55Į plays an 
important role in the regulation of mitochondrial gene expression in response to cues 
such as exposure to cold or exercise, it has been suggested that it may not be
essential for mitochondrial function under basal conditions [101]. This also appears 
to be the case for protein synthesis. FurthHU VXSSRUWLQJ WKH UROH RI (55Į
RYHUH[SUHVVLRQ RI D FRQVWLWXWLYHO\ DFWLYH (55Į 93-(55Į increased protein 
synthesis by over 50%. These results show that when activated, (55Į LWVHOI can 
increase protein synthesis and myotube hypertrophy, suggesting that the transcription 
RI JHQHV E\ (55Į may be crucial for PGC-Į DQG 3*&-ȕ WR LQFUHDVH SURWHLQ
synthesis. The identification of new genes regulated by PGC-Į(55Į DQG 3*&-
ȕ(55ĮPD\WKHUHIRUHHOXFLGDWHSRWHQWLDOPHFKDQLVPVE\ZKLFK3*&-ĮDQG3*&-
ȕUHJXODWH protein synthesis. Lastly, this study also shows that PGC-Į(55ĮDQG
PGC-ȕ(55Į PD\ QHJDWLYHO\ UHJXODWH WKH $kt and mTOR signalling pathways. 
While the functional significance of this is unknown, these observations demonstrate
that the PGC-Į- and PGC-1ȕ-induced increase in protein synthesis is independent 
from Akt/mTOR signalling.
Recent work published during the preparation of this thesis has shown that a specific 
isoform of PGC-Į 3*&-Į OHDGV WR PXVFOH K\SHUWURSK\ YLD WKH LQGXFWLRQ RI
insulin-like growth factor-1 (IGF-1) and repression of myostatin [259], which are 
positive and negative regulators of protein synthesis respectively [260, 261]. These 
observations support the present findings that, at least for the alpha isoform, PGC-1
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can regulate protein synthesis and therefore skeletal muscle growth. However, the 
induction of IGF-1 would suggest increased Akt activity, which is the opposite of
what was observed in this study. PGC-ĮDOVRGLGQRWUHJXODWHPDQ\PLWRFKRQGULDO
genes that are known to be regulated by PGC-1Į DQG LWV HIIHFW RQ PXVFOH
K\SHUWURSK\ZDV DFWXDOO\ LQGHSHQGHQWRI(55ĮDFWLYLW\7KHUHIRUHDOWKRXJK3*&-
ĮDOVRDSSHDUVWRKDYHSRVLWLYHHIIHFWVRQVNHOHWDOPXVFOHJURZWKLWLVOLNHO\WKDW
these effects are via a distinct mechanism to which PGC-Į UHJXODWHV SURWHLQ
synthesis in the current study.
Lastly, it is important to note that while myotube diameter was increased in the 
current study, there are several limitations to this method which cannot be 
overlooked. Although myotube diameter was assessed from multiple measurements 
along the length of the myotube, this technique assumes that all myotubes are 
cylindrical, which is often not the case when these cells are grown in vitro [262].
Many myotubes are also branched and there is a large variability in myotube sizes, 
even within the same field of view. Furthermore, myotubes often extend in length 
beyond the field of view, and therefore only a segment of the myotube is measured. 
These factors need to be taken into consideration when interpreting this data. The 
increase in myotube diameter seen in the current study can also not be solely 
attributed to the increase in protein synthesis. As PGC-ĮDQG3*C-ȕDOVRDWWHQXDWH
protein degradation in C2C12 myotubes [219], an increase in myotube diameter 
could be a result of both increased protein synthesis and reduced protein degradation. 
In conclusion, this study has shown for the first time that the transcriptional
coactivators, PGC-Į DQG 3*&-ȕ FDQ increase protein synthesis and myotube 
hypertrophy in C2C12 myotubes. This effect was independent from the Akt and
P725VLJQDOOLQJSDWKZD\VEXWGHSHQGHQWRQ(55Į7KHUHIRUH3*&-ĮDQG3*&-
ȕ LQ FRQMXQFWLRQ ZLWK (55Į PD\ increase protein synthesis by regulating the 
expression of one or several genes/proteins in skeletal muscle. These genes and 
proteins are yet to be identified, and future studies identifying further downstream 
transcriptional targets of PGC-Į(55ĮDQG3*&-ȕ(55ĮZLOOLPSURYHWKHFXUUHQW
knowledge of how PGC-Į DQG 3*&-ȕ LQFUHDVH protein synthesis in C2C12 
myotubes and potentially mature skeletal muscle.
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Chapter 3
Identification of Genes and Proteins Regulated 
by PGC-1Į and PGC-ȕLQ&&0\RWXEHV
3.1 Introduction
Understanding the molecular regulation of protein synthesis in skeletal muscle is 
essential for developing therapeutic interventions aimed at increasing muscle growth,
or preventing skeletal muscle atrophy, during conditions characterised by perturbed 
skeletal muscle function. In Chapter two, it was established that the transcriptional 
coactivators, PGC-ĮDQG3*&-ȕ, can increase protein synthesis in mouse C2C12 
myotubes. This effect was independent from the well-known positive regulators of 
skeletal muscle protein synthesis, Akt and mTOR [39, 47], but was dependent on the 
transcription factor (55Į. The PGC-Į(55Į DQG 3*&-ȕ(55Į WUDQVFULSWLRQDO
pathways are known to regulate the expression of many genes and proteins involved 
in skeletal muscle mitochondrial biogenesis and oxidative phosphorylation [160, 172,
190]. However, the downstream targets that are regulated by PGC-ĮDQG3*&-ȕ
that may be involved in protein synthesis have not been identified.
High throughput gene and protein screening using microarray and iTRAQ (Isobaric 
Tags for Relative and Absolute Quantification) techniques respectively, are 
appropriate tools to detect differentially expressed genes and proteins in response to 
disease or following experimental manipulation [85, 263, 264]. Bioinformatics 
analysis of this data, such as Gene Set Enrichment Analysis (GSEA), ranks gene and 
protein expression data into pathways of biological significance. This method 
focuses on groups of genes that share a common biological function, rather than 
single gene analysis, and is considered a powerful method to interpret global gene 
and protein expression data [265]. GSEA involves the identification of Gene 
Ontology (GO) terms to categorise gene targets based on their cellular component, 
molecular function or biological process; and pathway mapping (Kyoto 
Encyclopaedia of Genes and Genomes; KEGG) to identify biological pathways that 
may be differentially regulated [266]. GSEA has previously identified several genes 
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that are down-regulated in diabetic skeletal muscle, are up-regulated following PGC-
Į RYHUH[SUHVVLRQ LQ && P\RWXEHV [157]. Using this technique may provide 
insight into the PGC-Į- and PGC-ȕ-controlled biological functions that increase 
protein synthesis in C2C12 myotubes.
Data generated from microarray analysis can also be used to create novel gene 
expression signatures (GES). A GES generally represents a small subset of genes, 
identified via non-biased statistical analysis, that are most consistently regulated in a 
microarray. Application of a GES has identified a set of genes that best predict 
survival in breast cancer [264], as well as a set of genes related to reduced 
mitochondrial content and neuromuscular junctions in sarcopenic rat skeletal muscle 
[85]. Combining analytical and bioinformatics approaches such as a GES and GSEA
may be an effective strategy to identify genes and proteins regulated by PGC-ĮDQG
PGC-ȕ, which regulate protein turnover in C2C12 myotubes.
The primary aim of this study was to identify the global gene and protein expression 
changes that occur in response to PGC-Į DQG 3*&-ȕ RYHUH[SUHVVLRQ in C2C12 
myotubes, and identify the potential functional and biological significance of these 
changes by GSEA. A secondary aim was to create a GES to represent the most 
consistent transcriptional changes in response to PGC-Į DQG 3*&-ȕ
overexpression. Lastly, it was of interest to measure the genes identified in the GES, 
as well as other highly regulated genes, in human models known to show increased 
or decreased rates of protein synthesis. Together, these experimental approaches will 
significantly add to the understanding of the gene transcription and protein signalling 
pathways that are regulated by PGC-ĮDQG3*&-ȕLQVNHOHWDOPXVFOH
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3.2 Methods
3.2.1 Cell Culture
C2C12
Mouse C2C12 myoblasts (American type culture collection; ATCC, Manassas, VA) 
were incubated at 37°C with 5% CO2, in high-glucose Dulbecco’s Modified Eagle 
Medium (DMEM) supplemented with 10% FBS, 100 U/ml penicillin and 100 μg/ml 
streptomycin (Invitrogen, Carlsbad, CA). Myoblasts were plated at a density of 1.5 x 
104/cm2 in 6 and 12-well plates. Upon confluence (~48 hrs), medium was changed to 
high-glucose DMEM supplemented with 2% HS (Invitrogen), 100 U/ml penicillin 
and 100 μg/ml streptomycin for 4-5 days until multinucleated myotubes had formed.
Medium was changed every 48 hours. 
Adenoviral Infections
Myotubes were infected with adenoviruses expressing GFP, hPGC-ĮRUK3*&-ȕ
using an MOI 100. Medium was changed after 48 hours and cells were harvested 
after 72 hours for RNA and protein.
3.2.2 RNA extraction 
RNA was extracted using Tri-Reagent solution (Ambion Inc., Austin, TX) according 
to manufacturer’s protocol. RNA concentrations were determined using the 
NanoDrop 2000 (NanoDrop products, Wilmington, DE). Following extraction, RNA 
was treated with 1 unit/μg of DNase I (Invitrogen) and incubated at 37ºC for 30 min 
to remove any DNA contamination of the samples. For the microarray, 2 μg of RNA 
was sent to the Australian Genomic Research Facility (AGRF; Parkville, VIC) for 
further analysis. For qPCR, 1 μg of RNA was reverse transcribed to complementary 
DNA (cDNA) using a High Capacity cDNA reverse transcription kit (Applied 
Biosystems, Forster City, CA) according to manufacturer’s protocol. The cDNA was 
diluted to 5 ng/μl in nuclease free water (NFW). 
3.2.3 Protein extraction
Myotubes were lysed in RIPA buffer (Merck-Millipore, Kilsyth, VIC) with 1 μL/mL 
protease inhibitor cocktail (Sigma-Aldrich) and 10 μL/mL Halt Phosphatase 
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Inhibitor Single-Use Cocktail (Thermo scientific, Rockford, IL). Protein 
concentrations were determined using the bicinchoninic acid (BCA) Protein Assay 
Kit (Pierce Biotechnology, Rockford, IL) according to the manufacturer’s protocol, 
and absorbance was measured at 562 nm on a Synergy 2 Microplate Reader (BioTek, 
Winooski, VT). Approximately 100 μg of protein for each sample was sent to 
Proteomics International (Nedlands, WA) for analysis.
3.2.4 DNA microarray 
The DNA microarray, data transformation and ANOVA analyses were performed by 
the AGRF (Parkville, VIC). The quality and quantity of the RNA extracted from the
C2C12 myotubes overexpressed with GFP, PGC-Į DQG 3*&-ȕ (a total of 6
samples per treatment) were determined initially with the Agilent Bioanalyzer and 
RNA 600 Nano Assay kit (Agilent Technologies, Paolo Alto, CA). A total of 500 ng
of RNA was labelled using the Total Prep RNA amplification kit (Ambion). Labelled 
cRNA (0.05 μg/μl) was then combined with the GEX-HYB Hybridisation Buffer in a 
30 μl final volume and hybridized to the Illumina Mouse-6v2 Expression Beadchip
(Illumina Inc., San Diego, CA) overnight at 58oC for 16 hours. The chips were 
washed as outlined in the Illumina manual, coupled with Cy3, and scanned in the 
Illumina iScan Reader using GenomeStudio software (Illumina Inc.). Raw signal 
intensity values were subjected to variance stabilisation transformation including 
background correction, log2 transformation and variance stabilisation using the 
lumiR package of R Bioconductor (www.Bioconductor.org) [267, 268]. ANOVA of 
normalised Illumina probe intensity values was performed using Partek® Genomic 
SuiteTM software, version 6.6 (Partek Inc., St. Louis, MO). Pairwise comparison of 
sample groups was performed using ANOVA. Differentially expressed genes were 
selected by a change in expression level over 50% (fold-change > ± 1.5) in compared 
groups, and “nominal” ANOVA p-value < 0.05. 
3.2.5 Isobaric Tags for Relative and Absolute Quantification (iTRAQ)
Sample preparation and Isobaric Tags for Relative and Absolute Quantification 
(iTRAQ) labelling and analyses were performed as described previously [269] by 
Proteomics International (Nedlands, WA). Briefly, protein samples were precipitated 
individually with acetone and resuspended in 0.5 M triethylammonium bicarbonate, 
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pH 8.5. Samples were then reduced, alkylated and trypsin-digested according to the 
iTRAQ protocol (Applied Biosystems). Peptides from uninfected myotubes as well 
as GFP-, PGC-Į- or PGC-ȕ- infected myotubes were labelled with iTRAQ 
reagents 114 (uninfected samples), 115 (GFP), 116 (PGC-Į and 117 (PGC-ȕ.
Labelled peptides were combined, desalted on a Strata-X 33μm polymeric reversed 
phase column (Phenomenex, Torrance, CA) and dissolved in 10% acetonitrile with 
10 mM KH2PO4, pH 3.0. Samples were then separated by strong cation exchange 
liquid chromatography on a PolySulfoethyl column (4.6 x 100 mm, 5 μm, 300 Å) 
using an Agilent 1100 HPLC system (Agilent Technologies, Paolo Alto, CA). A 0-
400 mM KCl gradient was used to elute fractions, which were desalted again before 
separation on a C18 PepMap100, 3 mm column (LC Packings-Dionex, Sunnyvale, 
CA) using an Ultimate 3000 nano HPLC system (Dionex). Peptide fractions were 
resolved on a 10-40% acetonitrile/0.1% trifluoroacetic acid gradient, spotted onto an 
AnchorChip MALDI plate using a ProBot robotic spotter (Dionex), and analysed on 
a 5800 MALDI TOF/TOD Analyser (AB Sciex, Foster City, CA). Peptide samples 
were identified and quantitated using ProteinPilot 4.0.8085 software (AB Sciex), and 
false discovery rate was estimated using reversed sequences. Sequences were 
searched against the Swissprot database (taxonomy = mus musculus). For each 
protein ratio (116 or 117 relative to 115), a p-value of < 0.05 was considered 
significant. 
3.2.6 Analysis of microarray and iTRAQ data
Gene Set Enrichment Analysis (GSEA) of microarray and iTRAQ data
Following the identification of genes and proteins that were differentially regulated
with overexpression of PGC-ĮDQG3*&-ȕgene-set enrichment analyses (GSEA) 
was performed using Database for Annotation, Visualisation and Integrated 
Discovery (DAVID) v6.7 (http://david.abcc.ncifcrf.gov) [270, 271]. DAVID 
provides an unbiased approach to rank gene and protein expression data into 
pathways of biological significance by identifying groups of genes or proteins that 
are enriched and functionally related. Using DAVID, Gene Ontology (GO) and 
Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway mapping was 
performed. GO categorisation uses a selection of defined terms representing gene 
product properties to group genes and/or proteins with their possible roles or 
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functions. These GO terms describe either a cellular component (CC), molecular 
function (MF) or a biological process (BP). KEGG pathway mapping uses molecular 
pathway maps for biological interpretation of higher-level systemic functions of 
large-scale data sets [266]. These include pathways involved in metabolism, genetic 
and environmental information processing, cellular processes, organisation systems
and human diseases. From these analyses, GO terms and KEGG pathways were
identified for PGC-ĮDQG3*&-ȕIURPERWKWKHPLFURDUUD\DQGL75$4GDWD
Gene expression signature (GES) from microarray data
To identify an optimal set of genes, called a gene expression signature (GES) [264],
that reflects the overall state of the C2C12 myotubes following the overexpression of 
PGC-Į DQG 3*&-ȕ D FRPELQDWLRQ RI Diagonal Linear Discriminant Analysis 
(DLDA) and the Signal to Noise Ratio (SNR) statistics were used [272]. DLDA 
algorithm was used to generate gene sets that classified arrays into each treatment 
group. Using a Forward Step-Wise Variable Selection, sets of genes from the dataset 
with optimal predictive power were identified and ranked according to their SNR 
statistic. To eliminate genes that were co-regulated, SPSS software version 14.1 was 
used to reduce signature genes to a small subset that were discriminating and 
displayed divergent expression profiles that were not highly correlated to each other. 
The result of these analyses was the identification of a subset of transcripts, the GES, 
which exhibit the best predictive performance to discriminate between the different 
groups. 
Biased selection of genes from the microarray
To elucidate possible mechanisms by which PGC-Į DQG3*&-ȕ UHJXODWH SURWHLQ
synthesis, genes that were highly regulated by PGC-Į DQG3*&-ȕ were selected 
based on their gene ontology functions and processes. Nine genes were biasedly 
selected that had GO terms linked to growth and protein synthesis. The expression of 
these genes was then measured via real-time qPCR.
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3.2.7 Gene validation: Real-time polymerase chain reaction
To confirm the gene expression profile of the GES and the selected genes potentially 
involved in muscle growth, gene expression was analysed using real-time qPCR.
These genes were also measured in skeletal muscle samples from subjects before and 
after an acute bout of resistance exercise (REX), and in muscle samples from patients 
with amyotrophic lateral sclerosis (ALS), and healthy age/sex matched controls.
Real-time qPCR was performed using a Stratagene Mx3000P qPCR System and the 
MxPro qPCR software (Stratagene, La Jolla, CA). Cycling conditions for the PCR 
consisted of one denaturing cycle at 95°C for 2 minutes, followed by 40 cycles of 
denaturing at 95°C for 5 seconds and annealing at 60°C for 20 seconds, and 
elongation at 72°C for 60 seconds. A dissociation curve was generated to show that 
only one product had been amplified during the PCR. Each 20 μL reaction contained 
0.5 x Power SYBR Green PCR Master Mix (Applied Biosystems), 25 ng of cDNA, 
and the forward and reverse primers for the gene of interest. Primers were designed 
using Primer 3 (www.primer3.sourceforge.net) and the sequences cross checked for 
gene specificity using a BLAST search (www.ncbi.nlm.gov/BLAST). Primers were 
synthesised by Gene Works (Adelaide, SA). Genes amplified in the PCR are shown 
in Tables 3.01 and 3.02. All samples were measured in triplicate. To compensate for 
variations in input RNA amounts and efficiency of the reverse transcription, data was 
normalised ribosomal protein, 36B4 (also known as RPLPO) mRNA.
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Table 3.01 Mouse Primers used in the real-time qPCR 
Primer
GenBank 
accession no. Forward Primer (5’-3’) Reverse Primer (5’-3’)
Ppp1R16a NM_033371.2 GCTGCACATCGCCGCTGCTA GGCCCGCAGGAGTGCATCTT 
MRPS9 NM_023514.3 CACGGCACAGGCGGTCGTTT CAAGCGTATGGCGCCTGCCT 
TARBP2 NM_009319.1 CAGCTGCACTGGTCAGGGCC GTGCAGCCTGGCCCACGATT 
CDC14B NM_172587.2 GCGTGAAGAAGAGCCGCAGC ACCATGGCCAGATTGAGTGGTCC 
EXOC1 NM_027270.1 CACCACGTGTGGACCGCACA TCGCCACGGCGTTCAGCATT 
TRIM25 NM_009546.2 CCCGAGCATGGCGAGTGCAT GCTGGTCTCTGCTGCGTCGA 
TRIM32 NM_053084.1 GTGGACTCGCGTCGGAGCTG GGGCAGCGGACGCCATTGAT 
eEF1A2 NM_007906.2 CAGTTCACCTCTCAGGTTATCATCCT GCCGTGTGACAGTCGATGAC 
eIF2B4 NM_001127356.1 CTTCTCCCACCTGCCTCAGTA CAGAGGATGGGATGCTCATGTA 
eIF4E3 NM_025829.4 ACCATTGGAGAGCAGTTCACAGA TCACGCTGACTCCGATGATC 
VEGF-A NM_001025250.3 AAGCCAGCACATAGGAGAGATGA TCTTTCTTTGGTCTGCATTCACA 
Caspase1 NM_009807.2 AAAAGCCCAGAAGTTATGGAAAGA GACGTGTACGAGTGGTTGTATTCAT 
TCEAL7 NM_001127169.1 AACCCTGCGGAGCACTTG TGAAGCAACCTCTGTCTGAAATTG 
TSC22D3 NM_001077364.1 TTCTCCATCTCCTTCTTTTCTTCTCT CTCCGGAGGCACTGTTATCC 
ASPRV1 NM_026414.2 TTGGCACAGACGTCTTGCA GCAGGTGCGGTGTTCGA 
Prnp NM_011170.2 CACCGAGACCGATGTGAAGA GGTACTGGGTGACGCACATCT 
36B4 NM_007475.5 TTGTGGGAGCAGACAATGTG AGTCCTCCTTGGTGAACACG 
Table 3.02 Human Primers used in the real-time qPCR 
Primer
GenBank 
accession no. Forward Primer (5’-3’) Reverse Primer (5’-3’)
Ppp1R16a NM_032902.5 ACGCCCCTTGATGTGTGCGG GAGGGCGTCGTGCTTGTGCT 
MRPS9 NM_182640.2 GCCCTGTGTGTCCTACGGCG CAGAGGCCTTGCTTCCGGGC 
TARBP2 NM_134323.1 TCAGCAGTCTGAGTGCAACC GTGCCACTCCCAATCTCAAT 
CDC14B NM_003671.3 TCGACCTCGCCGGGTGTGAA ACACGTCGTCCTGGGGGTCC 
EXOC1 NM_018261.3 AGGCCTGCACCAATGCTGCT CTGGCCAGTCTCCGGGCAAA 
TRIM25 NM_005082.4 CGACCTGGAGGCCACCCTGA CCGCACATCCTGCTGCCTGT 
TRIM32 NM_012210.3 GGAGGCCACAGCGTCTGCTG GGCAACCACTTCCTCCGGGC 
eEF1A2 NM_001958.3 CGTGGGCGTGAACAAAATG TCGTAGCGCTTCTCGCTGTA 
eIF2B4 NM_172195.3 CCGGTGTATTGCCCTGCTT CATTAGGCGGTGTTGTGTAATCC 
eIF4E3 NM_001134651.1 GCAGCAGATGATGAAGTAATAGGAGTT AGTGCCCATCTGTTCTGTAGGGA 
VEGF-A NM_001171623.1 CCCACTGAGGAGTCCAACATC GGCCTTGGTGAGGTTTGATC 
Caspase1 NM_001223.4 CTGCTCTTCCACACCAGATAATGT TCCAATAAAAACAGAGCCCATTG 
TCEAL7 NM_152278.3 CGCCCGTATGGAGAATTTGA GAAGCAGCCTCTGTCTAAAATTCC 
TSC22D3 NM_198057.2 TGGCCATAGACAACAAGATCGA TCACAGCATACATCAGATGATTCTTC 
ASPRV1 NM_152792.2 GAGGTCACTGATGGCGATCTG GGCCACCTTTACCACATTCTCA 
Prnp NM_000311.3 ATGGAGCGCGTGGTTGA GGCCTGAGATTCCCTCTCGTA 
36B4 NM_001002 GTGATGTGCAGCTGATCAAGACT GATGACCAGCCCAAAGGAGA 
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3.2.8 Human skeletal muscle samples
Resistance Exercise (REX) Methods
The skeletal muscle samples were a gift from Dr Paul Della Gatta, Deakin 
University.
Subjects
Eight untrained, but recreationally active Australian individuals volunteered to take 
part in the exercise component of the study (mean ± SD age 22.0 ± 0.5 yrs, height 
1.79 ± 0.05 m, body mass 83.3 ± 19.1 kg and BMI 24.1 ± 0.1 kg.m-2). Exclusion 
criteria included resistance training within the past six months, medication, or a 
history of a condition or illness that would present as a health risk during strenuous 
resistance exercise. Before participating in the study, the nature, purpose and risks of 
the study were explained to the subjects. They then provided informed written 
consent. All experimental procedures involved in this study were formally approved 
by the Deakin University Human Research Ethics Committee (EC 18-2004).
Experimental design
Each subject in the exercise group completed a familiarisation session prior to the 
experimental protocol to learn how to perform each exercise, and to determine their 
individual 1 repetition maximum (1 RM). During the session, a 5 RM test was 
performed for each subject for the leg press, squat (assisted by the Smith machine) 
and leg extension. 1 RM was then calculated using the Brzycki equation (1 RM =
weight lifted (kg)/1.0278–[reps to fatigue x 0.0278]). The familiarisation session 
took place at least 7 days prior to allow sufficient recovery time before the 
experimental trial commenced.
For the 24 h preceding exercise, and the day of the trial, the subjects consumed a 
standard diet (20% fat, 14% protein and 66% carbohydrate) and abstained from 
alcohol, caffeine, tobacco and additional exercise. On the morning of the trial, 
subjects presented to the laboratory in a fasted state. Following 30 min of supine 
resting, a muscle sample was collected from the vastus lateralis under local 
anaesthesia (Xylocaine 1%) by percutaneous needle biopsy technique modified to 
include suction. Excised muscle tissue from each biopsy was immediately frozen and 
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stored in liquid nitrogen for later analysis. Subjects then completed a single bout of 
resistance exercise, specifically targeting muscles of the leg. Following 5 min of light 
cycling for warm-up, subjects completed two sets of eight to twelve repetitions of 
bilateral leg press, squat and leg extension at 80% 1-RM. This was followed by a 
third set to voluntary fatigue, also at 80% 1-RM. Subjects were allowed 1 min rest 
between exercises and 3 min rest between sets. The entire exercise protocol lasted
2025 min. This intensity of this exercise protocol was similar to other studies on 
resistance exercise [273-275], but lower than other studies involving purely eccentric 
exercise that caused severe muscle damage [276, 277].
Additional muscle samples were collected at 2 h and 4 h after the exercise. The 
following morning, subjects again reported to the laboratory in a fasted state for the 
collection of a muscle sample 24 h post-exercise. To minimise the potential for 
inflammation arising from the biopsy procedure itself, biopsies were collected from 
separate incisions at least 2 cm distal from previous sites. 
RNA extraction
7RWDO FHOOXODU51$ZDV H[WUDFWHG XVLQJ WKH7ǀ7$//<51$.LW $PELRQ ,QF
according to the manufacturer’s protocol. RNA quality and concentration were 
determined using the Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, 
CA). RNA (1 μg) was reverse transcribed to complementary DNA (cDNA) using a 
High Capacity cDNA reverse transcription kit (Applied Biosystems).
Statistics
A one-way repeat measures ANOVA with a Bonferroni adjustment was to 
investigate the effect of exercise on the genes of interest.
Amyotrophic Lateral Sclerosis (ALS) methods
Skeletal muscle samples from were provided by the Eurobiobank and Telethon 
(GUP 07001) [155].
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Subjects
Skeletal muscle biopsies were obtained from fourteen patients diagnosed with ALS 
[278] and 10 age-matched healthy control subjects (Table 3.03). At the time of the 
biopsy, the duration of illness was 3-48 months. The research protocol was 
approved by the institutional ethics committees and informed consent was obtained 
from all participants according to the Declaration of Helsinki (BMJ 1991; 
302:1194) [279].
Table 3.03 Characteristics of subjects included in the study
Control ALS
Patients (n) 10 14
Male/Female 7/3 10/4
Age (years)     
Mean ± SD 53 ± 17 59 ± 9
Range 25-73 33-79
Muscle biopsies
For the ALS patients biopsies were taken from the vastus lateralis muscle using 
either Bergstrom or open biopsy procedures. For the healthy control subjects 
biopsies were taken from the vastus lateralis muscle using the Bergstrom technique. 
All biopsies were immediately frozen in liquid nitrogen and stored at -80°C until 
analysed.  
RNA Extraction
Total RNA was extracted from 5-20 mg skeletal muscle samples using Tri-Reagent® 
Solution (Ambion Inc.) according to the manufacturer’s protocol.  First-strand cDNA 
was generated from 1μg RNA in 20μL reaction buffer using the AMV reverse 
transcriptase (RT) kit and random hexomer primers (500ng) according to 
manufacturer’s protocol (Promega, Madison WI).
Statistics 
A one-way ANOVA with a Dunnett C post-hoc test was used for all analyses when 
comparing control and ALS subjects.
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3.3 Results
3.3.1 Microarray and iTRAQ analyses
To investigate the transcriptional and translational effects following PGC-Į and 
PGC-ȕRYHUH[SUHVVLRQLQ&&P\RWXEHVERWKPLFURDUUD\ genomic and iTRAQ
proteomic analyses were performed. In the microarray analyses, PGC-Įand PGC-
ȕZHUH IRXQG WR significantly regulate 1019 and 3054 genes respectively, with a 
greater than 1.5-fold increase or decrease in expression levels when compared to the 
GFP control group. Using iTRAQ quantification, PGC-ĮDQG3*&-ȕUHJXODWHG 166 
and 68 proteins, respectively.
3.3.2 Gene Ontology (GO) terms
The genes and proteins significantly regulated by PGC-ĮRU3*&-ȕRYHUH[SUHVVLRQ
identified by microarray and iTRAQ analyses, respectively, were next submitted to 
GSEA through DAVID bioinformatics platform (http://david.abcc.ncifcrf.gov).
GSEA revealed genes clustered significantly with a range of mitochondrial and
metabolic related GO terms. Genes and proteins differentially expressed specifically 
by PGC-ȕ DOVR FOXVWHUHG VLJQLILFDQWO\ ZLWK PXVFOH FRQWUDFWLOH DQG F\WRVNHOHWDO
related GO terms. An overview of these GO terms is represented in Figure 3.01 for 
both genes and proteins, where overlapping terms have been grouped together. The 
full lists of GO terms are in Appendix 1 (Tables S1-4). The majority of GO terms for 
both PGC-Į DQG 3*&-ȕbelonged to mitochondrial biology, nucleotide binding, 
the ribosome and ribonucleoprotein complex, oxidative metabolism and energy 
production. These GO terms were generally reflected in the iTRAQ analyses, despite 
fewer proteins being identified compared to microarray expression profiling.
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Figure 3.01 Pie charts representing the major gene ontology (GO) terms used to group genes and 
proteins regulated by PGC-Į DQG 3*&-ȕ. (A) GO terms identified from microarray analyses of 
genes regulated by PGC-ĮDQG3*&-ȕRYHUH[SUHVVLRQLQ&&P\RWXEHV%*2WHUPVLGHQWLILHG
from iTRAQ analyses of proteins regulated by PGC-Į and PGC-ȕRverexpression. The total number 
of genes and proteins analysed are shown above each pie chart. Genes and proteins were selected 
based on P < 0.05 Bonferroni’s multiple comparison test, and on a 1.5-fold change for microarray 
genes. CC = cellular component, MF = molecular function, BP = biological process. 
3.3.3 KEGG pathway mapping
KEGG pathway mapping (http://www.genome.jp/kegg/) of the genes regulated by 
PGC-Į DQd PGC-ȕ identified signalling pathways significantly associated with
oxidative phosphorylation (OXPHOS) in both normal and disease states, and in the 
citrate cycle associated with carbohydrate and fatty acid metabolism (Tables 3.04
and 3.05). These pathways were essentially confirmed at the protein level using 
iTRAQ quantification, although fewer pathways were listed for PGC-ȕGXHWRIHZHU
proteins being identified by the iTRAQ analyses. Furthermore, a significant 
association of proteins involved in glycolysis and gluconeogenesis pathways were 
identified in PGC-ĮDQG3*&-ȕH[SUHVVHGO\VDWHs, but not at the gene expression 
level. Overall, the effects of PGC-ĮDQG3*&-ȕoverexpression generated similar
profiles at both the transcriptional and translational level. 
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Table 3.04 KEGG pathway analyses of PGC-Į-regulated genes and proteins 
Analysis Term Count Fold Enrichment P-Value
Microarray Oxidative phosphorylation 62 8.0 2.80E-39
Parkinson’s Disease 62 7.8 1.55E-38
Huntington’s disease 64 5.9 6.31E-31
Alzheimer’s disease 61 5.6 3.92E-28
Citrate cycle (TCA cycle) 18 9.7 2.05E-11
Cardiac muscle contraction 25 5.4 1.20E-09
Pyruvate metabolism 12 4.9 0.003
Fatty acid metabolism 11 4.1 0.039
Alanine, aspartate & glutamate 
metabolism
9 5.0 0.044
  
iTRAQ Citrate cycle (TCA cycle) 9 16.7 3.5E-06
Ribosome 12 7.7 2.9E-05
Oxidative phosphorylation 13 5.7 2.0E-04
Parkinson’s disease 13 5.6 2.5E-04
Alzheimer’s disease 14 4.4 0.001
Glycolysis/Gluconeogenesis 9 7.6 0.002
Huntington’s disease 13 4.1 0.007
Fatty acid metabolism 7 8.9 0.011
Table 3.05 KEGG pathway analyses of PGC-ȕ-regulated genes and proteins
Analysis Term Count Fold Enrichment P-Value
Microarray Oxidative phosphorylation 72 3.5 6.41E-23
Parkinson’s Disease 66 3.2 1.85E-17
Alzheimer’s disease 78 2.7 3.28E-16
Huntington’s disease 73 2.5 6.29E-13
Citrate cycle (TCA cycle) 18 3.7 1.05E-04
Cardiac muscle contraction 31 2.5 1.53E-04
Hypertrophic cardiomyopathy 30 2.3 0.003
Sugar metabolism 18 2.6 0.035
 
iTRAQ Citrate cycle (TCA cycle) 5 23.7 0.002
Glycolysis/Gluconeogenesis 5 10.8 0.050
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3.3.4 GES of microarray data
Analysis was performed to identify the genes that were highly regulated by PGC-Į
and PGC-ȕGHYHORSLQJDQRQ-biased gene expression signature (GES). The top 33
genes regulated by PGC-ĮDQG3*&-ȕare listed in Appendix 2 (Table S5). The top 
7 genes that were highly regulated by PGC-ĮDQG3*&-ȕZHUHVHOHFWHd for further 
analysis and are shown in Table 3.06. The expression of these targets was validated 
via real-time qPCR (Figure 3.02). Overexpression of PGC-ĮDQG3*&-ȕLQFUHDVHG
the expression of protein phosphatase 1, regulatory subunit 16A (Ppp1R16a), 
mitochondrial ribosomal protein sub-unit 9 (MRPS9), TAR HIV-1 RNA binding 
protein 2 (TARBP2), and cell division cycle 14 homolog B (CDC14B) (Figure 
3.02A). In contrast, exocyst complex component 1 (EXOC1), Tripartite motif-
containing protein 25 (TRIM25), and Tripartite motif-containing protein 32
(TRIM32) were down-regulated (Figure 3.02B). Although the GES identified 
TRIM25 to be regulated by PGC-ȕRQO\DQG75,032 to be regulated by PGC-Į
only, the expression of these genes was reduced in response to both PGC-Į DQG
PGC-ȕRYHUH[SUHVVLRQZKHQPHDVXUHGYLD real-time qPCR. 
Table 3.06 Microarray profile of genes chosen from the GES regulated by both PGC-ĮDQG3*&-ȕ
Primer
GenBank 
accession no. Direction vs. GFP PGC-Į3-value PGC-ȕ3-value
Ppp1R16a NM_033371.2 Up 0.001 5.77E-11
MRPS9 NM_023514.3 Up 6.61E-06 4.35E-12
TARBP2 NM_009319.1 Up 9.03E-04 3.30E-11
CDC14B NM_172587.2 Up 0.018 2.76E-10
EXOC1 NM_027270.1 Down 8.04E-05 6.35E-12
TRIM25* NM_009546.2 Down 5.15E-09
TRIM32** NM_053084.1 Down 0.001
* PGC-ȕRQO\3*&-ĮRQO\
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Figure 3.02 mRNA levels of genes highly regulated by PGC-ĮDQG3*&-ȕIURPWKH*(6YDOLGDWed 
by qPCR. (A) Genes up-regulated by PGC-ĮDQG3*&-ȕIURPWKH*(6%*HQHVGRZQ-regulated 
by PGC-ĮDQGRU3*&-ȕIURPWKH*(69DOXHVZHUHQRUPDOLVHGWR%P51$H[SUHVVLRQP <
0.05, ** P < 0.01, *** P < 0.001 compared to GFP. 
 
3.3.5 Biased selection of genes from the microarray 
To elucidate possible mechanisms by which PGC-Į DQG PGC-ȕ UHJXODWH SURWHLQ
synthesis, the top regulated genes that may potentially be involved in skeletal muscle 
development and growth were explored. The genes that were highly regulated by 
PGC-ĮDQG PGC-ȕDUH VKRZQ LQ7DEOH07. The expression of these genes was
validated via qPCR (Figure 3.03). Overexpression of PGC-Į RU 3*C-ȕ OHG WR D
large increase in mRNA for eukaryotic translation elongation factor 1 alpha 2
(eEF1A2), eukaryotic translation initiation factor 2B, subunit 4 (eIF2B4), eukaryotic 
translation initiation factor 4E family member 3 (eIF4E3), and vascular endothelial 
growth factor-A (VEGF-A) (Figure 3.03A). In contrast, Caspase1, transcription 
elongation factor A SII-like 7 (TCEAL7), TSC22 domain family protein 3
(TSC22D3), aspartic peptidase retroviral-like 1 (Asprv1) and Prion Protein (Prnp)
were all decreased in response to PGC-Į DQG 3*&-ȕ RYHUH[SUHVVLRQ )LJXUH
3.03B).
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Table 3.07 PGC-ĮDQG3*&-ȕUHJXODWHGJHQHVREWDLQHGIURPPLFURDUUD\DQGVHOHFWHGIRUYDOLGDWLRQ
based on their potential roles in protein turnover.
Primer
GenBank 
accession no. Direction vs. GFP PGC-Į3-value PGC-ȕ3-value
eEF1A2 NM_007906.2 Up 5.42E-16 3.46E-18
eIF2B4 NM_001127356.1 Up 5.12E-07 3.49E-11
eIF4E3 NM_025829.4 Up 1.97E-06 1.30E-08
VEGF-A NM_001025250.3 Up 1.81E-05 4.49E-07
Caspase1 NM_009807.2 Down 2.02E-09 4.11E-12
TCEAL7 NM_001127169.1 Down 3.51E-12 5.78E-15
TSC22D3 NM_001077364.1 Down 5.62E-07 1.11E-11
ASPRV1 NM_026414.2 Down 7.26E-09 4.63E-10
Prion protein NM_011170.2 Down 2.65E-07 9.91E-12
Figure 3.03 mRNA levels of genes selected biasedly from the microarray, validated by qPCR. (A) 
Genes up-regulated by PGC-ĮDQG3*&-ȕIURPWKHPLFURDUUD\%*HQHVGRZQ-regulated by PGC-
ĮDQG3*&-ȕIURPWKHPLFURDUUD\P < 0.05, ** P < 0.01, *** P < 0.001 compared to GFP.
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3.3.6 Regulation of genes in models of muscle hypertrophy and atrophy
It was of interest to establish the potential clinical relevance of these observations. 
To do so, the expression levels of the genes from the non-biased and biased 
approaches were measured in a human model of stimulated muscle protein synthesis, 
acute resistance exercise (REX), and in a model of severe muscle atrophy, 
amyotrophic lateral sclerosis (ALS).
Resistance exercise
In response to resistance exercise, PGC-ĮP51$LQFUHDVHGDFXWHO\DWDQGKRXUV
post-exercise, but was then reduced after 24 hours (Figure 3.04A).  In contrast PGC-
ȕP51$ZDVGHFUHDVHGDWDQGKRXUVSRVWH[HUFLVH)LJXUH04B). This was 
associated with significant increases in Ppp1R16a and CDC14B (Figure 3.05A), and 
decreases in EXOC1 and TRIM32 (Figure 3.05B), genes selected from the non-
biased GES. Additionally, resistance exercise led to significant increases in genes 
selected from the biased approach, including eEF1A2, eIF2B4, eIF4E3 and VEGF-A
at 2 hours post-exercise (Figure 3.06A). After 24 hours, the expression of eIF2B4 
increased further, while VEGF-A, eEF1A2 and eIF4E3 expression returned to, or 
was slightly below, pre-exercise levels. From the selected genes that were down-
regulated in the microarray, only TSC22D3 was decreased following resistance 
exercise, while Caspase1 and Prnp were increased 24 hours post-exercise (Figure 
3.06B). Out of all genes investigated, VEGF-A, a known target of PGC-1ĮDQG3*&-
ȕPLUURUHG3*&-ĮH[SUHVVLRQYHU\FORVHO\
Figure 3.04 PGC-Į DQG 3*&-ȕ P51$ H[SUHVVLRQ in skeletal muscle after an acute bout of 
resistance exercise in humans. (A) PGC-ĮP51$, and (B) PGC-ȕP51$ZKHQPHDVXUHGDQG
24 hours after resistance exercise. Values were normalised to 36B4 mRNA expression. * P < 0.05, ** 
P < 0.01 compared to Pre-exercise.
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Figure 3.05 mRNA expression of the gene expression signature (GES) genes that are regulated by 
PGC-Į DQG 3*&-ȕ LQ VNHOHWDOPXVFOH DIWHr an acute bout of resistance exercise in humans. (A) 
Genes that were up-regulated in the GES, and (B) genes that were down-regulated in the GES, when 
measured 2, 4 and 24 hours after resistance exercise. Values were normalised to 36B4 mRNA 
expression. * P < 0.05, ** P < 0.01 compared to pre-exercise (Pre).
 
Figure 3.06 mRNA expression of biasedly-selected genes that are regulated by PGC-ĮDQG3*&-ȕ
in skeletal muscle after an acute bout of resistance exercise in humans. (A) Genes that were up-
regulated in the microarray, and (B) genes that were down-regulated in the microarray, when 
measured 2, 4 and 24 hours after resistance exercise. Values were normalised to 36B4 mRNA 
expression. * P < 0.05, ** P < 0.01, *** P < 0.001 compared to pre-exercise (Pre).
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ALS patients
Our group has previously shown that PGC-Į DQG 3*&-ȕ P51$ OHYHOV DUH
decreased in atrophied skeletal muscle from patients with ALS [155]. Figure 3.07
shows that PGC-Į$DQG PGC-ȕ%P51$ZHUH decreased by 52% and 63%, 
respectively. Of the genes selected from the GES, MRPS9 was decreased (Figure 
3.08A), and TRIM25 and TRIM32 were increased (Figure 3.08B), showing inverse 
regulation when compared to PGC-Į DQG 3*&-ȕ RYHUH[SUHVVLRQ However, 
TARBP2 expression was also increased, which is similar to what was observed from
the microarray. ALS skeletal muscle also displayed inverse regulation of genes 
selected from the biased approach, including decreases in eEF1A2 and VEGF-A
(Figure 3.09A), and increases in TSC22D3, Asprv1 and Prnp (Figure 3.09B).
Figure 3.07 PGC-ĮDQG3*&-ȕP51$H[SUHVVLRQLQ skeletal muscle of ALS (amyotrophic lateral 
sclerosis) and control patients. (A) PGC-ĮP51$DQG%3*&-ȕP51$Values were normalised 
to 36B4 mRNA expression. ** P < 0.01 compared to Control.
 
Figure 3.08 mRNA expression of gene expression signature (GES) genes that are regulated by PGC-
ĮDQG3*&-ȕ LQ VNHOHWDOPXVFOHRI$/6 (amyotrophic lateral sclerosis) and control patients. (A) 
Genes that were up-regulated in the GES, and (B) genes that were down-regulated in the GES. Values 
were normalised to 36B4 mRNA expression. * P < 0.05 compared to Control.
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Figure 3.09 mRNA expression of biasedly-selected genes that are regulated by PGC-ĮDQG3*&-ȕ
in skeletal muscle of ALS (amyotrophic lateral sclerosis) and control patients. (A) Genes that were up-
regulated in the microarray, and (B) genes that were down-regulated in the microarray. Values were 
normalised to 36B4 mRNA expression. * P < 0.05 compared to Control.
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3.4 Discussion
Understanding the downstream PGC-1Į- and PGC-ȕ-regulated targets increasing 
protein synthesis will aid in developing targeted therapeutic approaches to increase 
skeletal muscle mass during catabolic wasting conditions. This study aimed to 
identify global gene and protein expression changes that occur in response to PGC-
Į DQG 3*&-ȕ RYHUH[SUHVVLRQ LQ &&P\RWXEHV and create an unbiased GES 
characterising the PGC-Į- and PGC-ȕ-regulated targets that may be involved in 
increasing protein synthesis. Several observations were made. Firstly, GSEA 
revealed that many genes differentially expressed by PGC-Į DQG 3*&-ȕ
overexpression clustered significantly with a range of GO terms related to
mitochondrial biology, oxidative metabolism, nucleotide binding, and the ribosome
and ribonucleoprotein complex. These findings were generally reflected at the 
protein level via iTRAQ analysis. Genes and proteins differentially regulated by 
PGC-ȕ DOVR FOXVWHUHGZLWKPXVFOH FRQWUDFWLOH DQG F\WRVNHOHWDO UHODWHG *2 WHUPV
KEGG pathway mapping of the genes and proteins regulated by PGC-ĮDQG3*&-
ȕ LGHQWLILHG signalling pathways associated with OXPHOS in normal and disease 
states, and in the citrate cycle associated with glucose and fatty acid metabolism. 
Secondly, the non-biased GES identified the top regulated genes by PGC-Į DQG
PGC-1ȕ. In addition, highly regulated genes that may potentially be involved in 
muscle growth were biasedly selected and also explored. Thirdly, PGC-ĮP51$
was increased and PGC-ȕ P51$ ZDV GHFUHDVHG LQ KXPDQ VNHOHWDO PXVFOH
following resistance exercise, while PGC-Į DQG 3*&-ȕ ZHUH ERWK GHFUHDVHG LQ
skeletal muscle of ALS patients. Lastly, several of the differentially expressed genes 
identified from both the non-biased and biased selections were also differentially 
regulated in human skeletal muscle following resistance exercise and/or in skeletal 
muscle of ALS patients. 
3.4.1 GSEA
GSEA is a popular method to identify differentially expressed genes and proteins
that may commonly regulate biological functions and intracellular signalling 
pathways [265]. Many GO terms identified using GSEA were associated with 
mitochondrial biology and oxidative metabolism. GO terms associated with the 
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ribosome and ribonucleoprotein complex were also common, supporting the role of 
PGC-ĮDQG3*&-ȕ LQ UHJXODWLQJSURWHLQ V\QWKHVLVThese findings are consistent 
with enriched GO terms in skeletal muscle of PGC-Į WUDQVJHQLFPLFH [280], and 
other cell culture models overexpressing PGC-Į [157]. Ribosomal biogenesis is 
decreased during denervation-induced atrophy, contributing to the decrease in 
protein synthesis [281]. Interestingly, this is paralleled with an increase in 
Akt/mTOR activity, showing that other mechanisms control ribosomal 
biogenesis/activity during inactivity. As PGC-1Į DQG 3*&-ȕ DUH DOVR UHGXFHG LQ
denervated muscle [65], and do not require Akt/mTOR to increase protein synthesis, 
it may be possible that PGC-ĮDQG3*&-ȕLQFrease protein synthesis by increasing 
the transcription of these ribosomal genes. The effect of PGC-Į DQG 3*&-ȕ RQ
ribosomal biogenesis should be a future area of research. 
Genes and proteins differentially expressed by PGC-ȕ DQG SURWHLQV IRU3*&-Į
also clustered with muscle contractile and cytoskeletal related GO terms. In Chapter 
2, it was established that PGC-ĮDQG3*&-ȕUHJXODWHSURWHLQV\QWKHVLVYLD(55Į
Interestingly, geQHH[SUHVVLRQSURILOLQJLQ(55Į-null cardiac muscle reveals down-
regulation of genes that cluster with GO terms involved in heart and muscle 
development, muscle contraction, and protein metabolism and transcription [282].
Together these observations suggest that PGC-Į(55Į DQG 3*&-ȕ(55Į PD\
increase the synthesis of structural and contractile proteins in skeletal muscle.  
KEGG pathway mapping of the genes regulated by PGC-ĮDQG3*&-ȕZDVDOVR
associated with cardiac muscle contraction, as well as OXPHOS in normal and 
disease states, and in the citrate cycle associated with glucose and fatty acid 
metabolism. Again, similar KEGG pathways are enriched in PGC-Į WUDQVJHQLF
skeletal muscle [280]. Interestingly, some of these disease states are associated with 
mitochondrial defects as well as muscle atrophy [152, 283-287].
3.4.2 GES
The GES created from the microarray data identified an increase in Ppp1R16a, 
MRPS9, TARBP2, and CDC14B, and a decrease in EXOC1, TRIM25 and TRIM32. 
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Genes up-regulated in the GES
The regulation and function of Ppp1R16a, MRPS9, TRBP2 and CDC14B have not 
previously been investigated in skeletal muscle. Ppp1R16a, also known as Myosin 
phosphatase-targeting subunit 3 (MYPT3), is part of the MYPT family, which 
specifically target protein phosphatase 1c (PP1c) [288]. While its role in skeletal 
muscle is unknown, it is known to target myosin light chain phosphatase and is 
involved in the regulation of smooth muscle contraction [288]. MRPS9 is involved in 
mitochondrial protein synthesis in a yeast cell line [289], however its role in 
mammalian cells is unknown. As PGC-Į DQG 3*&-ȕ UHJXODWH PDQ\ JHQHV
involved in mitochondrial biogenesis in skeletal muscle [162, 171, 172], this may be 
another gene by which PGC-ĮDQG3*&-ȕPHGLDWHWKHir effects on mitochondria. 
CDC14B is known for its regulation of the cell cycle, particularly in the termination 
of cell mitosis [290], however its role in differentiated cells such as myotubes has not 
been investigated. TARBP2 inhibits the phosphorylation of the eukaryotic translation 
initiation factor eIF2A, by the dsRNA-regulated protein kinase (PKR) in murine 
embryo fibroblasts [291]. This removes the inhibition of translation initiation and 
likely increases protein synthesis in these cells [291].
Genes down-regulated in the GES
EXOC1 (also known as Sec3) is a protein of the exocyst complex; a multiple protein 
complex involved in targeting secretory vesicles to the cell membrane during 
exocytosis [292, 293]. Other members of the exocyst complex regulate exocytosis of
the glucose transporter type 4 (GLUT4) in adipocytes in response to insulin [294,
295], although their role in skeletal muscle has not been identified. TRIM25 is a
member of the RING-finger B-box coiled-coil (RBCC) motif family, and is involved 
in estrogen-dependent cell proliferation and organ development [296]. Its expression 
is lowest in skeletal muscle compared to other tissues [297], suggesting that it may 
play a minor role in skeletal muscle; although this has not been investigated. 
TRIM32 is an E3 ubiquitin ligase that degrades thin myofibrillar contractile proteins 
(i.e. actin, tropomyosin and troponin) during muscular atrophy [298]. Short-hairpin 
RNA (shRNA) down-regulation of TRIM32 attenuates the decrease in muscle fibre 
diameter and loss of thin myofibrillar proteins during fasting [298]. PGC-Į DQG
PGC-ȕ DWWHQXDWH skeletal muscle protein degradation by down-regulating other
ubiquitin ligases, Atrogin-1 and Muscle Ring Finger-1 (MuRF1) [219]. The PGC-Į-
81 
 
and PGC-ȕ-induced decrease in TRIM32 observed in the current study may also 
attenuate protein degradation in skeletal muscle.
3.4.3 Biasedly selected genes
In addition to the genes identified by the GES, the top regulated genes that may 
potentially be involved in skeletal muscle development and growth were explored. In 
response to PGC-Į DQG 3*&-ȕ RYHUH[SUHVVLRQ eEF1A2, eIF2B4, eIF4E3, and 
VEGF-A mRNA was increased, while Caspase1, TCEAL7, TSC22D3, Asprv1, and 
Prnp mRNA was decreased. 
Up-regulated genes
eEF1A2, eIF2B4, and eIF4E3 are all members of protein families known to 
positively regulate translation initiation and elongation [38, 299, 300]. The 
eukaryotic elongation factor, eEF1A2, is known for its role in muscle growth. 
Deletion of eEF1A2 results in severe muscle wasting, weakness, and degeneration of 
motor neurons in wasted mice [301, 302], while overexpression of eEF1A2 prevents 
apoptosis in myotubes in vitro [303]. However the role of eEF1A2 in skeletal muscle 
protein synthesis has not been defined. The translation initiation factor, eIF2B4 (also 
known as eIF%į, LVSDUWRIDQH,)%FRPSOH[FRQVLVWLQJRIĮ-ȕ-Ȗ-į- DQGİ- sub-
units [304]:KLOHWKHUROHRIH,)%įLQVNHOHWDOPXVFOHLVQRWFOHDUWKHİ-sub-unit
protects from the sepsis-induced decrease in protein synthesis in rat skeletal muscle 
[304]. eIF%įP51$ LV LQFUHDVHG LQ VNHOHWDOPXVFOH DIWHU UHVLVWDQFH H[ercise in 
rats [305], suggesting that it may also be involved in the exercise-induced increase in 
protein synthesis. Another translation initiation factor, eIF4E3, is part of the eIF4E 
family which consists of eIF4E1, eIF4E2 and eIF4E3 [306]. The role of eIF4E3 has 
not been investigated in skeletal muscle, although eIF4E1 increases protein synthesis 
in this tissue [38, 307]. However, eIF4E3 is thought to oppose the role of eIF4E1 in 
other tissues [308, 309], suggesting that it may decrease translation initiation.
Lastly, VEGF-A (also known as VEGF) is a major regulator of angiogenesis, and its 
expression is induced by both PGC-ĮDQG3*&-ȕin skeletal muscle [110, 170]. In 
the current experiment, VEGF-A mirrored PGC-ĮH[SUHVVLRQYHU\FORVHO\VEGF-
A expression is increased after acute resistance exercise [310], and recent studies 
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show that VEGF-A can improve muscle regeneration [311, 312]. VEGF-A has also 
been implicated in the pathogenesis of ALS. Reduced circulating levels of VEGF-A
are thought to predispose mice and humans to ALS [313], while genetically 
increasing VEGF-A in rodent models of ALS prevents motor neuron degeneration 
and prolongs survival in rodents [314-316].
Down-regulated genes
The role of TSC22D3 in mammalian tissues is unknown, although other TSC22D 
family members negatively regulate cell proliferation and growth in salivary gland 
cancer cells [317], and cardiac myofibroblast differentiation [318]. Asprv1 is 
involved in proteolysis and regeneration in the skin [319], however its role in other 
tissues is unknown. In contrast, TCEAL7 [320], Prnp [321, 322], and Caspase 1 
[323] may play a role in skeletal muscle growth and wasting. Overexpression of 
TCEAL7 in C2C12 myoblasts decreases proliferation and enhances differentiation 
[320], although its role in terminally differentiated myotubes is unknown. Caspase1 
activity is increased in skeletal muscle undergoing cancer cachexia [324], and other 
caspase family members are known to contribute to protein degradation during 
muscle atrophy [325]. Lastly, Prnp expression is elevated in diseased skeletal muscle 
[326, 327], and skeletal muscle-specific overexpression of Prnp causes muscle 
atrophy and degeneration in vivo [328]. However, reducing Prnp levels decreases 
muscle weight and force production [329], and impairs skeletal muscle regeneration 
in vivo [321]. The role of Prnp in skeletal muscle therefore requires further 
investigation.  
3.4.4 Human clinical models
To determine the clinical relevance of these observations, the expression of PGC-Į
and PGC-ȕDVZHOODVWKHgenes selected from the GES and biased approach, were 
measured in skeletal muscle before and after acute resistance exercise, and in muscle 
samples from ALS patients. Similar to previous studies [330], PGC-ĮP51$ZDV
increased transiently following resistance exercise, while both PGC-ĮDQG3*&-ȕ
were decreased in skeletal muscle of ALS patients [155]. Many genes that were up-
regulated by PGC-Į DQG 3*&-ȕ RYHUH[SUHVVLRQ DOVR IROORZHG WKLV H[SUHVVLRQ
pattern. Of interest, Ppp1R16a, eEF1A2, eIF2B4, and VEGF-A, were increased in 
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skeletal muscle after resistance exercise, while eEF1A2 and VEGF-A were also 
decreased in skeletal muscle of ALS patients. These genes are potentially involved in
skeletal muscle contraction, protein synthesis, and growth [288, 301, 302, 305, 311,
312], and therefore may be involved in the PGC-Į- and PGC-ȕ-induced increase in 
protein synthesis. Future studies are required to determine if these genes may play 
direct roles in regulating skeletal muscle protein synthesis under healthy and diseased 
conditions.
Of the genes that were down-regulated by PGC-Į DQG 3*&-ȕ RYHUH[SUHVVLRQ
TSC22D3 and TRIM32 were also decreased following acute resistance exercise, 
whereas TSC22D3, TRIM32 and Prnp were increased in atrophied skeletal muscle of 
ALS patients. While the role of TSC22D3 in skeletal muscle is unknown, TRIM32 is 
a known ubiquitin ligase in skeletal muscle [298], and overexpression if Prnp causes 
muscle atrophy and degeneration [328]. These observations suggest that TRIM32, 
Prnp, and potentially TSC22D3, may contribute to the PGC-Į- and PGC-ȕ-
induced attenuation of skeletal muscle atrophy.
3.4.5 Summary and Conclusions
PGC-ĮDQG3*&-ȕSRVLWLYHO\UHJXODWHVNHOHWDOPXVFOHPDVVE\LQFUHDVLQJSURWHLQ
synthesis and decreasing protein degradation, however the downstream molecular
mechanisms mediating these responses are relatively unknown. The current study 
used GSEA to identify common biological functions and pathways that are regulated 
by PGC-ĮDQG3*&-ȕ)XUWKHUDQDO\VLVKDVLGHQWLILHGQRYHOJHQHWDUJHWVWKDWZHUH
up- or down-regulated in response to PGC-ĮDQG3*&-ȕRYHUH[SUHVVLRQLQ&&
myotubes. Many of the up-regulated genes were also increased in skeletal muscle 
following resistance exercise (a positive stimulator of protein synthesis [32, 34, 35]),
and decreased in ALS skeletal muscle (a condition with reduced capacity for skeletal 
muscle protein synthesis [15]), suggesting that they may play a role in the PGC-Į-
and PGC-ȕ-induced increase in protein synthesis. In contrast, genes that were 
down-regulated displayed inverse expression in these models, suggesting that their 
decreased expression by PGC-ĮDQG3*&-1ȕPD\FRQWULEXWH WR WKHDWWHQXDWLRQRI
muscle atrophy. These findings provide novel avenues to investigate the effects of 
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PGC-Į DQG 3*&-ȕ LQ VNHOHWDO PXVFOH SURWHLQ WXUQRYHU, however further 
investigation into the role of these genes is required.
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Chapter 4
PGC-1Į and PGC-1ȕ regulate creatine uptake 
via ERRĮ/CrT
4.1 Introduction
Creatine is found at high concentrations in highly metabolically active tissues such as 
skeletal muscle, heart and brain [230]. It plays an important role in maintaining 
cellular energy homeostasis by resynthesising ATP when in its phosphorylated form, 
phosphocreatine. Traditionally, creatine supplementation, in combination with 
resistance training, has been used to assist with skeletal muscle growth [231-233].
More recently, its use in the clinical setting has become of interest. Skeletal muscle 
creatine levels are reduced in many conditions associated with skeletal muscle 
atrophy, such as in patients with muscular dystrophy, and inflammatory, congenital 
and mitochondrial myopathies [229]. Supplementation with creatine monohydrate in 
these patients leads to gains in muscular strength and total body weight [234].
Creatine supplementation also stimulates muscle hypertrophy during rehabilitative 
strength training following limb immobilisation [235], attenuates corticosteroid-
induced muscle wasting in rats [236], and reduces muscular degeneration in mdx 
mice [237]. Creatine therefore appears to be an effective strategy for improving 
skeletal muscle mass in such conditions. However, creatine supplementation does not 
always increase intracellular creatine content, which is controlled via the Na+/Cl-
dependent Creatine transporter (CrT) [238]. Long-term creatine supplementation 
decreases CrT content in rat skeletal muscle [238], and may therefore not be 
effective for longer term use. Furthermore, CrT mRNA is significantly reduced in 
skeletal muscle of patients with various myopathies, suggesting that CrT levels may 
be the limiting factor to increase intracellular creatine content in response to creatine 
supplementation [239, 240]. Understanding the molecular mechanisms regulating the
expression and/or activity of the CrT is therefore important to maximise the 
efficiency and benefits of creatine supplementation in skeletal muscle.
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Currently, little is known about how the CrT is regulated. In healthy rodent skeletal 
muscle, high-dose creatine supplementation (initially increasing intracellular 
creatine) decreases CrT content [238]ZKLOHGHSOHWLRQRILQWUDFHOOXODUFUHDWLQHE\ȕ-
*XDQLGLQRSURSULRQLF DFLG ȕ-GPA), a competitive inhibitor of the CrT, increases 
sarcolemmal CrT expression [241, 242]. Furthermore, slow-twitch oxidative muscle 
fibres have increased CrT and rates of creatine uptake, but have a lower intracellular 
total creatine pool, when compared to fast-twitch glycolytic fibres [243, 244].
However the molecular mechanisms regulating these changes in CrT expression and 
therefore creatine uptake in skeletal muscle are unknown.
The transcriptional coactivators, peroxisome proliferator-activated receptor gamma
coactivator-Į(PGC-1Į) and PGC-1ȕ, are also highly expressed in oxidative muscle 
fibres where they regulate many genes involved energy metabolism, substrate 
oxidation and growth [96, 219]. In particular, they regulate the uptake of two major 
fuel sources in skeletal muscle, glucose and fatty acids. Overexpression of PGC-Į
or PGC-ȕLQrodent skeletal muscle or myotubes results in increased expression of 
the glucose transporter type 4 (GLUT4), with parallel increases in insulin-stimulated 
glucose transport [142, 167]. Similarly, PGC-ĮDQG3*&-ȕLQFUHDVH the expression
of the fatty acid transporter, CD36, as well as many genes associated with fat 
oxidation in skeletal muscle [164, 167]. As creatine is also an important substrate for 
energy production, it is plausible that PGC-ĮRU3*&-ȕmay also regulate the CrT,
and therefore creatine uptake, in skeletal muscle. Furthermore, as many of the 
metabolic effects that PGC-ĮDQGRU3*&-ȕKDYHRQVNHOHWDOPXVFOHKHDOWKLQYROYH
WKHFRDFWLYDWLRQDQGUHJXODWLRQRI(55ĮLWLVSRVVLble that PGC-ĮDQG3*&-ȕPD\
UHJXODWHWKH&U7DQGFUHDWLQHXSWDNHLQDQ(55Į-dependent manner.
In Chapter two, it was established that PGC-Į DQG 3*&-ȕ FDQ LQFUHDVH SURWHLQ
synthesis in mouse C2C12 myotubes. This effect was dependent on the coactivation
of the transcription factor, estrogen-related receptor-DOSKD (55Į EXW WKH
downstream targets regulating this increase in protein synthesis remain elusive. 
Creatine supplementation in vivo increases muscle growth, and although it remains 
controversial on whether this is a result of increased rates of protein synthesis [246,
247], creatine has been shown to increase the synthesis of contractile proteins in 
differentiating myotubes in vitro [248, 249]. It is also noteworthy that many 
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conditions associated with decreased CrT levels and reduced muscle mass [234,
239], also show reduced levels of PGC-Į RU 3*&-ȕ [65, 245]. Therefore it is
possible that PGC-ĮDQG3*&-ȕ may increase protein synthesis by regulating CrT 
levels and increasing intracellular creatine content.
The primary aim of this study was to determine if PGC-Į DQGRU 3*&-ȕ FDQ
increase the expression of the CrT, and therefore regulate creatine uptake in L6 
myotubes. If so, a secondary aim was to determine whether this effect was dependent 
RQ WKH WUDQVFULSWLRQ IDFWRU(55ĮDQGZKHWKHU(55ĮFDQGLUHFWO\ELQG WR WKH&U7
promoter to increase its expression. Finally, it was of interest to determine if the 
PGC-Į- and PGC-ȕ-induced increase in protein synthesis takes places via their up-
regulation of CrT mRNA and creatine uptake.
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4.2 Methods
4.2.1 Cell culture
This study used L6 rat myoblasts (American type culture collection; ATCC, 
Manassas, VA) instead of C2C12 myotubes due to the siRNA sequences being 
specific to the rat. L6 myoblasts were incubated at 37°C with 5% CO2, in high-
glucose Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% 
foetal bovine serum (FBS) 100 U/ml penicillin and 100 μg/ml streptomycin 
(Invitrogen, Carlsbad, CA). Myoblasts were plated at a density of 2 x 104/cm2 in 12-
well plates. Upon confluence (~48 hours), medium was changed to high-glucose 
DMEM supplemented with 2% horse serum (Invitrogen) 100 U/ml penicillin and 100 
μg/ml streptomycin for 6-7 days until multinucleated myotubes had formed. For CrT 
siRNA experiments, medium without penicillin or streptomycin was used. Medium 
was changed every 48 hours. 
4.2.2 CrT siRNA transfections
Myotubes were transfected with 60 pmol pre-designed Stealth RNAiTM siRNA for 
the CrT gene (SLC6A8 solute carrier class 6, member 8) (cat no. RSS328932, 
RSS328933 and RSS328934) or the Stealth RNAi siRNA Negative Control Medium
GC (scramble siRNA; Invitrogen). Transfections were performed using 2μL/well 
Lipofectamine 2000 Transfection Reagent diluted in Opti-MEM Reduced Serum 
Medium (Invitrogen). Medium was replaced after 24 hours. For optimisation of the 
different siRNA sequences, myotubes were harvested for RNA after 72 hours. For all 
other experiments, myotubes were infected with GFP, hPGC-ĮRUK3*&-ȕfor 48 
hours following the transfection. Myotubes were harvested at 72 hours for RNA, 
protein and creatine uptake assays, and 96 hours for protein synthesis assays. 
4.2.3 Adenoviral Infections
siERRa combined with PGC-1 experiments
To infect cells, the required amount of adenovirus was added to fresh cell culture 
medium and then added to each well. Myotubes were infected with an adenovirus 
expressing VL51$IRU(55ĮVL(55ĮRU LWVFRQWUROVL683(5XVLQJDQ02,
After 24 hours, P\RWXEHVZHUH LQIHFWHGZLWK DQ DGGLWLRQDO GRVH RI VL(55Į RU LWV
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control vector), as well as GFP, hPGC-ĮRUK3*&-ȕDWDQ02,RI&HOOVZHUH
harvested after 72 hours for RNA, protein and creatine uptake assays.
VP16-(55ĮH[SHULPHQWV
Myotubes were iQIHFWHGZLWKDQDGHQRYLUXVH[SUHVVLQJ(55ĮZLWKDKHWHURJHQHRXV
strong transcriptional activation domain, VP16-(55Į RU LWV FRQWURO93-control, 
using an MOI of 100. Cells were harvested after 72 hours for RNA, protein, and 
creatine uptake assays. 
4.2.4 Messenger RNA (mRNA) expression
RNA extraction
RNA was extracted using Tri-Reagent solution (Ambion Inc., Austin, TX) according 
to manufacturer’s protocol. RNA concentrations were determined using the 
NanoDrop 2000 (NanoDrop products, Wilmington, DE). RNA (1 μg) was reverse 
transcribed to complementary DNA (cDNA) using a High Capacity cDNA reverse 
transcription kit (Applied Biosystems, Forster City, CA) according to manufacturer’s 
protocol. cDNA was diluted to 5 ng/μl in nuclease free water (NFW). 
Real-time polymerase chain reaction
Real-time quantitative polymerase chain reaction (qPCR) was performed using a 
Stratagene Mx3000P qPCR System and the MxPro qPCR software (Stratagene, La 
Jolla, CA). Cycling conditions for the PCR consisted of one denaturing cycle at 95°C 
for 2 minutes, followed by 40 cycles of denaturing at 95°C for 5 seconds and 
annealing at 60°C for 20 seconds, and elongation at 72°C for 60 seconds. A 
dissociation curve was generated to show that only one product had been amplified 
during the PCR. Each 20 μL reaction contained 0.5 x Power SYBR Green PCR
Master Mix (Applied Biosystems), 25 ng of cDNA, and the forward and reverse 
primers for the gene of interest. Primers were designed to cross exons using Primer 3 
(www.primer3.sourceforge.net) and the sequences cross checked for gene specificity 
using a BLAST search (www.ncbi.nlm.gov/BLAST). Primers were synthesised by 
Gene Works (Adelaide, SA). Genes amplified in the PCR are shown in Table 4.01. 
All samples were measured in triplicate. To compensate for variations in input RNA 
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amounts and efficiency of the reverse transcription, data was normalised ribosomal 
protein, 36B4 (also known as RPLPO) mRNA. 
Table 4.01 Primers used in the real-time qPCR
Primer
GenBank accession 
no. Forward Primer (5’-3’) Reverse Primer (5’-3’)
Rat CrT NM_017348.2 CTGTCTCCTCAGGGCAAAAG CTAAAGCTGGGGCTGCTATG 
Rat 36B4 NM_022402.2 CCAGAGGTGCTGGACATCACAGAG TGGAGTGAGGCACTGAGGCAAC 
4.2.5 Protein expression
Protein extraction
Myotubes were lysed in RIPA buffer (Merck-Millipore, Kilsyth, VIC) with 1 μL/mL 
protease inhibitor cocktail (Sigma-Aldrich, St Louis, MO) and 10 μL/mL Halt 
Phosphatase Inhibitor Single-Use Cocktail (Thermo scientific, Rockford, IL). Protein 
concentrations were determined using the bicinchoninic acid (BCA) Protein Assay 
Kit (Pierce Biotechnology, Rockford, IL) according to the manufacturer’s protocol, 
and absorbance was measured on a Synergy 2 Microplate Reader (BioTek, 
Winooski, VT). 
Western Blotting
Electrophoresis was performed using a 4-12% NuPAGE® Novex Bis-Tris Gel 
(Invitrogen) in NuPAGE® SDS MOPS Running Buffer (Invitrogen). Twenty 
micrograms of protein was loaded into each well of a 10-well gel. Protein transfer 
was performed in a Bjerrum buffer containing 50 mM Tris, 17 mM glycine and 10 % 
methanol using polyvinylidene difluoride (PVDF) membranes (Merck-Millipore).
The membranes were blocked with 5 % bovine serum albumin (BSA; Sigma-
Aldrich) in PBS for one hour, and incubated overnight at 4ºC with the following 
primary antibodies diluted in 5% BSA in PBS: PGC-Į0HUFN-Millipore); PGC-ȕ
1RYXV %LRORJLFDOV /LWWOHWRQ &2 (55Į (SLWRPLFV %XUOLQJDPH &$ and 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH; Sigma-Aldrich). All primary 
antibodies were diluted 1:1,000, except for GAPDH which was diluted 1:10,000). 
Following washing, the membranes were incubated for 1 hour with either IRDye® 
800CW Goat Anti-Rabbit IgG (H+L) (LI-COR Biosciences, Lincoln NE), or Alexa 
Fluor® 680 Rabbit Anti-Mouse IgG (H+L) (Invitrogen), diluted 1:5,000 in PBS 
containing 50% Odyssey Blocking Buffer. Proteins were visualised on an Odyssey 
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Infrared Imaging System (LI-COR Biosciences) and densitometry was achieved 
using Odyssey Application Software 3.0 (LI-COR Biosciences). All blots were 
normalised to GAPDH protein.
4.2.6 Creatine Uptake Assay
Creatine uptake was determine by measuring the incorporation of radiolabelled
[14C]-creatine (American Radiolabeled Chemicals, St Louis, MO) into the myotubes. 
During the last hour of adenoviral infections, myotubes were incubated in creatine 
uptake buffer consisting of DMEM with 2% FBS (Invitrogen), 100 μM creatine 
(Sigma-Aldrich), and 1 μCi/mL [14C]-Creatine. To stop the reaction, myotubes were 
washed in PBS and lysed in 500 μL 0.5 N NaOH/0.1% Triton X-100 (Sigma-
Aldrich). Samples were mixed with Ultima Gold scintillation liquid (Perkin Elmer, 
Boston, MA) and the uptake of [14C]-Creatine was measured using a Wallac 1409 
DSA liquid scintillation counter (Perkin Elmer). Counts were normalised to protein 
content determined via the BCA Protein Assay Kit (Pierce Biotechnology).
4.2.7 Protein synthesis
Protein synthesis was determined by measuring the incorporation of radio-labelled 
[3H]-tyrosine (Perkin Elmer) into the myotubes (modified from [254]). After 
adenoviral infections, myotubes were incubated in 1 μCi/ml of radio-labelled [3H]-
tyrosine and 2 mM L-tyrosine (Sigma-Aldrich). The use of excess non-radioactive 
tyrosine in the medium gives an accurate indication of protein synthesis rates without 
alterations in the free intracellular tyrosine pool [255]. The reaction was stopped by 
washing the cells with cold PBS, and then 0.5 ml of cold 10% trichloroacetic acid 
(TCA; Sigma-Aldrich) was added to each well. After scraping, myotubes sat on ice 
for 1 hour to precipitate the protein, followed by centrifugation at 20,000 x g for 10 
minutes. The supernatant was removed, and the precipitates were dissolved in 0.1 M 
NaOH/1% Triton X-100 (Sigma-Aldrich) overnight at room temperature. The 
samples were mixed with Ultima Gold scintillation liquid (Perkin Elmer) and 
myotube protein radioactivity was measured using a Wallac 1409 DSA liquid 
scintillation counter (Perkin Elmer) and expressed as counts per minute (CPM). 
Counts were normalised to total genomic DNA which was extracted using the 
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Allprep DNA/RNA mini kit (Qiagen, Clifton Hill, VIC), as per the manufacturer’s 
protocol. DNA was quantified using the NanoDrop 2000 (NanoDrop products).
4.2.8 Myotube Diameter
Myotubes were visualised using an Olympus IX70 microscope (Olympus, Mt 
Waverly, VIC), and digital images were obtained using a DS-U3 microscope camera 
and NIS-Elements imaging software (Nikon Instruments Inc., Melville, NY). 
Approximately 10 myotubes from 10 different fields of view were analysed for 
myotube diameter for each condition. Three measurements along each myotube were 
made to allow for differences in diameter across the length of the myotube
4.2.9 Chromatin immunoprecipitation (ChIP)
Cell culture and adenoviral infections
Adenoviruses expressing LacZ, FLAG-tagged PGC-Į (55Į, and short hairpin 
RNA (shRNA) for GFP and (55ĮZHUHDJLIWIURP1DWDVKD.UDOOL6FULSSV5HVHDUFK
Institute, La Jolla, CA) and have been described previously [212, 331]. C2C12 
myoblasts were maintained in DMEM with 10% FBS (Invitrogen, Carlsbad, CA) at 
37 °C with 5% CO2. Confluent myoblasts were differentiated into myotubes by the
addition of DMEM with 2% horse serum (Invitrogen). Myotubes were infected on 
day 4 of differentiation with adenoviruses expressing shRNAs (at MOI 50), and on 
day 6 of differentiation with adenoviruses expressing LacZ (control) and FLAG-
PGC-1Į (at MOI 50), together with a second dose of shRNA-expressing 
adenoviruses (at MOI 25). The cells were harvested 24 h later. 
ChIP assay
ChIP assays were performed with adenovirus-infected C2C12 myotubes as described 
previously [173]. C2C12 myotubes were cross-linked for 10 minutes at 37º in 1% 
formaldehyde in PBS.  After quenching, sonication to ~500bp fragments, and pre-
clearing by treatment with protein A/G sepharose, soluble chromatin was 
immunoprecipitated with the following antibodies: anti-GFP (control), anti-FLAG 
(clone M2) for the detection of FLAG-Tagged PGC-Į RU DQWL-(55Į (Epitomics, 
Burlingame, CA). Genomic DNA in the immunopurified complex was quantified by 
PCR using CrT primers: Forward: 5’ GGATCCCATGGAATCAGGTCTT and 
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Reverse: 5’ GGCAACTGGGAAACAGAAATCA, which amplifies a region 
containing DQ(55Į response element (ERRE) upstream of the transcriptional start-
site. Data were normalised to total genomic DNA input and expressed relative to the 
PCR values in the anti-GFP control samples. 
4.2.10 Statistics
Statistical analyses were performed using either a t-test or a two-way analysis of 
variance (ANOVA) (Prism, GraphPad Software, La Jolla, CA). Multiple t-tests were 
used for post-hoc analysis to determine differences between groups if significant 
interactions were found. The level of significance was set at P < 0.05 for paired t-test 
analysis, while a Bonferroni adjustment was used for the two-way ANOVA reducing 
the level of significance to P < 0.0125. All data is presented as mean ± standard error 
of the mean (SEM) and as fold-change relative to GFP control, unless otherwise 
stated.
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4.3 Results
4.3.1 PGC-ĮDQG3*&-ȕregulate CrT mRNA
Overexpression of PGC-Į DQG 3*C-ȕ LQ /P\RWXEHV led to a 2.1-and 1.7-fold 
increase in CrT mRNA expression respectively (Figure 4.01).
Figure 4.01 CrT mRNA expression in GFP, PGC-Į DQG3*&-ȕ LQIHFWHG/P\RWXEHV. Samples 
were harvested 48 hours after infection. Values were normalised to 36B4 mRNA expression. n = 5 per 
group. *P < 0.01 compared to GFP.
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4.3.2 PGC-ĮDQG3*&-ȕregulate creatine uptake via the creatine 
transporter.
As PGC-Į DQG3*&-ȕ LQFUHDVH&U7P51$ H[SUHVVLRQ, creatine uptake into the 
cells was also measured. To confirm that the effect of PGC-Į DQG 3*&-ȕ RQ
creatine uptake was via their increase in CrT levels, myotubes were co-transfected 
with siRNA for CrT. The efficiency of the CrT siRNA was determined by 
transfecting L6 myotubes with three different CrT sequences, cat no. RSS328932,
RSS328933 and RSS328934 (hereon referred to as 932, 933 and 934, respectively),
as well as the scramble siRNA control. Figure 4.02A shows that there was a 71%, 
65% and 69% decrease in CrT mRNA expression with the 932, 933, and 934 siRNA 
sequences respectively. CrT protein expression was unable to be measured due to 
antibody unavailability [332, 333]. Sequences 932 and 934 were then used for future 
experiments to ensure optimal knockdown of CrT. Figure 4.02B shows CrT mRNA 
expression when myotubes were transfected with CrT siRNA and overexpressed
with PGC-ĮDQG3*&-ȕTransfection with CrT siRNA lead to a 52% decrease in 
CrT mRNA in the GFP group. PGC-ĮDQGPGC-ȕLQFUHDVHG&U7P51$E\-
and 1.7-fold respectively, however this was attenuated with the co-transfection of the 
CrT siRNA.
Figure 4.02 CrT mRNA expression in L6 myotubes. (A) CrT mRNA expression measured 72 hours 
after transfection with CrT siRNAs 932, 933 and 934, compared to the scramble siRNA control. 
Values were normalised to 36B4 mRNA. *P < 0.01 compared to scramble siRNA. (B) CrT mRNA
expression in GFP, hPGC-Į- and hPGC-ȕ-infected L6 myotubes, co-transfected with either 
scramble or CrT siRNA. Values were normalised to 36B4 mRNA. n = 5 per group. *P < 0.0125
compared to GFP scramble siRNA; #P < 0.0125 compared to scramble siRNA for each group. 
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Figure 4.03A and figure 4.03B show protein expression via western blot analysis for 
PGC-ĮDQG3*&-ȕUHVSHFWLYHO\WRFRQILUPWKHLURYHUH[SUHVVLRQLQWKHVHVDPSOHV
No differences were seen in PGC-ĮRU3*&-ȕSURWHLQOHYHOVEHWZHHQVFUDPEOHDQG
CrT siRNA.
Figure 4.03 PGC-Į DQG 3*&-ȕ protein expression GFP-, hPGC-Į- and hPGC-ȕ-infected L6 
myotubes, co-transfected with either scramble or CrT siRNA. Samples were harvested after 72 hours. 
(A) PGC-ĮSURWHLQDQG%3*&-ȕSURWHLQ%DQGVZHUHQRUPDOLVHGWR*$3'+SURWHLQQ SHU
group. *P < 0.0125 compared to GFP-scramble siRNA.
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Figure 4.04 shows that PGC-Į DQG 3*&-ȕ RYHUH[SUHVVLRQ LQFUHDVHG FUHDWLQH
uptake by 1.8- and 1.6-fold respectively, when compared to GFP. Similar to the 
expression of CrT mRNA, co-transfection with CrT siRNA reduced creatine uptake 
by 40% in the GFP samples and prevented the PGC-Į- and PGC-ȕ-induced 
increase in creatine uptake.
Figure 4.04 Creatine uptake in GFP, PGC-ĮDQG3*&-ȕLQIHFWHG/P\RWXEHVFR-transfected with 
either scramble or CrT siRNA. [14C]-creatine incorporation was measured during the last hour of 
infection. n = 6 per group, repeated in 3 experiments. *P < 0.0125 compared to GFP scramble siRNA;
#P < 0.0125 compared to scramble siRNA for each group. 
 
4.3.3 PGC-ĮDQG3*&-ȕUHJXODWHCr7DQGFUHDWLQHXSWDNHYLD(55Į
To determine if PGC-Į DQG 3*&-ȕ UHJXODWH creatine transport YLD (55Į /
myotubes were co-infected with VL(55ĮRUits control vector siSUPER. Figure 4.05A
VKRZVSURWHLQH[SUHVVLRQ IRU(55Į WRFRQILUP LWVNQRFNGRZQ LQ/P\otubes. As 
expected [100, 190], PGC-Į DQG 3*&-ȕ RYHUH[SUHVVLRQ OHDG WR D VLJQLILFDQW
LQFUHDVHLQ(55ĮSUotein. ,QIHFWLRQZLWKVL(55ĮUHGXFHG(55ĮSURWHLQLQDOOJURXSV
when compared to siSUPER. However, when compared to GFP, (55ĮSURWHLQZDV
still higher in the PGC-Į DQG 3*&-ȕ JURXSV Figure 4.05B and C show protein 
expression for PGC-ĮDQG3*&-ȕ respectively, to confirm their overexpression in 
the samples. PGC-Į H[SUHVVLRQZDV LQFUHDVHG LQ ERWK WKH VL683(5 DQG VL(55Į
groups when compared to GFP (Figure 4.05B). PGC-ȕ H[SUHVVLRQ ZDV DOVR
increased in both groups; however it was lower in the PGC-ȕ-VL(55Į group when 
compared to the PGC-ȕ-siSUPER group (Figure 4.05C).
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Figure 4.05 (55Į3*&-ĮDQG3*&-ȕSURWHLQH[SUHVVLRQ LQ/P\RWXEHV LQIHFWHGZLWK VL(55Į
and PGC-1 adenoviruses. 0\RWXEHV ZHUH LQIHFWHG ZLWK HLWKHU VL683(5 RU VL(55Į IROORZHG E\
infection with GFP, hPGC-ĮRUK3*&-ȕ6DPSOHVZHUHKDUYHVWHGDIWHUKRXUV$(55Įprotein, 
(B) PGC-ĮSURWHLQDQG&3*&-ȕSURWHLQ%DQGVZHUHQRUPDOLVHGto GAPDH protein. n = 4 per 
group. *P < 0.0125 compared to GFP-siSUPER; **P < 0.0125 compared to GFP-VL(55Į #P <
0.0125 compared to siSUPER for each group. 
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.QRFNGRZQRI(55ĮUHGXFHG&U7P51$E\LQWKH*)3LQIHFWHGVDPSOHVDQG
also prevented the increase in CrT mRNA that was seen with PGC-ĮDQG3*&-ȕ
overexpression (Figure 4.06A). PGC-Į DQG 3*&-ȕ RYHUH[SUHVVLRQ increased
creatine uptake in the siSUPER control samples (Figure 4.06B). Knockdown of 
(55ĮLQKLELWHGWKLVLQFUHDVHLQFUHDWLQHXSWDNHbut had no effect on creatine uptake 
in the GFP samples. 
 
Figure 4.06 CrT mRNA and creatine uptake in / P\RWXEHV LQIHFWHG ZLWK VL(55Į DQG 3*&-1
adenoviruses. 0\RWXEHVZHUH LQIHFWHGZLWK HLWKHU VL683(5RU VL(55Į IROORZHGE\ LQIHFWLRQZLWK
GFP, hPGC-Į RU K3*&-ȕ Samples were harvested after 72 hours. (A) CrT mRNA expression, 
normalised to 36B4 mRNA expression. (B) Creatine uptake, determined by [14C]-creatine 
incorporation during the last hour of infection. n = 6 per group, repeated in 3 experiments. *P <
0.0125 compared to GFP siSUPER; #P < 0.0125 compared to siSUPER for each virus.
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4.3.4 Constitutivel\DFWLYH(55ĮLQFUHDVHV&U7H[SUHVVLRQDQGFUHDWLQH
uptake.
7KHSUHYLRXVUHVXOWVVKRZWKDW(55ĮPD\UHJXODWHFUHDWLQHXSWDNHZKHQDFWLYDWHGE\
PGC-ĮRU3*&-ȕEXWKDGQRHIIHFWXQGHUEDVDOFRQGLWLRQV7RIXUWKHUVXSSRUWWKH
UROHRI(55ĮLQWKHUHJXODWLRQ of creatine uptake, L6 myotubes were expressed with 
DFRQVWLWXWLYHO\DFWLYHIRUPRI(55Į93-(55ĮDQGLWVFRQWURO93-control).  
Figure 4.07 shows that infection with VP16-(55Į DW DQ 02, RI  OHDG WR
approximately a 4-IROGLQFUHDVHLQ(55ĮSURWHLQ
Figure 4.07 (55ĮSURWHLQLQ/P\RWXEHVLQIHFWHGZLWK93-(55Į93-control was the control 
adenovirus. Samples were harvested after 48 hours. Bands were normalised to GAPDH protein. n = 4 
per group. *P < 0.01 compared to VP16-control.
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VP16-(55Į LQIection increased CrT mRNA by approximately 8-fold when 
compared to VP16-control (Figure 4.08A). Furthermore, creatine uptake was 
increased by roughly 2.2-fold when compared to the VP16-control group (Figure 
4.08B).
Figure 4.08 CrT mRNA and creatine uptake in L6 myotubes infected with VP16-(55Į 6DPSOHV
were harvested after 72 hours of infection. (A) CrT mRNA expression, normalised to 36B4 mRNA. 
(B) Creatine uptake, determined by [14C]-creatine incorporation during the last hour of infection. n = 6 
per group, repeated in 3 experiments. *P < 0.01 compared to VP16-control. 
 
4.3.5 (55ĮLVHVVHQWLDOIRUUHFUXLWPHQWRI3*&-ĮWRWKH&U7SURPRWHU
To WHVW LI(55ĮDQG3*&-ĮDFWGLUHFWO\ DW WKHCrT gene to induce its expression, 
ChIP was performed to determine ZKHWKHU (55Į DQG 3*&-Į LQWHUDFW physically 
with the CrT promoter. Analysis of the CrT genomic sequence indicated a putative 
(55ĮELQGLQJVLWHmatching the known 9 bp ERRE consensus 5’-TNAAGGTCA-3’ 
[244] and conserved across species (Figure 4.09A), suggesting that CrT is a direct 
target of PGC-Į DQG (55Į. To determine binding of endogenous (55Į and 
exogenous adenovirally-expressed PGC-ĮDWWKLVUHJLRQcrosslinked chromatin was 
immunoprecipitated with antibodies against either GFP (control antibody measuring 
background), FLAG-tagged PGC-ĮRU(55ĮDQGWKHHQULFKPHQWRIWKH&U7ORFXV
DNA in the immunoprecipitated material was measured. Both PGC-Į DQG (55Į
were detected at the CrT ERRE (Figure 4.09B). (55ĮZDVGHWHFWHGDWWKHCrT locus 
only when PGC-ĮZDVH[SUHVVHGLHZKHQHQGRJHQRXV(55ĮOHYHOVZHUHLQGXFHG
[238]. Knockdown of HQGRJHQRXV(55Į H[SUHVVLRQ E\ VhRNA ablated binding of 
PGC-ĮWRWKHCrT ERRE (Figure 4.09BGHPRQVWUDWLQJDFULWLFDOUROHIRU(55ĮLQ
recruitment of the PGC-ĮFRDFWLYDWRUWRthe CrT promoter.
102 
 
 
Figure 4.09 PGC-ĮDQG(55ĮELQGDQ(55(LQ WKHILUVW LQWURQRI WKH&U7SURPRWHU $Graphic 
representation of the ERRE located in the first intron of the CrT promoter across species (University 
of California, Santa Cruz, genome browser). (B) ChIPs were performed using antibodies against GFP 
(control), FLAG (PGC-Į DQG (55Į LQ && P\RWXEHV LQIHFWHG ZLWK DGHQRYLUXVHV H[SUHVVLQJ
LacZ (control) or PGC-ĮLQWKHDEVHQFH(shGFP) RUSUHVHQFHRIVK51$IRU(55ĮVK(55ĮThe 
abundance of CrT ERRE is expressed relative to each region in the control, GFP samples. Data are 
mean ± SD of two independent experiments (n = 5). 
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4.3.6 PGC-ĮDQG3*&-ȕLQFUHDVH protein synthesis and myotube 
diameter independently of CrT
To determine whether the PGC-Į-and PGC-ȕ-induced increase in protein synthesis 
was via their increase in CrT and creatine transport, [3H]-tyrosine incorporation was 
measured in these samples. Figure 4.10A shows that PGC-Į DQG 3*&-ȕ
overexpression lead to a 19% and 23% increase in protein synthesis respectively,
when compared to GFP. However this effect was not influenced by the knock-down 
of the CrT. Similarly, knockdown of CrT did not affect myotube diameter in L6 
myotubes (Figure 4.10A & B).
Figure 4.10 Protein synthesis and myotube diameter in GFP-, PGC-Į- and PGC-ȕ-infected L6 
myotubes, co-transfected with either scramble or CrT siRNA. (A) Protein synthesis, measured via 
[3H]-tyrosine incorporation for 24 hours following adenovirus infection. n = 6 per group, repeated in 3 
experiments. (B) Average myotube diameter from 10 myotubes per visual field (10 visual fields for 
each group). (C) Representative images of GFP, PGC-Į DQG 3*&-ȕ LQIHFWHG P\RWXEHV ZLWK
scramble or CrT siRNA. *P < 0.0125 compared to GFP-scramble siRNA. 
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4.4 Discussion 
Skeletal muscle creatine levels are reduced in many conditions associated with 
skeletal muscle atrophy [229], and creatine supplementation increases muscular 
strength and mass under such conditions [234]. However, the ability for creatine to 
enter the cell is dependent on the CrT, and CrT levels are often reduced in diseased 
skeletal muscle [239]. As such, understanding the molecular mechanisms that 
regulate the CrT and creatine uptake into skeletal muscle is important for restoring or 
increasing intracellular creatine levels and improving skeletal muscle health. This 
study aimed to determine whether PGC-Į DQG 3*&-ȕ FDQ UHJXODWH WKH&U7 DQG
creatine uptake in rat L6 myotubes, and whether PGC-Į DQG 3*&-ȕ LQFUHDVH
protein synthesis by increasing the CrT and intracellular creatine uptake. Several 
novels observations were made. Firstly, overexpression of PGC-Į RU 3*&-ȕ
increased CrT mRNA as well as creatine uptake into L6 myotubes. Secondly, these
effects were GHSHQGHQW RQ WKH WUDQVFULSWLRQ IDFWRU (55Į 7KLUGO\ 3*&-Į DQG
(55Į GLUHFWO\ ELQG to the CrT promoter to induce its expression. And lastly, the 
PGC-Į- and PGC-ȕ-induced increase in protein synthesis and myotube diameter
was not associated with CrT or intracellular creatine content.
In skeletal muscle, PGC-Į DQG 3*&-ȕ DUH expressed in a similar manner to the 
CrT, as they are highly expressed in oxidative muscle fibres [163, 177] and down-
regulated in many disease conditions associated with skeletal muscle atrophy [65,
155]. PGC-ĮDQG3*&-ȕUHgulate the expression of many genes involved in energy 
metabolism [96]. Therefore, it was of interest to determine whether they may
regulate CrT expression and creatine uptake, which are critical to maintaining 
cellular energy homeostasis. For the first time, this study has shown that 
overexpression of PGC-Į RU 3*&-1ȕ increase CrT mRNA and uptake of [14C]-
Creatine in L6 myotubes. It is important to note that CrT protein levels were unable 
to be measured due to a lack of specific antibodies [333]. However, the increased 
creatine uptake is a good indication of CrT function [334]. In addition, knockdown of 
the CrT using siRNA completely ablated this effect. As decreased intracellular 
creatine is thought to regulate CrT expression [241, 242], it is possible that under 
normal conditions, a decrease in creatine within the muscle may signal to PGC-Į
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and PGC-ȕWRLQFUHDVH&U7H[SUHVVLRQ3*&-ĮDFWLYLW\ LV induced in response to 
metabolic stress [94, 335], in particular, by activation from the energy sensor, 5'
adenosine monophosphate-activated protein kinase (AMPK) [134, 136]. Increased 
levels of phosphocreatine down-regulate AMPK in mouse myotubes in vitro [336],
ZKLOH WUHDWPHQWZLWK ȕ-GPA, a competitive inhibitor of the CrT, increases AMPK 
expression in the soleus muscle of mice [152]. Interestingly, PGC-Į DQG3*&-ȕ
P51$ DUH DOVR VOLJKWO\ LQFUHDVHG DIWHU ȕ-GPA treatment [152]. Furthermore,
activation of AMPK by 5-aminoimidazole-4-carboxamide-1-ȕ-D-ribonucleoside 
(AICAR) increases creatine transport and CrT content in rodent cardiomyocytes
[337]; whether this is directly via PGC-Į or PGC-ȕ however, has not been
investigated. Moreover, it is unknown whether PGC-ȕFDQEHUHJXODWHGE\$03.,
and therefore further investigation is required into signalling mechanisms that may 
be responsible for the induction of PGC-ȕ, as well as PGC-Į to increase CrT
expression and creatine uptake in skeletal muscle.  
In skeletal muscle, PGC-Į DQG 3*&-ȕ LQGXFH WKH H[SUHVVLRQ RI PDQ\ JHQHV
involved in energy metabolism and mitochondrial function via their co-activation of 
(55Į [160, 190]. In chapter 2, it was established that PGC-ĮDQG3*&-ȕLQFUHDVH
protein synthesis in C2C12 myotubes, and that this effect is also dependent on 
(55Į ,W ZDV WKHUHIRUH RI LQWHUHVW WR GHWHUPLQH ZKHWKHU 3GC-Į DQG 3*&-ȕ
increase CrT mRNA expression and creatLQHXSWDNHYLD(55Į.QRFNGRZQRI(55Į
using siRNA inhibited the PGC-Į- and PGC-ȕ-induced increase in CrT mRNA 
DQGFUHDWLQHXSWDNH LQ/P\RWXEHV+RZHYHUNQRFNGRZQRI(55ĮGLGQRWDIIHFW
creatine uptake under basal conditions (i.e. in the GFP-infected cells), despite a 25% 
decrease in CrT mRNA. The lack of effect on basal creatine uptake is in line with 
other studies that suggest (55Įis active only when coactivated by PGC-ĮRU3*&-
1ȕ[212]. IWZDVLQWHUHVWLQJWKDW&U7P51$ZDVGHFUHDVHGVKRZLQJWKDW(55ĮPD\
have been partially active under basal conditions. However additional studies are 
required to determine this. )XUWKHU VXSSRUWLQJ WKH UROHRI(55Į LQ creatine uptake,
RYHUH[SUHVVLRQRI D FRQVWLWXWLYHO\ DFWLYH(55Į LQFUHDVHG&U7P51$DQGFUHDWLQH
uptake by 8- and 2.2-fold respectively. Lastly, ChIP assays revealed that PGC-ĮDQG
(55Į GLUHFWO\ interact with the CrT promoter. These findings, together with the 
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(55ĮNQRFNGRZQ H[SHULPHQWV VXJJHVW WKDW(55Į LV FUXFLDO IRU WKH3*&-Į- and 
PGC-ȕ-induced increase in CrT mRNA and creatine uptake.
Creatine supplementation increases strength, fat-free mass, and muscle fibre size
when used in combination with resistance training [231-233], or in the treatment of 
myopathies presenting with muscle atrophy [234-236]. Whether this is due to an 
increase in protein synthesis is debateable [246, 247], although early studies show 
that creatine increases the synthesis of contractile proteins in differentiating 
myotubes in vitro [248, 249]. The current study has observed that the PGC-Į(55Į
and PGC-ȕ(55Į WUDQVFULSWLRQDO SDWKZD\V UHVXOW LQ LQFUHDVHG &U7 P51$
expression and creatine uptake in L6 myotubes. It is therefore plausible that PGC-Į
and PGC-ȕPD\LQFUHDVHSURWHLQV\QWKHVLVE\LQFUHDVing CrT mRNA in myotubes.
However, knockdown of CrT mRNA and inhibiting creatine uptake did not affect the 
PGC-Į- or PGC-ȕ-induced increase in protein synthesis or myotube diameter in 
L6 myotubes. This is the first study to measure protein synthesis in myotubes after 
decreasing CrT mRNA and intracellular creatine levels, however these findings are 
in line with studies that have shown that creatine supplementation does not increase 
protein synthesis in vivo [246, 247]. These studies also show that creatine 
supplementation increases muscle fibre size, however knocking down the CrT and 
decreasing creatine uptake in the current study did not effect myotube size in vitro.
In summary, this study has shown for the first time that overexpression of the 
transcriptional coactivators, PGC-Į DQG 3*&-ȕ can increase CrT mRNA and 
creatine uptake in L6 myotubes LQDQ(55Į-dependent manner. These novel findings
provide insight into how the CrT and creatine uptake are regulated in skeletal 
muscle, which may assist in the treatment of patients suffering from myopathies 
characterised by decreased CrT and intracellular creatine levels. Finally, knockdown 
of the CrT and decreased creatine uptake does not affect protein synthesis or 
myotube diameter in L6 myotubes.
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Chapter 5 
General Discussion, Conclusions and Future
Directions
5.1 Summary of Major Findings
Skeletal muscle mass is regulated by a fine balance between protein synthesis and 
protein degradation [31]. Decreased rates of protein synthesis in combination with 
increased rates of protein degradation result in skeletal muscle atrophy, a devastating 
condition contributing to increased morbidity and mortality. Understanding the 
molecular and physiological mechanisms involved in the regulation of muscle mass 
is therefore a prerequisite for developing therapeutic interventions to improve
clinical outcomes. The transcriptional coactivators, PGC-1Į and PGC-1ȕ, positively 
regulate skeletal muscle mass via their attenuation of protein degradation. However, 
their effect on protein synthesis is unknown. The general aim of this thesis was to 
investigate the roles of PGC-Į and PGC-1ȕ in the regulation of protein synthesis in 
C2C12 myotubes, a rodent skeletal muscle cell line.
In Chapter 2, it was shown for the first time that overexpression of PGC-Į DQG
PGC-ȕLQFUHDVHGSURWHLQV\QWKHVLVDQGP\RWXEHGLDPHWHULQ&&P\RWXEHV This 
effect on protein synthesis also occurred in myotubes treated with dexamethasone,
suggesting that PGC-Į DQG 3*&-ȕ PD\ KDYH WKH SRWHQWLDO WR LQFUHDVH SURWHLQ
synthesis in vivo during systemic wasting diseases. Secondly, this increase in protein 
synthesis was independent of Akt and mTOR signalling, as this effect was not 
prevented after treatment with inhibitors of these pathways. Interestingly, the 
phosphorylation of Akt and p70S6k was suppressed after PGC-Į DQG 3*&-ȕ
overexpression, although the functional significance of these findings is unknown. 
Lastly, knockdown of the transcription factor, estrogen-related receptor alpha
((55Į) using siRNA prevented the PGC-Į- and PGC-ȕ-induced increase in 
protein synthesis and myotube diameter, while expression of a constitutively active 
(55Į H[DFHUEDWHG WKLV HIIHFW Like many other important PGC-Į- or PGC-ȕ-
PHGLDWHGSURFHVVHV LQVNHOHWDOPXVFOH(55ĮLV WKHUHIRUH UHTXLUHG IRU3*&-ĮDQG
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PGC-ȕ WR LQFUHDVH SURWHLQ V\QWKHVLV LQ && P\RWXEHV ,Q DGGLWLRQ WR WKHLU
already known effect on the attenuation of myotube protein degradation, these 
findings show that PGC-Į DQG 3*&-ȕ FDQ also increase protein synthesis, and 
therefore present as attractive targets for the development of treatment strategies to 
alleviate the debilitating effects of muscle atrophy. However, further investigation 
into the downstream targets regulated by PGC-ĮDQG3*&-ȕLVUHTXLUHG
In Chapter 3, global gene and protein expression profiling was undertaken to 
investigate potential downstream targets that PGC-ĮDQG3*&-ȕPD\ UHJXODWH WR
positively influence muscle mass. Gene set enrichment analysis (GSEA) identified 
several Gene Ontology (GO) terms and Kyoto Encyclopedia of Genes and Genomes
(KEGG) pathways differentially regulated in response to PGC-Į RU PGC-ȕ
overexpression in C2C12 myotubes. Common GO terms were related to 
mitochondrial biology, energy metabolism, nucleotide binding, and the ribosome.
Genes and proteins differentially expressed, specifically by PGC-ȕ, also clustered 
significantly with muscle contractile and cytoskeletal related GO terms. Similar to 
the GO terms, KEGG pathway mapping identified pathways associated with 
oxidative phosphorylation in both normal and disease states, and carbohydrate and 
fatty acid metabolism. 
Further analysis of the genes differentially regulated in the microarray led to the 
identification of a non-biased gene expression signature (GES) which revealed the 
top regulated genes by PGC-ĮDQG3*&-ȕ,QDGGLWLRQKLJKO\UHJXODWHGJHQHVthat
may potentially be involved in muscle growth were biasedly selected and also 
explored. Of the up-regulated genes identified in the non-biased and biased 
approaches, protein phosphatase 1, regulatory subunit 16A (Ppp1R16a), eukaryotic 
translation elongation factor 1 alpha 2 (eEF1A2), eukaryotic translation initiation 
factor 2B, subunit 4 (eIF2B4), and vascular endothelial growth factor-A (VEGF-A) 
were of interest. Similar to PGC-Į H[SUHVVLRQ DOO RI WKHVH JHQHV ZHUH DOVR
significantly elevated in skeletal muscle after resistance exercise. Furthermore, 
eEF1A2 and VEGF-A mRNA were decreased in skeletal muscle of amyotrophic 
lateral sclerosis (ALS) patients, which corresponded with decreases in both PGC-Į
and PGC-ȕP51$7KHVHREVHUYDWLRQVSURYLGHSRWHQWLDO GRZQVWUHDP WDUJHWV WKat 
111 
 
PGC-Į DQG 3*&-ȕ PD\ UHJXODWH WR LQFUHDVH SURWHLQ V\QWKHVLV IRU IXWXUH
investigation.
In contrast, of the genes that were down-regulated by PGC-Į DQG 3*&-ȕ
Tripartite motif-containing protein 32 (TRIM32) and TSC22 domain family protein 3
(TSC22D3) were also decreased after resistance exercise and increased in skeletal 
muscle of ALS patients. TRIM32 is a ubiquitin ligase known to induce protein 
degradation in skeletal muscle [298], and its down-regulation by PGC-ĮDQG3*&-
ȕVXJJHVWVDQHZDGGLWLRQDOPHFKDQLVPE\ZKLFK3*&-ĮDQG3*&-ȕDWWHQXDWH
protein degradation. Lastly, Prion protein (Prnp) mRNA was also increased in 
skeletal muscle of ALS patients. This protein is increased in skeletal muscle during 
other myopathies [326, 327], and skeletal muscle-specific overexpression if Prnp 
causes muscle atrophy and degeneration in vivo [328]. It would be interesting to 
determine the effects of the PGC-Į- and PGC-ȕ-induced down-regulation of Prnp 
on skeletal muscle growth. Overall, the genes identified in Chapter 3 present as 
interesting new potential targets that may be involved in the regulation of skeletal 
muscle mass by PGC-ĮRU3*&-ȕ
Lastly, Chapter 4 established that overexpression of PGC-ĮDQG3*&-ȕLQFUHDVHG
Creatine transporter (CrT) mRNA expression and creatine uptake in L6 myotubes. 
This effect was again dependent on the transcriptiRQIDFWRU(55ĮDQGLWZDVVKRZQ
that PGC-ĮDQG(55ĮGLUHFWO\ELQGWRWKH&U7SURPRWHUWRLQGXFHLWVH[SUHVVLRQIn 
skeletal muscle, PGC-Į(55Į RU 3*&-ȕ(55Į DUH NQRZQ WR LQFUHDVH
mitochondrial biogenesis, the expression of OXPHOS genes, mitochondrial fusion, 
fatty acid oxidation, oxidative muscle fibre phenotype, and angiogenesis. Creatine 
uptake, as well as protein synthesis, can now be added to this list. These findings 
provide a commonality between muscle atrophy, mitochondrial impairments, and 
reduced intracellular creatine and CrT expression that is often observed during 
myopathies. This may provide a basis for a treatment strategy aimed at improving 
various aspects of skeletal muscle diseases. Lastly, the PGC-Į- and PGC-ȕ-
induced increase in protein synthesis was not dependent on the CrT, and therefore 
other mechanisms may be responsible for the increase in muscle mass seen in
response to increasing intracellular creatine. 
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5.2 Future directions
 
5.2.1 The effect of PGC-ĮDQG3*&-ȕRQSURWHLQVynthesis in vivo.
Rationale
In Chapter 2, it was shown that overexpression of PGC-Į DQG 3*&-ȕ LQFUHDVHV
protein synthesis in C2C12 myotubes in vitro7KLVHIIHFWZDVGHSHQGHQWRQ(55Į
These studies suggest that PGC-Į DQG 3*&-ȕPD\ LQFUHDVH SURWHLQ V\Qthesis in 
vivo YLD(55Į, however this has not been investigated.
Aims
To investigate the effect of PGC-Į(55ĮDQG PGC-ȕ(55Į on protein synthesis 
in vivo.
Key methods
PGC-Į DQG 3*&-ȕ RYHUH[SUHVVLRQ in vivo can be achieved using recombinant 
adeno-associated viruses (rAAV) to infect mature skeletal muscle in mice. rAAVs 
are small single-stranded DNA viruses that are currently seen as attractive gene 
therapy tools to induce long-term gene expression changes without any associated 
pathological effects [338]. This technique also allows gene expression to be induced 
(i.e. after a catabolic stimulus), rather than using transgenic expression tools that
require the target of interest to be overexpressed from the embryo. Currently, rAAVs 
are being used in several clinical trials for the treatment of muscular dystrophies 
[339]. rAAVs overexpressing PGC-Į RU 3*&-ȕ FRXOG EH LQIHFWHG LQWR (55Į
knockout mice [340], and appropriate wild-type controls. In addition to basal 
conditions, these infections would also be carried out in different models known to 
decrease skeletal muscle protein synthesis, such as hindlimb immobilisation [341]
and dexamethasone treatment [224, 342]. Outcome measures include measurement 
of protein synthesis, muscle fibre diameter and contractile function in vivo, as well as 
gene and protein expression analyses of potential downstream targets. The 
assessment of protein synthesis in vivo can be determined as described previously 
[343]. Briefly, following optimisation of the infection and treatment conditions, mice 
are injected intravenously with [13C] leucine. Hindlimb muscles are extracted for the 
isolation of mixed, mitochondrial, and sarcoplasmic muscle proteins. Muscle 
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samples are then homogenized, hydrolysed, and the protein-derived amino acids 
purified by cation exchange chromatography. Measurement of [13C]-leucine 
enrichment in muscle proteins is performed using a gas chromatography–isotope 
ratio mass spectrometer. Contractile function can be measured as described 
previously [344]. In brief, mice are anesthetized and the tibialis anterior (TA)
muscle is exposed by a single incision. The TA muscle is stimulated by 
supramaximal (10 V) 0.2 ms square-wave pulses for 300 ms in duration, delivered 
via two wire electrodes adjacent to the femoral nerve. Muscle length (Lo) can be 
determined from maximal twitch force (Pt) and maximum tetanic force production 
(Po) recorded from the plateau of a full frequency-force curve. Optimum fibre length 
(Lf) can be determined by multiplying Lo by the TA Lf/Lo ratio of 0.6 [345]. An 
isometric contraction will be initiated and held for 100 ms to allow a plateau in 
maximal force. Muscle lengthening occurs at a velocity of 2 Lf/s at progressively 
increasing magnitudes of stretch at 5, 10, 20, 30 and 40% of Lf with Po determined 
prior to each lengthening contraction. This protocol examines the functional deficits 
following successive lengthening contractions of increasing magnitude. Muscle fibre 
diameter can be measured by microscopic examination of muscle sections, while
gene and protein expression analyses can be performed using real-time qPCR and 
western blotting respectively. 
Significance
PGC-ĮDQG3*&-ȕLQFUHDVHSURWHLQV\QWKHVLVin vitro, and this is dependent on the 
WUDQVFULSWLRQIDFWRU(55ĮThe proposed study is required to determine whether this 
observation can be extended to in vivo models. An additional benefit of this model is 
the use of rAAVs to overexpress the gene of interest. Previous in vivo models 
investigating the effects of PGC-ĮRU3*&-ȕRQVNHOetal muscle mass have used 
transgenic models to investigate their effects [153, 191, 219]. Therefore, the gene of 
interest is overexpressed before the onset of a catabolic stimulus. Using an rAAV, it 
can be determined if PGC-Į DQG3*&-ȕ FDQ LQFUHDVH SURWHLQ V\QWKHVLV DIWHU WKH
onset of certain catabolic stimuli. This is more relevant to a human clinical setting, 
whereby treatment is usually given after a disease or condition has presented with 
symptoms. Results from the proposed study would be useful to identify possible 
molecular targets to therapeutically stimulate protein synthesis during catabolic 
conditions in vivo.
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5.2.2 Identifying the molecular mechanisms required for the PGC-Į- and 
PGC-ȕ-induced increase in protein synthesis
Rationale
In Chapter 3, bioinformatic analysis identified several genes that were differentially 
expressed in response to PGC-ĮRU3*&-ȕRYHUH[SUHVVLRQLQZKLFKWKHLUIXQFWLRQV
in skeletal muscle have not been well characterised. Of interest, Ppp1R16a, eEF1A2,
eIF2B4, and VEGF-A, were increased in skeletal muscle after resistance exercise,
while eEF1A2 and VEGF-A were also decreased in skeletal muscle of ALS patients. 
These are known conditions of increased and decreased muscle protein synthesis 
respectively. However, whether these genes are involved in the regulation of protein 
synthesis by PGC-ĮDQG3*&-ȕLVXQNQRZQ
Aims
To determine if Ppp1R16a, eEF1A2, eIF2B4, and VEGF-A are required for the 
PGC-Į DQG 3*&-ȕ-induced increase in protein synthesis in C2C12 myotubes in 
vitro.
Key Methods
To determine if Ppp1R16a, eEF1A2, eIF2B4, and VEGF-A are involved in 
regulating protein synthesis, siRNAs can be designed to knockdown their expression 
in vitro. Experiments can then be carried out using similar methods as in Chapters 2 
and 4. Briefly, C2C12 myoblasts are grown and differentiated into myotubes. After 
optimisation conditions for each specific siRNA sequence, myotubes are transfected 
with siRNA for 24 hours to knockdown the gene of interest. Myotubes are then 
infected with adenoviruses expressing GFP, hPGC-Į RU KPGC-ȕ IRU  KRXUV
Protein synthesis is determined by [3H]-tyrosine incorporation over 24 hours into the 
myotubes, while myotube diameter is measured via microscopic examination.
Significance
The proposed study is required to determine if the differentially regulated genes 
identified in Chapter 3 may be involved in the PGC-Į- and PGC-ȕ-induced 
increase in protein synthesis in vitro. Identifying new targets that are regulated by 
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PGC-Į(55Į DQG 3*&-ȕ(55Į WUDQVFULSWLRQDO DFWLYLW\ WKDW DUH LQYROYHG LQ
protein synthesis will help elucidate the mechanisms by which PGC-ĮDQG3*&-ȕ
increase protein synthesis in skeletal muscle. Following on from this, further in vivo
studies can be undertaken to confirm findings from these cell culture models.
5.2.3 Identifying the role of novel genes down-regulated by PGC-ĮDQG
PGC-ȕLQ&&P\RWXEHV
Rationale
PGC-ĮDQG3*&-ȕDUHNQRZQWRDWWHQXDWHSURWHLQGHJUDGDWLRQLQVNHOHWDOPXVFOH
via their down-regulation of genes involved in proteasomal and lysosomal 
proteolysis [219]. In Chapter 3, several novel genes were identified that were down-
regulated by PGC-ĮDQG3*C-ȕRYHUH[SUHVVLRQ2IWKHVH, TRIM32 and Prnp were 
also increased in atrophied skeletal muscle of ALS patients. TRIM32 is a known 
ubiquitin ligase in skeletal muscle [298], suggesting another gene that PGC-ĮDQG
PGC-ȕPD\UHJXODWHWRLQKLEit protein degradation. Overexpression if Prnp causes 
muscle atrophy and degeneration in vivo [328], although its effects on protein 
degradation are unknown.
Aims
To determine if TRIM32 and/or Prnp are involved in the PGC-Į- and PGC-ȕ-
induced attenuation of protein degradation in C2C12 myotubes in vitro.
Key Methods
To determine if TRIM32 or Prnp are involved in protein degradation regulated by 
PGC-Į DQG 3*&-ȕ, siRNAs can be designed to knockdown their expression in 
vitro. Cell culture experiments can then be carried out using similar methods as in 
Chapters 2 and 4. Briefly, C2C12 myoblasts are grown and differentiated into 
myotubes. After optimisation conditions for each specific siRNA sequence, 
myotubes are transfected with siRNA for 24 hours to knockdown the gene of 
interest. Myotubes are then infected with adenoviruses expressing GFP, hPGC-ĮRU
hPGC-ȕ IRU  KRXUV Protein degradation in vitro is measured as described 
previously [40]. Briefly, after the desired changes in gene expression are induced, 
myotubes are labelled with [3H]-tyrosine for 24 hours. Myotubes are then washed 
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and incubated in serum free medium for a further 24 hours, and the [3H]-tyrosine 
(radioactivity) released into the media during this time is measured. Myotube 
diameter would also be assessed by microscopic examination.
Significance
The proposed study is required to determine the functional significance of the PGC-
Į- and PGC-ȕ-induced down-regulation of TRIM32 and Prnp in C2C12 myotubes. 
Identifying new targets regulated by PGC-Į and PGC-ȕ that are involved in 
muscle growth or wasting will assist in identifying therapeutic strategies to prevent 
or lessen the debilitating effects of muscle atrophy.
5.2.4 Interaction of PGC-1ȕDQG(55Į with the CrT promoter
Rationale
In skeletal muscle, PGC-Į(55Į DQG 3*&-ȕ(55Į DUH NQRZQ WR LQFUHDVH WKH
transcription of genes involved in mitochondrial biogenesis, oxidative 
phosphorylation, mitochondrial fusion, fatty acid oxidation, oxidative muscle fibre
phenotype, and angiogenesis. In Chapter 4, it was shown that PGC-ĮDQG3*&-ȕ
increase CrT mRNA and creatine uptake in L6 myotubes; an effect was dependent on 
(55ĮFurthermore, ChIP assays revealed that PGC-ĮDQG(55ĮLQWHUDFWGLUHFWO\
with the CrT promoter to increase CrT expression. However, it is unknown if PGC-
ȕFDQDOVRGLUHFWO\LQWHUDFWZLWK(55ĮRQWKH&U7SURPRWHU
Aim
To identify if PGC-1ȕ LQWHUDFWVGLUHFWO\ZLWK(55ĮRQWKH&U7SURPRWHU
Key methods
ChIP assays can be performed with adenovirus-infected C2C12 myotubes as 
described previously in Chapter 4, but with the use of PGC-ȕDGHQRYLUXVLQVWHDGRI
PGC-Į. Briefly, myotubes are infected on day 4 of differentiation with adenoviruses 
expressing shRNAs IRU (55Į RU *)3, and on day 6 of differentiation with 
adenoviruses expressing LacZ and FLAG-PGC-1ȕ, together with a second dose of 
shRNA-expressing adenoviruses. The cells are harvested 24 h later, and chromatin is
immunoprecipitated with the following antibodies: anti-GFP, anti-FLAG for the
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detection of FLAG-Tagged PGC-ȕ, or anti-(55Į *HQRPLF '1$ SUHVHQW LQ WKH
immunopurified complex is quantified by real-time qPCR using mouse CrT primers: 
Forward: 5’ GGATCCCATGGAATCAGGTCTT and Reverse: 5’ 
GGCAACTGGGAAACAGAAATCA, which amplifies a region FRQWDLQLQJDQ(55Į
response element (ERRE) upstream of the transcriptional start-site. 
Significance
The proposed study will confirm whether PGC-ȕFDQGLUHFWO\ LQWHUDFWZLWK(55Į
and bind to the CrT to increase its gene expression. These findings will add to the list 
of gene targets that PGC-Į(55Į DQG 3*&-ȕ(55Į DUH NQRZQ WR UHJXODWH LQ
skeletal muscle, and further increase the understanding of how CrT expression and 
creatine transport are regulated in skeletal muscle. 
5.2.5 The effect of PGC-ĮDQGPGC-ȕRQFUHDWLQHXSWDNHin vivo
Rationale
Decreased intracellular creatine and CrT levels are characteristic of many 
myopathies [229, 239]. In Chapter 4, it was shown that overexpression of PGC-Į
and PGC-ȕLQFUHDVHVCrT mRNA and creatine uptake in L6 myotubes in vitro. This 
HIIHFW ZDV GHSHQGHQW RQ (55ĮWhether PGC-Į DQG 3*&-ȕ can increase CrT
mRNA and creatine uptake in vivo has not been investigated.
Aims
To investigate the effect of PGC-Į(55Į and PGC-ȕ(55Į on CrT mRNA 
expression and creatine uptake in skeletal muscle in vivo.
Key methods
PGC-Į DQG 3*&-ȕ RYHUH[SUHVVLRQ in vivo can be achieved using rAAVs as 
described in section 5.2.1 above. rAAVs overexpressing PGC-ĮRU3*&-ȕFRXOG
EH LQIHFWHG LQWR (55Į NQRFNRXW PLFH [340], and appropriate wild-type controls. 
Creatine uptake in vivo can be measured by using hindlimb perfusion of [14C]-
Creatine in into skeletal muscle, as described previously [242]. Briefly, after 
perfusion of [14C]-Creatine for the desired time period, metabolites from the muscle 
sections are extracted using perchloric acid. Radioactivity present in the 
118 
 
Phosphocreatine (PCr) and creatine pools can be measured in a similar manner to in 
vitro studies, using liquid scintillation counter. The net amount of radiolabel found 
within the muscle represents the creatine uptake rate for that period
Significance
PGC-ĮDQG3*&-ȕ LQFUHDVHCrT mRNA and creatine uptake in vitro, and this is 
GHSHQGHQW RQ WKH WUDQVFULSWLRQ IDFWRU (55Į 7KH SURSRVHG VWXG\ LV UHTXLUHG WR
determine whether this observation can be extended to in vivo models. Identifying 
the molecular mechanisms regulating creatine transport in skeletal muscle is essential 
for developing therapeutic strategies to increase intracellular creatine in myopathies 
associated with decreased creatine levels. 
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Appendices
Appendix 1. 
 
Complete list of Gene Ontology (GO) terms identified from the up- and 
down- regulated genes and proteins by PGC-ĮDQG3*&-ȕ
 
Table S1 Complete list of GO terms identified by analysis of PGC-Į-differentially expressed genes.
GO Term Category Count  
(No. of 
genes) 
Fold  
Enrichment 
P-Value 
GO:0005739~mitochondrion CC 361 4.8 2.36E-169 
GO:0044429~mitochondrial part CC 187 6.2 6.29E-100 
GO:0031966~mitochondrial membrane CC 136 6.4 1.44E-72 
GO:0005740~mitochondrial envelope CC 139 6.2 9.32E-72 
GO:0005743~mitochondrial inner membrane CC 115 6.8 3.20E-63 
GO:0019866~organelle inner membrane CC 117 6.5 2.05E-62 
GO:0031967~organelle envelope CC 144 4.6 3.80E-56 
GO:0031975~envelope CC 144 4.6 6.36E-56 
GO:0006091~generation of precursor 
metabolites and energy 
BP 91 7.1 2.47E-49 
GO:0031090~organelle membrane CC 161 3.5 7.89E-45 
GO:0022900~electron transport chain BP 55 7.8 1.55E-38 
GO:0070469~respiratory chain CC 43 11.5 5.09E-34 
GO:0055114~oxidation reduction BP 114 3.5 4.39E-29 
GO:0005759~mitochondrial matrix CC 59 6.3 9.52E-29 
GO:0031980~mitochondrial lumen CC 59 6.3 9.52E-29 
GO:0045333~cellular respiration BP 29 10.0 3.50E-18 
GO:0015980~energy derivation by oxidation of 
organic compounds 
BP 33 6.8 3.81E-15 
GO:0051186~cofactor metabolic process BP 43 4.8 2.98E-14 
GO:0044455~mitochondrial membrane part CC 23 8.2 1.47E-12 
GO:0006732~coenzyme metabolic process BP 35 2.7 6.94E-12 
GO:0007005~mitochondrion organization BP 28 9.7 2.05E-11 
GO:0048037~cofactor binding MF 43 5.9 1.70E-10 
GO:0006084~acetyl-CoA metabolic process BP 17 11.2 3.16E-10 
GO:0009060~aerobic respiration BP 16 12.1 4.38E-10 
GO:0003954~NADH dehydrogenase activity MF 15 12.4 6.35E-10 
GO:0008137~NADH dehydrogenase 
(ubiquinone) activity 
MF 15 12.4 6.35E-10 
GO:0050136~NADH dehydrogenase (quinone) 
activity 
MF 15 12.4 6.35E-10 
GO:0015077~monovalent inorganic cation 
transmembrane transporter activity 
MF 25 5.4 1.20E-09 
GO:0006099~tricarboxylic acid cycle BP 14 5.7 3.59E-09 
GO:0016655~oxidoreductase activity, acting on 
NADH or NADPH, quinone or similar compound 
as acceptor 
MF 15 3.9 4.70E-09 
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GO:0051188~cofactor biosynthetic process BP 25 11.0 5.64E-09 
GO:0015078~hydrogen ion transmembrane 
transporter activity 
MF 24 12.4 1.37E-08 
GO:0046356~acetyl-CoA catabolic process BP 14 11.9 2.85E-08 
GO:0006119~oxidative phosphorylation BP 19 12.6 1.07E-07 
GO:0051187~cofactor catabolic process BP 15 4.4 1.21E-07 
GO:0022890~inorganic cation transmembrane 
transporter activity 
MF 28 6.9 1.76E-07 
GO:0016651~oxidoreductase activity, acting on 
NADH or NADPH 
MF 18 7.0 1.84E-07 
GO:0009109~coenzyme catabolic process BP 14 6.8 5.17E-07 
GO:0031968~organelle outer membrane CC 23 4.6 8.33E-07 
GO:0022904~respiratory electron transport 
chain 
BP 13 3.2 1.17E-06 
GO:0005840~ribosome CC 35 4.5 1.66E-06 
GO:0019867~outer membrane CC 23 3.5 2.39E-06 
GO:0050662~coenzyme binding MF 29 9.4 5.75E-06 
GO:0009108~coenzyme biosynthetic process BP 18 3.6 5.93E-06 
GO:0005741~mitochondrial outer membrane CC 21 6.4 1.09E-05 
GO:0005761~mitochondrial ribosome CC 15 6.4 1.09E-05 
GO:0000313~organellar ribosome CC 15 4.3 1.41E-05 
GO:0015002~heme-copper terminal oxidase 
activity 
MF 11 4.0 3.95E-05 
GO:0016676~oxidoreductase activity, acting on 
heme group of donors, oxygen as acceptor 
MF 11 9.5 5.35E-05 
GO:0004129~cytochrome-c oxidase activity MF 11 9.5 5.35E-05 
GO:0016675~oxidoreductase activity, acting on 
heme group of donors 
MF 11 9.5 5.35E-05 
GO:0006631~fatty acid metabolic process BP 29 9.5 5.35E-05 
GO:0051540~metal cluster binding MF 15 5.9 8.92E-05 
GO:0051536~iron-sulfur cluster binding MF 15 5.2 9.90E-05 
GO:0009055~electron carrier activity MF 30 3.3 1.89E-04 
GO:0000166~nucleotide binding MF 160 3.2 1.93E-04 
GO:0006626~protein targeting to 
mitochondrion 
BP 10 1.4 3.39E-04 
GO:0070585~protein localization in 
mitochondrion 
BP 10 8.7 3.62E-04 
GO:0005746~mitochondrial respiratory chain CC 9 8.6 7.37E-04 
GO:0051539~4 iron, 4 sulfur cluster binding MF 10 9.2 9.63E-04 
GO:0017076~purine nucleotide binding MF 139 1.5 1.27E-03 
GO:0019842~vitamin binding MF 21 3.4 2.13E-03 
GO:0055085~transmembrane transport BP 47 4.9 2.97E-03 
GO:0009144~purine nucleoside triphosphate 
metabolic process 
BP 19 4.1 4.30E-03 
GO:0006839~mitochondrial transport BP 12 1.5 0.01 
GO:0045259~proton-transporting ATP synthase 
complex 
CC 9 1.5 0.01 
GO:0009150~purine ribonucleotide metabolic 
process 
BP 20 1.5 0.01 
GO:0019725~cellular homeostasis BP 38 1.5 0.01 
GO:0001883~purine nucleoside binding MF 117 2.1 0.01 
GO:0030554~adenyl nucleotide binding MF 116 3.6 0.01 
GO:0046034~ATP metabolic process BP 17 5.8 0.01 
GO:0009205~purine ribonucleoside 
triphosphate metabolic process 
BP 18 3.4 0.01 
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GO:0045454~cell redox homeostasis BP 14 2.3 0.01 
GO:0001882~nucleoside binding MF 117 4.8 0.01 
GO:0009199~ribonucleoside triphosphate 
metabolic process 
BP 18 2.2 0.01 
GO:0009259~ribonucleotide metabolic process BP 20 13.3 0.01 
GO:0009141~nucleoside triphosphate 
metabolic process 
BP 19 3.8 0.01 
GO:0009145~purine nucleoside triphosphate 
biosynthetic process 
BP 17 3.6 0.02 
GO:0042773~ATP synthesis coupled electron 
transport 
BP 8 4.6 0.02 
GO:0009142~nucleoside triphosphate 
biosynthetic process 
BP 17 3.6 0.02 
GO:0009152~purine ribonucleotide 
biosynthetic process 
BP 18 2.9 0.02 
GO:0015405~P-P-bond-hydrolysis-driven 
transmembrane transporter activity 
MF 18 3.3 0.02 
GO:0019318~hexose metabolic process BP 23 3.4 0.03 
GO:0015399~primary active transmembrane 
transporter activity 
MF 18 3.7 0.03 
GO:0009260~ribonucleotide biosynthetic 
process 
BP 18 9.0 0.03 
GO:0044275~cellular carbohydrate catabolic 
process 
BP 13 3.6 0.03 
GO:0042775~mitochondrial ATP synthesis 
coupled electron transport 
BP 7 3.4 0.04 
GO:0006744~ubiquinone biosynthetic process BP 6 4.1 0.04 
GO:0006743~ubiquinone metabolic process BP 6 5.0 0.04 
CC = cellular component, MF = molecular function, BP = biological process. 
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Table S2 Complete list of GO terms identified by analysis of PGC-ȕ-differentially expressed genes.
GO Term Category Count 
(No. of 
genes) 
Fold  
Enrichment 
P-Value 
GO:0005739~mitochondrion CC 536 2.7 1.79E-124 
GO:0044429~mitochondrial part CC 253 3.2 5.43E-72 
GO:0005740~mitochondrial envelope CC 188 3.2 7.18E-52 
GO:0031966~mitochondrial membrane CC 180 3.2 6.88E-51 
GO:0005743~mitochondrial inner membrane CC 151 3.4 4.80E-45 
GO:0019866~organelle inner membrane CC 155 3.3 2.02E-44 
GO:0031967~organelle envelope CC 214 2.6 2.02E-42 
GO:0031975~envelope CC 214 2.6 4.06E-42 
GO:0031090~organelle membrane CC 266 2.2 3.50E-36 
GO:0006091~generation of precursor 
metabolites and energy 
BP 111 3.0 5.16E-25 
GO:0031980~mitochondrial lumen CC 81 3.3 5.50E-22 
GO:0005759~mitochondrial matrix CC 81 3.3 5.50E-22 
GO:0070469~respiratory chain CC 46 4.7 5.79E-20 
GO:0022900~electron transport chain BP 60 3.7 2.95E-18 
GO:0055114~oxidation reduction BP 179 1.9 2.97E-14 
GO:0043292~contractile fiber CC 49 3.4 3.25E-13 
GO:0005840~ribosome CC 74 2.5 3.18E-12 
GO:0030016~myofibril CC 46 3.3 7.73E-12 
GO:0051186~cofactor metabolic process BP 68 2.6 9.70E-11 
GO:0007005~mitochondrion organization BP 44 3.2 2.87E-09 
GO:0044449~contractile fiber part CC 42 3.2 5.43E-10 
GO:0045333~cellular respiration BP 32 3.8 1.79E-08 
GO:0006732~coenzyme metabolic process BP 53 2.6 1.30E-07 
GO:0030017~sarcomere CC 38 3.1 2.16E-08 
GO:0044455~mitochondrial membrane part CC 28 3.8 6.14E-08 
GO:0005761~mitochondrial ribosome CC 25 4.0 1.22E-07 
GO:0000313~organellar ribosome CC 25 4.0 1.22E-07 
GO:0015980~energy derivation by oxidation of 
organic compounds 
BP 40 2.9 1.72E-06 
GO:0003735~structural constituent of 
ribosome 
MF 52 2.4 8.95E-07 
GO:0008092~cytoskeletal protein binding MF 105 1.8 1.42E-06 
GO:0005829~cytosol CC 136 1.6 1.41E-06 
GO:0006412~translation BP 86 1.9 1.44E-05 
GO:0000166~nucleotide binding MF 396 1.3 8.17E-06 
GO:0017076~purine nucleotide binding MF 346 1.3 1.21E-05 
GO:0003779~actin binding MF 78 1.9 1.24E-05 
GO:0031968~organelle outer membrane CC 36 2.7 7.05E-06 
GO:0005741~mitochondrial outer membrane CC 34 2.8 8.78E-06 
GO:0006084~acetyl-CoA metabolic process BP 19 4.3 6.83E-05 
GO:0031974~membrane-enclosed lumen CC 246 1.4 1.34E-05 
GO:0019867~outer membrane CC 36 2.6 1.98E-05 
GO:0031674~I band CC 26 3.2 1.98E-05 
GO:0051187~cofactor catabolic process BP 19 4.1 1.35E-04 
GO:0030554~adenyl nucleotide binding MF 289 1.3 5.24E-05 
GO:0001883~purine nucleoside binding MF 291 1.3 5.29E-05 
GO:0050136~NADH dehydrogenase (quinone) 
activity 
MF 16 4.7 8.37E-05 
GO:0008137~NADH dehydrogenase MF 16 4.7 8.37E-05 
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(ubiquinone) activity 
GO:0003954~NADH dehydrogenase activity MF 16 4.7 8.37E-05 
GO:0001882~nucleoside binding MF 291 1.3 9.93E-05 
GO:0015078~hydrogen ion transmembrane 
transporter activity 
MF 32 2.8 1.10E-04 
GO:0009060~aerobic respiration BP 17 4.4 2.88E-04 
GO:0033279~ribosomal subunit CC 29 2.9 5.24E-05 
GO:0032553~ribonucleotide binding MF 327 1.3 1.88E-04 
GO:0032555~purine ribonucleotide binding MF 327 1.3 1.88E-04 
GO:0016528~sarcoplasm CC 20 3.7 9.31E-05 
GO:0043232~intracellular non-membrane-
bounded organelle 
CC 367 1.3 1.44E-04 
GO:0043228~non-membrane-bounded 
organelle 
CC 367 1.3 1.44E-04 
GO:0016529~sarcoplasmic reticulum CC 19 3.7 1.86E-04 
GO:0006099~tricarboxylic acid cycle BP 15 4.6 0.0012025 
GO:0015077~monovalent inorganic cation 
transmembrane transporter activity 
MF 32 2.6 5.20E-04 
GO:0055002~striated muscle cell development BP 24 3.1 0.0014828 
GO:0016651~oxidoreductase activity, acting on 
NADH or NADPH 
MF 23 3.2 5.85E-04 
GO:0051188~cofactor biosynthetic process BP 33 2.5 0.0018064 
GO:0016655~oxidoreductase activity, acting on 
NADH or NADPH, quinone or similar compound 
as acceptor 
MF 16 4.2 7.31E-04 
GO:0032559~adenyl ribonucleotide binding MF 270 1.3 7.61E-04 
GO:0046356~acetyl-CoA catabolic process BP 15 4.4 0.0025037 
GO:0006119~oxidative phosphorylation BP 24 3.0 0.0032361 
GO:0005524~ATP binding MF 266 1.3 0.0012749 
GO:0051146~striated muscle cell 
differentiation 
BP 32 2.5 0.0034395 
GO:0070013~intracellular organelle lumen CC 230 1.3 5.80E-04 
GO:0048037~cofactor binding MF 60 1.9 0.0015812 
GO:0043233~organelle lumen CC 230 1.3 7.11E-04 
GO:0055001~muscle cell development BP 25 2.9 0.0047741 
GO:0030529~ribonucleoprotein complex CC 109 1.6 8.38E-04 
GO:0009109~coenzyme catabolic process BP 16 3.9 0.0079039 
GO:0005198~structural molecule activity MF 100 1.6 0.0034305 
GO:0042692~muscle cell differentiation BP 37 2.2 0.0137265 
GO:0030018~Z disc CC 21 3.0 0.0022827 
GO:0005996~monosaccharide metabolic 
process 
BP 52 1.9 0.0169813 
GO:0060537~muscle tissue development BP 40 1.9 0.0170800 
GO:0016044~membrane organization BP 67 1.7 0.0264807 
GO:0022890~inorganic cation transmembrane 
transporter activity 
MF 38 2.1 0.0108924 
GO:0060537~muscle tissue development BP 40 2.1 0.0360468 
GO:0004129~cytochrome-c oxidase activity MF 13 4.0 0.0241856 
GO:0016676~oxidoreductase activity, acting on 
heme group of donors, oxygen as acceptor 
MF 13 4.0 0.0241856 
GO:0015002~heme-copper terminal oxidase 
activity 
MF 13 4.0 0.0241856 
GO:0016675~oxidoreductase activity, acting on 
heme group of donors 
MF 13 4.0 0.0241856 
GO:0030029~actin filament-based process BP 47 1.9 0.0852432 
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GO:0019725~cellular homeostasis BP 78 1.6 0.0935832 
GO:0014706~striated muscle tissue 
development 
BP 37 2.0 0.0992478 
GO:0031970~organelle envelope lumen CC 18 3.0 0.0172322 
GO:0006399~tRNA metabolic process BP 34 2.1 0.1084652 
GO:0050662~coenzyme binding MF 43 1.9 0.0452314 
GO:0005625~soluble fraction CC 32 2.1 0.0217746 
GO:0005758~mitochondrial intermembrane 
space 
CC 15 3.3 0.0245880 
GO:0009108~coenzyme biosynthetic process BP 23 2.5 0.1483761 
GO:0022904~respiratory electron transport 
chain 
BP 14 3.5 0.1548241 
GO:0009260~ribonucleotide biosynthetic 
process 
BP 33 2.1 0.1802321 
GO:0060538~skeletal muscle organ 
development 
BP 25 2.4 0.1944596 
GO:0008104~protein localization BP 146 1.4 0.2396605 
GO:0070585~protein localization in 
mitochondrion 
BP 12 3.8 0.2443469 
GO:0006626~protein targeting to 
mitochondrion 
BP 12 3.8 0.2443469 
GO:0005746~mitochondrial respiratory chain CC 10 4.4 0.0497257 
CC = cellular component, MF = molecular function, BP = biological process. 
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Table S3 Complete list of GO terms identified by analysis of PGC-Į-differentially expressed 
proteins.
GO Term Category Count 
(No. of 
proteins) 
Fold  
Enrichment 
P-Value 
GO:0006091~generation of precursor 
metabolites and energy 
BP 28 11 3.77E-17 
GO:0005739~mitochondrion CC 52 4 3.35E-15 
GO:0019866~organelle inner membrane CC 27 8 2.64E-14 
GO:0044429~mitochondrial part CC 31 6 3.99E-12 
GO:0005743~mitochondrial inner membrane CC 24 8 1.21E-11 
GO:0031966~mitochondrial membrane CC 26 7 1.85E-11 
GO:0005740~mitochondrial envelope CC 26 6 7.29E-11 
GO:0031967~organelle envelope CC 29 5 3.92E-10 
GO:0031975~envelope CC 29 5 4.29E-10 
GO:0031090~organelle membrane CC 33 4 1.06E-08 
GO:0005829~cytosol CC 24 4 3.06E-06 
GO:0033279~ribosomal subunit CC 10 14 6.56E-06 
GO:0003735~structural constituent of 
ribosome 
MF 13 8 1.99E-05 
GO:0005840~ribosome CC 14 7 2.73E-05 
GO:0006007~glucose catabolic process BP 9 17 4.03E-05 
GO:0019320~hexose catabolic process BP 9 17 4.03E-05 
GO:0046365~monosaccharide catabolic 
process 
BP 9 17 5.48E-05 
GO:0006412~translation BP 17 5 1.14E-04 
GO:0015935~small ribosomal subunit CC 7 23 1.14E-04 
GO:0044275~cellular carbohydrate catabolic 
process 
BP 9 15 1.28E-04 
GO:0006006~glucose metabolic process BP 12 9 1.44E-04 
GO:0000166~nucleotide binding MF 48 2 1.50E-04 
GO:0055114~oxidation reduction BP 24 4 1.95E-04 
GO:0006096~glycolysis BP 8 18 2.30E-04 
GO:0046164~alcohol catabolic process BP 9 14 2.42E-04 
GO:0030529~ribonucleoprotein complex CC 19 4 3.95E-04 
GO:0019318~hexose metabolic process BP 12 7 0.001 
GO:0015077~monovalent inorganic cation 
transmembrane transporter activity 
MF 9 10 0.001 
GO:0016052~carbohydrate catabolic process BP 9 11 0.001 
GO:0005198~structural molecule activity MF 18 4 0.002 
GO:0022900~electron transport chain BP 10 9 0.002 
GO:0045333~cellular respiration BP 8 13 0.002 
GO:0022890~inorganic cation 
transmembrane transporter activity 
MF 10 7 0.002 
GO:0042625~ATPase activity, coupled to 
transmembrane movement of ions 
MF 8 11 0.002 
GO:0006099~tricarboxylic acid cycle BP 6 26 0.003 
GO:0005996~monosaccharide metabolic 
process 
BP 12 6 0.003 
GO:0046356~acetyl-CoA catabolic process BP 6 25 0.003 
GO:0003988~acetyl-CoA C-acyltransferase 
activity 
MF 4 75 0.004 
GO:0015980~energy derivation by oxidation 
of organic compounds 
BP 9 9 0.006 
GO:0009060~aerobic respiration BP 6 22 0.006 
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GO:0009109~coenzyme catabolic process BP 6 21 0.009 
GO:0017076~purine nucleotide binding MF 39 2 0.011 
GO:0006084~acetyl-CoA metabolic process BP 6 19 0.012 
GO:0043232~intracellular non-membrane-
bounded organelle 
CC 39 2 0.014 
GO:0043228~non-membrane-bounded 
organelle 
CC 39 2 0.014 
GO:0051187~cofactor catabolic process BP 6 19 0.014 
GO:0070469~respiratory chain CC 7 10 0.014 
GO:0006754~ATP biosynthetic process BP 8 10 0.016 
GO:0003779~actin binding MF 13 4 0.017 
GO:0042626~ATPase activity, coupled to 
transmembrane movement of substances 
MF 8 8 0.023 
GO:0016820~hydrolase activity, acting on 
acid anhydrides, catalyzing transmembrane 
movement of substances 
MF 8 8 0.023 
GO:0043492~ATPase activity, coupled to 
movement of substances 
MF 8 8 0.023 
GO:0046034~ATP metabolic process BP 8 9 0.030 
GO:0030554~adenyl nucleotide binding MF 33 2 0.033 
GO:0009201~ribonucleoside triphosphate 
biosynthetic process 
BP 8 9 0.037 
GO:0009206~purine ribonucleoside 
triphosphate biosynthetic process 
BP 8 9 0.037 
GO:0008092~cytoskeletal protein binding MF 15 3 0.037 
GO:0042623~ATPase activity, coupled MF 11 5 0.039 
GO:0001883~purine nucleoside binding MF 33 2 0.039 
GO:0019829~cation-transporting ATPase 
activity 
MF 5 19 0.039 
GO:0009145~purine nucleoside triphosphate 
biosynthetic process 
BP 8 8 0.040 
GO:0015405~P-P-bond-hydrolysis-driven 
transmembrane transporter activity 
MF 8 7 0.042 
GO:0009142~nucleoside triphosphate 
biosynthetic process 
BP 8 8 0.042 
GO:0001882~nucleoside binding MF 33 2 0.044 
GO:0015399~primary active transmembrane 
transporter activity 
MF 8 7 0.044 
CC = cellular component, MF = molecular function, BP = biological process. 
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Table S4 Complete list of GO terms identified by analysis of PGC-ȕ-differentially expressed 
proteins.
GO Term Category Count 
(No. of 
proteins) 
Fold  
Enrichment 
P-Value 
GO:0006091~generation of precursor 
metabolites and energy 
BP 13 10 1.54E-06 
GO:0006096~glycolysis BP 7 5 5.57E-06 
GO:0031090~organelle membrane CC 18 4 1.10E-05 
GO:0005739~mitochondrion CC 22 33 3.06E-05 
GO:0006007~glucose catabolic process BP 7 6 7.02E-05 
GO:0019320~hexose catabolic process BP 7 6 7.32E-05 
GO:0044275~cellular carbohydrate catabolic 
process 
BP 7 28 8.56E-05 
GO:0031967~organelle envelope CC 14 28 8.56E-05 
GO:0046365~monosaccharide catabolic 
process 
BP 7 27 1.08E-04 
GO:0031975~envelope CC 14 8 1.43E-04 
GO:0046164~alcohol catabolic process BP 7 24 2.05E-04 
GO:0019866~organelle inner membrane CC 11 23 3.31E-04 
GO:0016052~carbohydrate catabolic process BP 7 6 3.56E-04 
GO:0044429~mitochondrial part CC 13 7 0.001 
GO:0031966~mitochondrial membrane CC 11 6 0.001 
GO:0005743~mitochondrial inner membrane CC 9 7 0.001 
GO:0003779~actin binding MF 10 18 0.001 
GO:0051494~negative regulation of 
cytoskeleton organization 
BP 5 6 0.003 
GO:0005740~mitochondrial envelope CC 11 7 0.007 
GO:0008092~cytoskeletal protein binding MF 11 14 0.010 
GO:0006006~glucose metabolic process BP 7 21 0.014 
GO:0043292~contractile fiber CC 6 4 0.019 
GO:0031674~I band CC 5 10 0.028 
GO:0051129~negative regulation of cellular 
component organization 
BP 6 3 0.042 
GO:0030029~actin filament-based process BP 7 22 0.042 
GO:0006099~tricarboxylic acid cycle BP 4 13 0.042 
CC = cellular component, MF = molecular function, BP = biological process. 
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Appendix 2.
Table S5 The top 33 genes identified in the Gene Expression Signature (GES).
GFP vs. PGC-1Į GFP vs. PGC-1ȕ
Gene Symbol
GenBank 
Accession no. Gene Symbol
GenBank 
Accession no.
0610042C05Rik NM_025343.2 LOC100048313 XM_001480281.1 
LOC100046395 XR_032392.1 LOC100047963 XM_001479238.1 
Tmem14c NM_025387.2 Mrps9 NM_023514.3 
1300001I01Rik NM_001081158.2 Tarbp2 NM_009319.1 
Brd7 NM_012047.1 Cdc14b NM_172587.2 
Exoc1 NM_027270.1 Ppp1r16a NM_033371.2 
9430038I01Rik XM_925223.2 Pgbpll NM_145147.5 
Poli NM_011972.1 LOC100044363 XM_001471994.1 
LOC100048313 XM_001480281.1 C78339 NM_001033192.2 
LOC100047963 XM_001479238.1 LOC100046741 XM_001476728.1 
Tarbp2 NM_009319.1 Xpnpep3 NM_177310.2 
Rpl26 NM_009080.2 0610042C05Rik NM_025343.2 
Acp6 NM_019800.3 9430038I01Rik XM_925223.2 
Trim32 NM_053084.1 Rccd1 NM_173445.1 
Gm889 NM_001033437.1 Trim25 NM_009546.2 
Ppp1r16a NM_033371.2 Ints1 NM_026748.1 
Ssbp4 XM_356132.1 Eif2a NM_001005509.1 
LOC100046741 XM_001476728.1 Ankmy2 NM_146033.2 
Cuedc1 NM_198013.1 Tmem14c NM_025387.2 
Atp5c1 NM_020615.3 AI314976 NM_207219.2 
Rapgefl1 NM_001080925.1 LOC100047126 XM_001477492.1 
C78339 NM_001033192.2 Asnsd1 NM_133728.2 
Ppap2a NM_008903.1 Ifngr1 NM_010511.2 
Cdc14b NM_172587.2 Snrpd3 NM_026095.4 
Daam2 NM_001008231.2 Ssbp4 XM_356132.1 
Abhd1 NR_003522.1 Hcfc1r1 NM_181821.1 
4930455C21Rik XM_148429.1 LOC381398 XM_355356.1 
Mnat1 NM_008612.1 scl0003651.1_17 XM_356680.1 
Nef3 NM_008691.2 Prpsap1 XM_181343.5 
Mrps9 NM_023514.3 7030401E22Rik   
Aifm1 NM_012019.2 Lyrm1 NM_029610.1 
Tlr6 NM_011604.2 Hnrpm NM_029804.1 
Smpd1 NM_011421.1 Plscr4 NM_178711.2 
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